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ABSTRACT 
Advances in medicine and healthcare have resulted in significant improvements for those 
children and adolescents living with a chronic health condition.  However, the treatments 
prescribed will only work if they are taken.  Rates of adherence to treatment in cystic fibrosis are 
low.  This is especially true for adherence to aerosol therapy, a particular concern considering the 
reliance on aerosol therapy for the treatment of Pseudomonas aeruginosa. 
The advent of Adaptive Aerosol Delivery™ (AAD) technology has enabled accurate and 
objective measurement of adherence to aerosol therapy treatment.  However, the factors which 
influence the process of adhering to aerosol therapy remain largely elusive.  Therefore, the 
current study aims to qualitatively explore the process of adhering to aerosol therapy in a clinical 
sample of adolescents with CF from both a patient and parent perspective. In addition, objective 
data downloaded from an AAD device (the I-neb™, Respironics, Chichester, UK) will be used to 
cue reflections on actual events around adherence. 
12 participants were interviewed (six parent-child dyads).  The participating adolescents 
were all aged between 11 and 16 years and had a CF diagnosis.  There were five mothers and one 
father who took part.  The parent and adolescent data were analysed separately using the 
Grounded Theory Method.  Nine core categories for the parent data and nine core categories for 
the adolescent data were developed into a coherent framework and represented as a theoretical 
formulation which described the process of adhering to aerosol therapy from both a parent and 
adolescent patient perspective.  The theoretical formulation highlights the complexity involved 
and details the numerous interacting biological, psychological, social and environmental 
influences on adherence to aerosol therapy.  These findings are discussed in relation to the 
existing literature and clinical implications are considered.  The results of the current study 
complement and extend previous research on adherence in CF. 
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1.0 INTRODUCTION 
1.1 Children and adolescents with a chronic health condition 
 Estimates of the numbers of children and adolescents living with a chronic health 
condition are not easy to establish.  The wide variety of data collection methods being utilised 
(e.g., medical files, questionnaires, lists of hospital diagnostic codes) and the considerable 
discrepancies regarding the definition of what constitutes a chronic health condition, makes 
establishing prevalence rates difficult (Zylke & DeAngelis, 2007).  The terms “chronic disease” 
and “chronic illness”, for example are often used interchangeably.  Williams (1997) defines a 
chronic disease as a “medically diagnosed ailment with a duration of six months or longer which 
shows little change or slow progression” (pg. 312).  Pless and Douglas (1971) define a chronic 
illness as a “physical, usually non-fatal condition that has lasted longer than three months in a 
given year or necessitated a period of continuous hospitalisation of more than one month; of 
sufficient severity to interfere with the child’s ordinary activities to some degree.”  The 
difficulties associated with measuring and defining chronic health conditions in children and 
adolescents led to a recent systematic review by van der Lee and colleagues (van der Lee, 
Mokkink, Grootenhuis, Heymans & Offringa, 2007) finding prevalence rates ranging from as 
little as 0.22% to upwards of 44%.  Although they were unable to establish a firm estimate, they 
suggest that prevalence rates of children and adolescents living with a chronic health condition 
have increased since the 1980’s and predict likely increases in the future. 
Spinks (2009) provides a useful list of examples of chronic health conditions which 
include: cystic fibrosis (CF), epilepsy, asthma, diabetes, sickle cell disease, leukaemia and other 
childhood cancers.  The disease burden placed upon individual children living with these 
conditions and their families is substantial (Taylor, 2006).  In addition, the increases in 
prevalence rates bring significant organisational and financial consequences, particularly for 
educational provision, health care planning and employment (Newacheck, & Halfon, 1998; van 
der Lee et al., 2007). 
1.2 Psychosocial aspects of chronic health conditions 
 The majority of children, adolescents and their families cope well with the demands of 
living with a chronic health condition (Taylor, 2006; Spinks, 2009).  Although that may be the 
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case, chronic health conditions can contribute to a number of psychosocial difficulties.  Barlow 
& Ellard (2006), for example, suggest that fatigue, pain and other physical symptoms, combined 
with the need for disease management regimes, may well impede many aspects of daily living 
for children, parents and siblings.  Children and adolescents face a number of specific challenges 
including having to adhere to an often complex treatment regimen, coming to terms with parental 
concerns, and managing worries that they may have regarding their own self-image (Miller & 
Wood, 1991). Children and adolescents with a chronic health condition can spend a significant 
amount of time in the hospital setting.  Pao and colleagues (Pao, Ballard, & Rosenstein, 2007) 
investigated the impact of what they described as “growing up in the hospital” and suggested that 
the effects on emotional, cognitive, and social development can be profound. 
Many of the above challenges place children and adolescents living with a chronic health 
condition at greater risk for developing emotional and behavioural adjustment problems.  There 
is evidence of a two-fold increase in risk of psychological maladjustment when compared to 
healthy controls (Lavigne & Faier-Routman, 1992; Hysing, Elgen, Gillberg, Lie, & Lundervold, 
2007).  In addition, it has been suggested that children and adolescents living with a chronic 
health condition are placed at greater risk of experiencing an overall lowered quality of life 
(Lebovidge, Lavigne, Donenberg, & Miller, 2003; Garnefski, Koopman, Kraaij, & ten Cate, 
2009). 
 The impact on families of caring for a child or adolescent with a chronic health condition 
should not be understated.  Coping with the initial diagnosis can come as a major shock (Cherry, 
1989) and parents can experience anxiety about their child’s future prognosis and overall well-
being (Barlow & Ellard, 2006).  Caring responsibilities can place heavy practical and emotion 
demands on parents (Magrab, 1985; Eiser, 1990).  Complex treatment regimens and specific 
requirements associated with chronic health conditions such as CF and diabetes can result in 
daily care needs becoming more demanding, particularly as the condition progresses or worsens 
(Boekaerts & Röder, 1999).  Balancing the above healthcare needs with daily work commitments 
and the needs of other members of the family can create an additional burden.  Siblings may 
receive less time and attention from parents and family days out can be disrupted or made 
impossible (Foster, Eiser, Oades, Sheldon, Tripp, Goldman, Rice & Trott, 2001; Barlow & 
Ellard, 2006). 
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In taking the above into account, it is perhaps unsurprising that caring for a child with a 
chronic health condition has been associated with higher rates of marital stress, divorce, paternal 
unemployment and financial difficulties (Reichman, Corman, & Noonan, 2004; van Dyck, 
Kogan, McPherson, Weissman, & Newacheck, 2004; Noonan, Reichman, Corman, 2005). 
1.3 Adherence to treatment in chronic health conditions 
  The World Health Organisation (WHO) has defined adherence as “the extent to which a 
person’s behaviour – taking medication, following a diet, and/or executing lifestyle changes – 
corresponds with agreed recommendations from a health care provider” (WHO, 2003 pg. 3).  
Poor adherence to treatment in chronic health conditions is a significant problem with adherence 
rates of 30% to 70% often being cited (Meichenbaum & Turk, 1987; Rapoff, 1999; Horne, 
2007).  Sub-optimal adherence is costly from a healthcare perspective and can contribute to a 
number of serious consequences from a patient perspective including increased morbidity, 
mortality and lowered quality of life (DiMatteo, Giordani, Lepper & Croghan, 2002; WHO, 
2003). 
1.3.1 Correlates of adherence to treatment 
By gaining a better understanding of the factors impacting adherence to treatment in 
chronic health conditions, interventions can be designed to improve it.  In turn, this should 
reduce the disease-related mortality, morbidity and unnecessary health-care costs discussed 
above.  In contrast to the adult literature, adherence to treatment for child and adolescent chronic 
health conditions has rarely been examined in relation to extant theoretical models.  Therefore, 
the following section will begin by discussing the research on correlates of adherence to 
treatment for children and adolescents before moving on to briefly describe some of the existing 
theoretical models that are primarily used in the examination of adherence to treatment for adult 
populations.  The research examining the interventions designed to increase adherence to 
treatment will also be discussed. 
1.3.1.1 Patient and family correlates 
Despite decades of research investigating the types of patients that are most likely to be 
non-adherent, little evidence has been found in relation to specific personality characteristics 
having an influence on adherence behaviour (McKim, Stones & Kozma, 1990; Bosley, Fosbury 
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& Cochrane, 1995).  However, age has consistently been shown to have an impact on adherence.  
It is more likely, for example, that rates of adherence will be lower in adolescents than in 
younger children (Jacobson, Hauser, Wolfsdorf, Houlihan, Milley, & Hrskowitz, 1987; 
Brownbridge & Fielding, 1994; Walders, Kopel, Koins-Mitchell, & McQuaid, 2005; Feldman, 
De Civita, Dobkin, Malleson, Meshefedjian, & Duffy, 2007).  The WHO defines adolescence as 
the period between 10 and 19 years of age (WHO, 2008).  It is a particular concern that rates of 
adherence are poor during this time because adolescence is the developmental stage associated 
with taking a greater responsibility for one’s own health in preparation for adulthood (Sarafino, 
2004; Berk, 2006).  Studies examining patient gender as a correlate of adherence are equivocal.  
Although there are studies that found males to be less adherent than females to CF and diabetes 
regimens (Lorenz, Christensen, & Pichert, 1985; Patterson, 1985; Naar-King, Idalski, Ellis, Frey, 
Templin, & Cunningham, 2006) an equal number of studies found that females were less 
adherent than males (Johnson, Freund, Silverstein, Hansen, & Malone, 1990; Patino, Sanchez, 
Eidson, & Delamater, 2005; Stewart, Lee, Waller, Hughes, Low, & Kennard, 2003). 
It has been consistently shown that patients with less knowledge about their treatment are 
less adherent (Gudas, Koocher, & Wyplj, 1991; Holmes, Chen, Streisand, Marschall, Souter, & 
Swift, 2006; Tebbi, Cumings, Kevon, Smith, Richards, & Mallon, 1986).  There are studies 
however, that have shown patients with greater knowledge are not necessarily more adherent 
(Beck, Fennell, Yost, Robinson, Geary, & Richards, 1980; McQuaid, Kopel, Klein, & Fritz, 
2003), suggesting that additional factors are implicated in the process of adherence to treatment.  
Indeed, some have argued that one consequence of a belief in the simplistic notion that increased 
knowledge about treatment leads to increased adherence is that the development of more 
sophisticated interventions, based on detailed theoretical models of health behaviour have been 
held back (Horne, 2007). 
In general, lower socioeconomic status and more specifically, lower parental education 
levels have been associated with poor adherence to regimens for CF, diabetes, renal disease and 
juvenile rheumatoid arthritis (Bobrow, AvRuskin, & Siller, 1985; Brownbridge & Fielding, 
1994; Denson-Lino, Willies-Jaccobo, Rosas, O’Conner, & Wilson, 1993; Patterson, 1985; 
Radius, Marshall, Rosenstock, Drachman, Schuberth, & Teets, 1978; Rapoff, Belmont, Lindsley, 
& Olson, 2005).  Although members from black and minority ethnic groups – particularly 
African-American and Hispanic – have been found to be less adherent to treatment (Snodgrass, 
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Vedanarayanan, Parker, & Parks, 2001; McQuaid et al., 2003), some argue that the use of race as 
a predictor of non-adherence is too simplistic.  Tucker et al (Tucker, Fennell, Pedersen, Higley, 
Wallack, & Peterson, 2002), for example, suggest that a “culturally sensitive model” should be 
applied, where factors related to adherence within different racial groups and not between them 
are studied.  Further studies have demonstrated that parental divorce (Brownbridge & Fielding, 
1994; Shemesh, Shneider, Savitzky, Arnott, Gondolesi, & Krieger, 2004) and patients in larger 
families or where mothers work outside of the home (Patterson, 1985; Tebbi et al., 1986) are less 
likely to be adherent to treatment regimens for cystic fibrosis and cancer. 
Adherence to treatment is less likely in those patients with emotional or behavioural 
difficulties (Brownbridge & Fielding, 1994; Greening, Stoppelbein, Konishi, Jordan, & Moll, 
2007).  This finding has been examined in greater detail (through the use of meta-analytic 
techniques) by DiMatteo and colleagues (DiMatteo, Lepper & Croghan, 2000) who found that 
depression is associated with poorer rates of adherence to a wide range of treatments.  The use of 
denial has been associated with lower adherence (Tamaroff, Festa, Adesman & Walco, 1992).  
Greater pessimism has been related to non-adherence to CF treatment regimens (Gudas et al., 
1991).  In addition, simply forgetting to take medications is one of the most frequently reported 
barriers by patients for a number of different chronic health conditions (Tucker et al., 2001; 
Shemesh et al., 2004; Modi & Quittner, 2006).  On the more positive side of patient adjustment 
and coping, higher self esteem (Friedman, Litt, King, Henson, Holtzman, & Halverson, 1986), a 
sense of optimism (Gudas et al., 1991), increased autonomy and independence (Friedman et al., 
1986), greater self-efficacy (Holmes et al., 2006), and greater problem-solving skills (McCaul, 
Glasgow, & Schafer, 1987) have all been associated with better adherence to treatment. 
A similar situation has been found in terms of positive family adjustment and coping.  
Perhaps unsurprisingly, greater family support, integration, expressiveness, harmony and 
organisation, have all been associated with improved rates of adherence (Friedman et al., 1986; 
McCaul et al., 1987).  Better family communication and problem solving have also been shown 
to have a positive effect on adherence to treatment (Bobrow et al., 1985; McQuaid, Walders, 
Kopel, Fritz & Klinnert, 2005).  More negative aspects of coping such as increased parental 
stress and poor coping, have been associated with lower adherence (Brownbridge & Fielding, 
1994; Gerson, Furth, Neu, & Fivush, 2004).  Studies have found the same effect for poor 
communication (Tubiana-Rufi, Moret, Czernichow, & Chwalow, 1998; Lewandowski & Drotar, 
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2007), increased parental depression (Bartlett, Krishnan, Riekert, Butz, Malveaux, & Rand, 
2004) and greater parental anxiety (Hazzard, Hutchinson, & Krawiecki, 1990). 
1.3.1.2 Disease-related correlates 
 In general, chronic health conditions of longer duration are associated with lower 
adherence (Brownbridge & Fielding, 1994; Rapoff, 2010).  In diabetes, research indicates that 
adherence deteriorates significantly over time, with the emergence of non-adherence being 
particularly evident an average of three and half years after the onset of the disease (Jacobson, 
Hauser, Lavori, Wolfsdorf, Herskowitz, & Milley, 1990).  There tends to be an oscillation of 
symptoms over time with many chronic health conditions and Rapoff (1989, pg.42) suggests that 
“adherence may be particularly difficult to sustain during periods when patients are relatively 
asymptomatic.”  Intuitively, the severity and frequency of symptoms and greater disease severity 
overall should motivate adherence in patients as they are likely to want to improve their 
situation.  Although greater disease severity has been related to higher adherence (Rapoff et al., 
2005), it is not always the case.  Some studies have shown for example, that increased symptom 
frequency and higher disease severity is associated with lower adherence to treatment 
(Brownbridge & Fielding, 1994; Feldman et al., 2007).  However, it may well be likely that 
because the above studies assessed adherence and symptoms concurrently rather than 
longitudinally, lower adherence actually produced the increased symptom frequency and overall 
deterioration. 
 The actual disease severity is not the only factor which can have an influence on 
adherence to treatment.  The patient and parent perceptions of severity have also been found to 
play an important role.  For example, the perceived severity of disease as reported by patients 
and parents were found to have greater predictive validity of adherence than those of providers 
(Rapoff & Barnard, 1991).  In addition, while patient perceptions of higher severity have been 
associated with lower adherence (Gudas et al., 1991) maternal perceptions of higher severity 
have been associated with better adherence (Radius et al., 1978).  Although increased parental 
monitoring and encouragement have been implicated in the explanation for the above findings, 
the fact that some studies suggest that patient and parent perceptions are differentially related to 
adherence have yet to be fully explained.        
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1.3.1.3 Regimen-related correlates 
Treatment regimens that are highly complex, long-term and interfere with other aspects 
of a person’s life may act as a barrier and have been associated with low levels of adherence 
(Turk & Meichenbaum, 1991; Lemanek, Kamps, & Chung, 2001; Feldman et al., 2007; April, 
Feldman, Zunzunegui, & Duffy, 2008).  In countries that do not provide state-run healthcare, 
treatment costs can be prohibitive for some families.  One study, for example, found that for 
parents with children diagnosed with paediatric rheumatic diseases, 41% said they had difficulty 
paying for physician-related charges and 25% said they had problems paying for medications 
(McCormick, Stemmler, & Athreya, 1986).  In contrast, a more recent study found that lower 
medication costs were related to higher adherence for children with asthma (Bender, Pedan, & 
Varasteh, (2006). 
Many treatments for chronic health conditions produce negative side effects.  This is not 
a phenomenon restricted only to chemically derived treatments.  Chest physiotherapy for patients 
with CF, for example, helps to effectively clear the lungs of excessive mucus but results in 
paroxysms of coughing and gagging (Allen, Panitch & Rubenstein, 2010).  However, 
surprisingly few studies have examined the influence of side-effects on adherence to treatment in 
children and adolescents.  In those that have, unpleasant-tasting medications have been related to 
lower adherence (Radius et al., 1978; Celano, Geller, Phillips, & Ziman. 1998).  Patient and 
parent perceptions of the efficacious nature of prescribed treatments have also been found to 
influence adherence.  In asthma and diabetes for example, higher levels of perceived benefits as 
rated by patients and parents have been associated with improved adherence (Bobrow et al., 
1885; McCaul et al., 1987).  
1.3.2 Theories and models of adherence to treatment 
1.3.2.1 The Health Belief Model 
 Social cognition models (i.e., those predominantly based on the assumption that the way 
in which people behave in social situations is a function of rational information processing and 
perceived individual cognitions) examine the precursors and predictors to health behaviours.  
Over the past five decades, the Health Belief Model (HBM: Rosenstock, 1974; Janz & Becker, 
1984) has been one of the most widely used theories in health behaviour research.  Although 
originally developed in the 1950s in order to predict preventative health behaviours (such as the 
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uptake of preventative screening programmes for hypertension), the HBM was later extended in 
an attempt to better understand adherence to prescribed treatment regimens (Taylor, 2006). 
In addition to specific demographic variables, the HBM posits five major components 
that help to predict or explain adherence (see Figure 1):  Firstly, “perceived susceptibility” 
(including the patient’s perceived risk of contracting or re-contracting a condition or the level of 
acceptance associated with an existing condition); secondly, “perceived severity” (which 
includes the patient’s evaluation of the medical and social consequences of contracting an illness 
or not receiving appropriate treatment); thirdly, “perceived benefits” (including the patient’s 
judgement of the likely benefits of adhering to medical advice or treatment); fourthly, “perceived 
barriers” (including the patient’s perception of obstacles weighed up against the likely benefits of 
adhering to medical advice or treatment); and finally, “cues to action” (internal and external 
cues, such as increased symptoms or being reminded by others). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The Health Belief Model 
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There have been several studies in the adult literature that support the predictions of the HBM for 
a wide range of health practices (Becker, 1974; Norman & Fitter, 1989; Harrison, Mullen, & 
Green, 1992).  There is also correlational support for components of the HBM in the child and 
adolescent adherence literature (Rapoff, 2010).  Although the HBM is one of the only health 
behaviour theories to have been adapted for use within child and adolescent chronic health (The 
Children’s Health Belief Model: CHBM), just one analogue study has tested the model’s 
predictive validity.   Bush & Iannotti (1990) found that 63% of the variance in children’s 
expected use of medication was predicted by the CHBM, with perceived severity and perceived 
benefit accounting for the majority of this. 
 Despite the above evidence, the HBM has been criticised on a number of grounds 
including for: the variations in the way the model’s variables have been conceptualised and 
measured; the focus placed on the conscious processing of information; its emphasis on the 
individual without due consideration for the influence of wider social and environmental 
influences; the way it suggests that behaviours can be predicted by attitudes and beliefs despite 
evidence to the contrary; and for the absence of the role of emotional factors such as fear and 
denial (Stroebe & Stroebe, 1995; Ogden, 2004; Rapoff, 2010).                
1.3.2.2 The Theory of Planned Behaviour 
 The Theory of Planned Behaviour (TPB: Ajzen, 1988) is an extension of the earlier 
Theory of Reasoned Action (TRA, Fishbein & Ajzen, 1975) and stresses behavioural intentions 
as the outcome of a permutation of numerous beliefs.  The theory suggests that intentions should 
be conceptualised as “plans of action in pursuit of behavioural goals” (Ajzen & Madden, 1986, 
pg. 455) and are determined by three major factors (see Figure 2): “attitude towards the 
behaviour” (including both positive and negative beliefs regarding the performing of a specific 
behaviour and the potential consequences involved); “subjective norms” (incorporating the 
perceived views of important people in the person’s life about whether they approve or 
disapprove of the behaviour in question and the person’s motivation to comply with these 
views); and “perceived behavioural control” (the individual’s perception as to whether 
performing the behaviour is easy or difficult based on a consideration of internal skills and 
abilities and external obstacles and opportunities, both of which are influenced by previous 
behaviour). 
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Figure 2: The Theory of Planned Behaviour 
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correlational studies have found support for the major components of the theory (Ajzen, 1991; 
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2006) which found that a medium-to-large change in intention (d=0.66) led to only a small-to-
medium change in behaviour (d=0.36).  The authors concluded that although intentions do have a 
significant impact on behaviour, they are less important than what correlational studies have 
previously suggested. 
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1.3.2.3 The Self Regulatory Model 
 The Self Regulatory Model (SRM: Leventhal, 1993; Leventhal, Zimmerman, & 
Gutmann, 1984) is based on approaches to problem solving and attempts to explain the way in 
which individuals perceive, conceptualise (form representations of a health threat) and cope with 
the problem of illness (including their emotional response to the health threat) in order to re-
establish their state of health.  The model incorporates three main stages of adaptation to illness 
(see Figure 3): “interpretation” (the patient’s attempts to make sense of their perceived 
symptoms); “coping” (adaptive and maladaptive ways of dealing with the problem in order to 
regain a sense of balance); and “appraisal” (the assessment of how successful, or otherwise that 
the coping stage has been).  The model is described as “self-regulatory” because the above three 
components interrelate in order to maintain a state of equilibrium (i.e., health).  The model 
proposes that illness disrupts normality and the individual is motivated to return to a “normal”, 
healthy state. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The Self Regulatory Model 
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A meta-analytic review of the SRM (Hagger & Orbell, 2003) demonstrated theoretically 
predictable relations between illness cognitions, coping and outcomes across the reviewed 
studies.  In addition, the review also indicated that individual tests of illness cognitions, coping 
behaviours and illness outcomes found that moderate-to-strong relationships existed between 
these variables.  In terms of adherence, Gonder-Frederick and Cox (1991) found that patients 
with diabetes used perceived symptoms to indicate their blood glucose levels and to guide self-
treatment.  A further study demonstrated that patients who believed their hypertension was an 
acute condition were less likely to continue taking their preventative medication than those who 
believed it to be a chronic condition (Meyer, Leventhal, & Guttman, 1985).  However, there have 
been a number of studies that have failed to show direct relationships between illness perceptions 
and levels of adherence, leading to criticisms of the SRMs utility and forcing research attempts 
to focus more on specific beliefs about treatment in a search for improved cognitive predictors 
(Marteau & Weinman, 2004).        
1.3.3 Interventions to improve adherence to treatment 
Although the above research and theoretical models may have advanced our 
understanding about the factors which influence adherence to treatment, research efforts have 
also concentrated on the ways in which adherence to treatment can be improved.  Much of this 
research has focussed on adult populations (Peterson, Takiya, Finley, 2003; Haynes, Yao, 
Degani, Kripalani, Garg, & McDonald 2005; Kripalani, Yao, & Haynes, 2007; Williams, Manias 
& Walker, 2008).  However, the evidence base regarding the effectiveness of interventions 
designed to increase adherence in children and adolescents is beginning to grow.  Although 
strategies that address issues such as depression or family systems difficulties have been 
proposed, adherence intervention strategies are usually categorised into three main groups: 
educational (i.e., providing more detailed information regarding treatment instructions or how to 
use medical equipment); organisational (i.e., improving healthcare provider communication or 
simplifying medical regimens); and behavioural (i.e. matching adherence behaviour with positive 
or negative consequences or modifying the environment to encourage better adherence) 
(Lemanek et al., 2001).  A recent review which meta-analysed 71 studies found that adherence to 
interventions across all three categories (educational, organisational and behavioural) increased 
adherence and resulted in positive health benefits for children with chronic illnesses (Graves, 
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Roberts, Rapoff, & Boyer, 2010).  In addition, the authors of the study found that the impact on 
health outcomes may be more compelling when educational and behavioural strategies were 
combined.  They did note however, that participant and methodological characteristics appear to 
influence intervention effect sizes and caution of the existence of significant heterogeneity within 
the data sets. 
Intervention studies are often hampered by difficulties in defining what constitutes 
adherence, the methods used to assess adherence and the designs used to assess multi-component 
intervention programmes (Lemanek et al., 2001).  In addition, van Dulmen and colleagues (van 
Dulmen, Sluijs, van Dijk, de Ridder, Heerdink, & Bensing, 2007) have criticised intervention 
studies for failing to provide a theoretical explanation of the operating mechanisms at work, 
resulting in an overall lack of explanatory power.  They suggest that a general lack of specific 
theories that adequately predict and explain non-adherence is one of the reasons for this.  
Overall, despite good progress having been made it has been suggested that there is still much to 
achieve with regards to adherence interventions for children and adolescents with a chronic 
health condition (Butz, 2006; Graves et al., 2010; Kahana, Drotar, & Frazier, 2008; Pai & Drotar, 
2010). 
1.3.4 Summary 
 Poor adherence to treatment in childhood chronic health conditions is a significant 
problem and can contribute to a number of serious consequences including increased morbidity, 
mortality and lowered quality of life.  Correlational research has demonstrated that adherence is 
influenced by a number of patient and family, disease-related and regimen-related attributes.  A 
number of theories and models have been proposed which attempt to better explain and predict 
the likelihood of adherence.  However, research on the effectiveness of these models is 
predominantly focussed on the adult population with fewer studies examining their use for child 
and adolescent adherence.  Although the models and research have advanced our understanding 
and enabled the development of interventions designed to improve adherence, much has yet to be 
achieved in this area and adherence problems prevail. 
1.4 Cystic fibrosis 
Cystic fibrosis (CF) is the most common life-threatening inherited disease amongst 
Caucasians (Davis, 2001; Walters & Mehta, 2007).  The disease is characterised by generalised 
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dysfunction of the exocrine glands and predominantly affects the respiratory and digestive 
systems.  With approximately 4% of the UK population carrying the recessive gene, birth 
prevalence rates in the UK are frequently cited as 1:2,000/2,500 live births (Bobadilla, Macek, 
Fine & Farrell, 2002; Dodge, Lewis, Stanton, & Wilsher, 2007).  CF was once regarded as an 
almost universally fatal childhood genetic disorder (Allen, et al., 2010) but life expectancy for 
people with CF has vastly improved in recent years, attributable largely to improvements in the 
management and treatment of the condition.  However, the benefits of improved treatment are 
dependent on adherence to the regimen, which remains problematic. 
 
1.4.1 Adherence to treatment in CF 
The daily treatment regimen for people with CF is burdensome and includes dietary 
management, vitamin supplementation, pancreatic enzyme replacement therapy, oral antibiotics, 
aerosol therapy (e.g., nebulised antibiotics, mucolytics and bronchodilators), exercise, chest 
physiotherapy and postural drainage (Arias Llorente, Bousono Garcia, & Diaz Martin, 2008; 
Thomson & Harris, 2008; McColley, 2010).  The situation is compounded for those individuals 
with additional co-morbidities (such as CF-related diabetes), as further treatments are also then 
required.  In the CF population, adherence to the treatment regimen is generally low with 
estimates varying according to age, type of treatment, and method of measurement (Abbott, 
Dodd & Webb, 1996; Zindani, Streetman, Streetman & Nasr, 2006; Barker & Quittner, 2010).  
Adherence to dietary recommendations, for example, has been recorded at 40% to 50% for adults 
(Abbott, Dodd, Bilton, & Webb, 1994) with rates of 16% to 20% being found in children 
(Anthony, Paxton, Bines & Phelan, 1999).  In child and adolescent populations adherence to 
pancreatic enzyme replacement therapy is reportedly very high (Modi, Lim, Yu, Geller, Wagner 
& Quittner, 2006) whereas particularly low levels are reported for chest physiotherapy (Quittner, 
Drotar, Ievers-Landis, Seider, Slocum, & Jacobsen, 2000).  In a study of children with CF 
designed to examine adherence to a number of treatment elements using multiple methods of 
assessment, Modi and colleagues (Modi et al., 2006) reported adherence rates ranging from 67% 
to 100% for self-report measures and 22% to 71% for more objective measures (e.g., pharmacy 
refill history and electronic monitors).  Each of the methods of measurement described in the 
above study has their own relative strengths and weaknesses and have been utilised in numerous 
studies investigating adherence in the CF population.  The variability of the methods of 
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measurement used may be an important factor when accounting for the inconsistency observed 
in studies of adherence (Modi et al., 2006; Duff & Latchford, 2010a).  
1.4.1.1 Measuring adherence to treatment in CF 
Patient and parent self-report is practical and inexpensive and is the most commonly used 
method of measuring adherence (Bryon, 1998; Rapoff, 1999; Burkhart & Dunbar-Jacob, 2002).  
Although the method is flexible and can be adapted to measure all of the treatment regimen 
components, self-report is often unreliable.  The measure is subjective and has been shown to be 
highly influenced by social desirability and recall biases leading to an over-estimation of 
reported adherence (Quittner, Modi, Lenmanek, Ievers-Landis, & Rapoff, 2008; Barker & 
Quittner, 2010).   
The daily phone diary (DPD) method has been utilised extensively in US CF populations 
and attempts to elicit information regarding activities over the last 24 hours in an less obtrusive 
manner (Quittner et al., 2008).  In doing this, the DPD method attempts to reduce social 
desirability bias and has been reported as demonstrating good reliability and validity (Quittner & 
Espelage, 1999).  However, the DPD method is still a form of self-report with other 
disadvantages including: the researcher having to be specially trained in its use; the time-
consuming nature of collecting data; and the complex nature of the resulting information (Modi 
& Quittner, 2006). 
Pharmacy databases record details of the type, quantity and dates of refills of medication 
dispensed and this information has also been utilised for the purposes of studying adherence in 
CF (Riekert, Mogayzel, Bilderback, Hale, & Boyle, 2007).  In identifying those patients who 
refill and fail to refill their prescriptions, a global estimate of adherence and non-adherence can 
be calculated for research purposes.  However, whilst this may provide accurate information for 
classifying those patients who fill in and collect their repeat prescription, pharmacy data only 
circuitously indicates whether medications were consumed or taken as directed (Myers & 
Midence, 1998; Briesacher, Andrade, Fouayz, & Chan, 2008).  In addition, they may fail to 
capture those medications dispensed directly within hospital settings (Modi et al., 2006). 
Electronic monitoring devices (EMDs) which utilise microchip technologies are 
considered a more objective and valid method of measuring adherence (Bender, Milgrom, & 
Apter, 2003).  In studies of CF, several EMDs have been used to measure adherence including 
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Medication Event Monitoring System (MEMS) caps (i.e., a cap which records medication bottle 
openings) and inhalation devices (Latchford, Duff, Quinn, Conway, & Conner, 2009; 
McNamara, McCormack, McDonald, Heaf, & Southern, 2009; Dziuban, Saab-Abazeed, 
Chaudhry, Streetman, & Nasr, 2010).  Although EMDs can provide an accurate and detailed 
measure of the date and time of treatment behaviour, there are certain difficulties associated with 
specific devices.  MEMS caps, for example, measure the frequency of the medication bottle 
being opened but do not necessarily measure whether the medication has been taken or not 
(Myers & Midence, 1998).  Although considered more valid, the results from studies utilising 
nebulisers may still be confounded due to inaccurate device technique and the phenomenon of 
“dumping” (i.e., administering and discarding excessive doses of medication) (Otsuki, Clerisme-
Beaty, Riekert, & Rand, 2008). 
The advent of Adaptive Aerosol Delivery™ (AAD) technology – which only 
electronically records nebuliser use on breath inhalation – provides a useful solution to 
“dumping” and progresses towards offering a “gold standard” measure of adherence (Duff & 
Latchford, 2010a).  McNamara and colleagues (McNamara et al., 2009) utilised one such device 
(I-neb™, Respironics, Chichester, UK) in a recent study designed to determine adherence to 
aerosol therapy in a paediatric CF population.  The I-neb™ device has a built-in Patient Logging 
System (PLS) capability which consists of a memory chip that can record up to 4000 treatments.  
PLS data from the I-neb™ was downloaded and used to calculate morning, evening and overall 
monthly adherence to aerosolised antibiotic therapy for over a year in a sample of children and 
adolescents infected with Pseudomonas aeruginosa (a naturally occurring bacteria, which if 
chronically established can lead to greater symptom severity and rapid decline in lung function 
for patients with CF) (Thomson & Harris, 2008).  Although overall monthly adherence was 
maintained between 60% and 70% over the year, considerable variation both between and within 
participants was demonstrated and adherence was found to be better in the evening than it was in 
the morning.  There are a number of potential explanations for these findings, but in the absence 
of detailed qualitative information exploring the experiences of adhering to aerosol therapy, 
further elucidation is not possible. 
For patients with CF, aerosolised treatments are used almost universally.  Newer AAD 
devices (such as the I-neb™) use electronic technology to adjust the timing of aerosol delivery to 
the patient’s individual breathing pattern.  This helps to counteract some of the difficulties 
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associated with older, continuously operating nebuliser devices where it was common for over 
half of the drug to be wasted while the patient exhales (Kesser & Geller, 2009).  Unlike the 
older, conventional nebulisers, the I-neb™ device is battery operated, silent, smaller and more 
portable.  The liquid-crystal-display screen incorporated into the I-neb™ provides the user with 
continuous feedback on the device functions along with more tactile patient feedback (i.e., the 
use of a cascading vibration system) at the end of a completed treatment (Denyer & Dyche, 
2010).  Denyer and Nikander (2010) suggest that “the combination of a high lung deposition, 
minimal loss of aerosol during exhalation, and short nebulisation times makes the I-neb AAD 
System especially valuable to patients that are on multiple daily nebulisation treatments, are 
using drugs that should not be wasted into the room air, or would benefit from a more efficient 
delivery system” (pg.57).  Indeed, studies investigating the acceptability of the device have 
found that the majority of patients rated the I-neb™ as either easy or very easy to use (Denyer, 
Black, Nikander, Dyche, & Prince, 2010; Denyer, Prince, Dixon, Agent, Pryor, & Hodson, 
2010).  The PLS capability provides additional feedback and can be actively utilised by 
clinicians to objectively monitor their patients and identify those who are not adhering to their 
aerosol therapy treatment (Denyer & Dyche, 2010).  However, despite the technological 
advances in systems used to deliver aerosol therapy treatments and the greater patient 
acceptability of these devices, adherence rates remain relatively low (Latchford et al., 2009; 
McNamara et al., 2009).  This is problematic given the prominence of aerosolised treatments in 
current CF drug-delivery regimens and the likely increase of their use in the future (Cystic 
Fibrosis Foundation, 2010; Duff & Latchford, 2010a). 
1.4.1.2 Correlates of adherence to treatment in CF 
Although studies have only recently begun to examine adherence difficulties to specific 
components of the treatment regimen in CF (e.g., Modi & Quittner, 2006), more general research 
on barriers to adherence has attempted to gain a greater understanding of what makes treatment 
problematic for patients and their families.  Much of this research has focussed on the adult CF 
population (e.g., Abbot et al., 1994; Conway, Pond, Hamnett, & Watson, 1996; Abbot & Gee, 
1998) and echoes the more general situation outlined earlier regarding chronic health condition 
studies investigating adult as opposed to child and adolescent adherence. 
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However, the last decade in particular has seen an increase in the number of research 
studies examining adherence within the child and adolescent CF population.  It has been 
consistently demonstrated in CF for example, that age plays a significant role; adherence 
decreases as children transition to adolescence with the poorest rates occurring at around the age 
of 16 (Quittner, et al., 2000; Zindani et al., 2006; Riekert, et al., 2007).  Foster and colleagues 
(Foster et al., 2001) suggest that parental involvement in early childhood may explain higher 
levels of adherence as do Modi et al (Modi, Marciel, Slater, Drotar, & Quittner, 2008) whose 
research demonstrated better adherence for both preadolescents (ages 8 – 11) and adolescents 
(ages 11 – 16).  These findings contrast with Drotar and Ievers (1994), however, who found that 
increased parental involvement was associated with lower levels of adherence.  The role of the 
family does appear to be important, with one longitudinal study demonstrating how family 
dysfunction can discourage optimal treatment adherence and, in turn, negatively impact on CF 
health outcomes (Patterson, Budd, Goetz, & Warwick, 1993).  In contrast, family cohesion and 
positive social support has been associated with better adherence to treatment both within 
chronic illness and within CF (Eddy, Carter, Kronenberger, Conradsen, Eid, Bourland, & 
Adams, 1998; Foster et al., 2001; DiMatteo, 2004).  The finding that parents and the family may 
be an important factor associated with adherence to treatment in CF is perhaps unsurprising 
when considering Bronfenbrenner’s (1977) Ecological Systems Theory.  A core principle of this 
theory is the notion of reciprocity, both between individuals and their environment and between 
individuals within the system.  The system clearly extends beyond the immediate family unit and 
so the finding that peer support for both CF patients and parents is thought to be an important 
factor associated with improved adherence (Barker, Cohen, Driscoll, Modi, Quittner, 2008) is 
again not surprising.  
A lack of treatment specific knowledge and misunderstandings regarding treatment 
requirements have been identified as further contributors to poor adherence in CF (Koocher, 
McGrath, Gudas, 1990; Modi & Quittner, 2006).  Ievers-Landis and colleagues (Ievers-Landis, 
Brown, Drotar, Caplan, Pishevar, & Lambert, 1999) reported these gaps and misunderstandings 
to be as high as 33% for mothers with school-aged children.   
Perhaps unsurprisingly, the time consuming and complex nature of the treatment regimen 
in CF has also been shown to contribute significantly to poor adherence in children and 
adolescents (Modi & Quittner, 2006; Williams, Mukhopadhyay, Dowell, & Coyle, 2007; Bucks, 
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Hawkins, Skinner, Horn, Seddon, & Horne, 2009; Bregnballe, Schiøtz, Boisen, Pressler, & 
Thastum, 2011).  Linked to the problem of time-management is the issue of forgetfulness (both 
intentional and unintentional) which has been found to act as another barrier to optimal 
adherence (Modi & Quittner, 2006; Dziuban et al., 2010; George, Rand-Giovannetti, Eakin, 
Borrelli, Zettler, & Riekert, 2010; Bregnballe et al., 2011). 
In examining adherence in children and adults with CF, Arias Llorente and colleagues 
(Arias Llorente et al., 2008) reported that treatment adherence decreases as the disease becomes 
more severe.  These results are in contrast to other studies however, which demonstrate an 
increase in treatment adherence with severity of CF (Michaud, Frappier, & Pless, 1991; Zindani 
et al., 2006).  In attempting to explore the relationships between illness perceptions, emotional 
representations, treatment beliefs and reported adherence in CF, Bucks and colleagues (Bucks et 
al., 2009) found that adolescents reported doubts about the necessity of chest physiotherapy and 
antibiotics.  Along with unrealistic beliefs about the chronicity of CF, these treatment beliefs 
were significant predictors of poor adherence.  The authors argue that their findings provide 
preliminary support for components of Leventhal’s Self-Regulatory Model (Leventhal, 1993; 
Leventhal et al., 1984) in explaining adherence in adolescents with CF.  They do express caution 
in interpreting the results of their study however, not least because of the problems highlighted 
above in relying on self-report to measure adherence outcomes. 
1.4.1.3 Interventions to improve adherence to treatment in CF 
A better understanding of the factors affecting adherence has enabled a limited number of 
interventions – designed to increase adherence to treatment in the CF population – to be 
developed and studied.  Stark et al (Stark, Quittner, Powers, Opipari-Arrigan, Bean, Duggan, & 
Stallings, 2009) for example, found that a combined group behavioural and nutrition education 
intervention, that involved both parents and children successfully increased adherence to dietary 
intake in children with CF.  In their systematic review, Bernard & Cohen (2004) found that 
behavioural techniques (e.g., behavioural modification and token economies) can increase 
adherence to diet and chest physiotherapy in CF.  However, the authors make a number of 
recommendations for future research and in particular suggest that CF research should diversify 
away from an emphasis on studies examining Caucasian females in the preadolescent age group.  
At present, there are no published studies that have examined the effectiveness of interventions 
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specifically designed to improve adherence to aerosol therapy (Duff & Latchford, 2010b).  
Again, as highlighted earlier, this is somewhat concerning when taking into account the 
importance of this type of therapy in the CF treatment regimen. 
1.5 Rationale for the current study 
Notwithstanding the difficulties associated with measurement, it is clear from examining 
the literature that adherence to treatment in CF is generally poor, and subject to the influence of a  
number of interacting factors, particularly in children and adolescents where the context of the 
family adds a further layer of complexity.  Barker & Quittner (2010) have attempted to discuss 
these complex interactions by proposing a developmental, biopsychosocial model of the disease 
that “highlights the bidirectional influences of age-related development on disease management 
and progression” (pg. 468).  Psychological and social factors are clearly important with Dziuban 
et al (2010) suggesting that in addition to the findings described above, other obstacles to 
treatment adherence “may lie deeper in the psychosocial framework” (pg. 456).  This may well 
be true, with one study finding that parents were actually unable to identify what was hindering 
their child’s adherence to aerosolised therapies perhaps suggesting the possible influence of 
deeper, less conscious processes (Modi & Quittner, 2006). 
Technological advances in systems and devices designed to administer aerosol therapy 
have resulted in treatments becoming quicker and more effective.  However, studies utilising 
intelligent data downloaded from these devices indicate that adherence rates to aerosol therapy 
remain low.  The absence of detailed qualitative information exploring the experiences of 
adhering to aerosol therapy has resulted in potential explanations for these findings being 
difficult to ascertain.  In addition, while much has been achieved in recent years in terms of 
interventions designed to treat adherence problems and thus maximise treatment potential 
(Bernard & Cohen, 2004; Kahana, et al., 2008); gaining a more detailed understanding of the 
factors influencing adherence to specific components of the CF treatment regimen may be 
essential if successful interventions are to continue being informed and further developed.  This 
is true for aerosol therapy, particularly within the adolescent CF population where adherence is 
low but fewer interventions have been specifically targeted (Duff & Oxley, 2007; McNamara et 
al., 2009; Duff & Latchford, 2010b). 
 28 
The above discussion highlights the need and value of utilising qualitative methodologies 
in attempting to uncover the likely, deep-rooted, multi-factorial influences on adherence to 
specific components of the treatment regimen within the adolescent CF population. 
1.5.1 Introducing the current study 
With the influence of parents and the family clearly being an important factor associated 
with adherence in adolescents, a need exists for a richer and more detailed understanding from 
both a patient and a parent perspective as to the process of adherence to treatment in CF.  The 
paucity of research examining adherence to specific components of the treatment regimen, 
particularly within the adolescent CF population, makes it especially important to gain this more 
focussed understanding.  With the prominence of aerosol therapy in current CF drug-delivery 
treatment regimens and the likely increase of their use in the future, it seems prudent to prioritise 
this as an area of enquiry.  Further benefits lie in the ability of AAD devices to provide an 
objective and accurate measure of adherence to aerosolised therapy treatments thus enabling 
accounts of adherence to be anchored in everyday life and understood in the context of day-to-
day behaviour. 
The current study, therefore, was designed to elicit the perspectives of adolescent patients 
and their parent on adhering to aerosol therapy.  In order to reduce potential bias and maximise 
the potential for obtaining rich and detailed accounts, it was decided to use qualitative methods 
and to interview patient and parent about their experiences of adherence over recent weeks. To 
provide a cue to participants about the actual rates of adherence, and to prompt discussion of 
particular events, the ability of the I-neb™ device to produce data on its use was utilised to 
provide a diary for each participant showing actual rates of adherence day-by-day for the 
previous week.  It is hoped that the findings of the study will complement and extend the 
previous research on adherence to treatment in CF and help to inform clinical and research 
practice. 
1.5.2 Research questions 
• How is the process of adhering to aerosol therapy experienced by both an adolescent 
patient and a parent? 
• What are the differences and commonalities in the experience of aerosol therapy 
compared to the other therapies used in CF? 
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• Does the use of PLS data downloaded from the I-neb™ device help to qualitatively 
explore the process of adhering to aerosol therapy? 
1.5.3 Research aim 
To qualitatively explore the process of adhering to aerosol therapy from both an 
adolescent patient and a parent perspective and to utilise a seven-day retrospective adherence 
data download taken from the I-neb™ device in order to further elucidate this process. 
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2.0 METHOD 
2.1 Design 
A qualitative research design employing semi-structured, face-to-face interviews was 
used for the purpose of this study.  The semi-structured interviews were conducted with six 
adolescent CF patients and their parent (n=12) on an individual, separate basis in an attempt to 
illicit participants own experiences, understandings and perspectives of the process of adhering 
to aerosol therapy treatment.  In order to anchor experiences in real life examples, part of the 
interview was guided by a seven-day retrospective printout of the Patient Logging System (PLS) 
data downloaded from the I-neb™ device.  The data generated from the interviews were 
transcribed and then analysed using the Grounded Theory Method (GTM).  The systematic 
coding of the data enabled the emergence of core categories which were then structured and 
presented as a separate theoretical formulation which represented both the parent and adolescent 
experiences of the process of adhering to aerosol therapy treatment. 
2.2 Methodological considerations 
This study used the GTM as the overarching approach to data collection and analysis.  
The following section will briefly outline the purpose of qualitative research, describe the GTM 
method and provide a rationale for its use. 
2.2.1 Qualitative research 
 Qualitative research seeks to provide rich and detailed descriptive accounts of the 
phenomenon under investigation (Geertz, 1973; Ritchie & Lewis, 2003; Smith, 2008).   In 
psychology, qualitative research is primarily concerned with accessing and exploring 
participants’ own unique meanings attached to their behaviour, thoughts and feelings (Willig, 
2008).  The ability of a qualitative approach in “exploring, describing and interpreting the 
personal and social experiences of participants” (Smith, 2008, pg. 2) positions it as a particularly 
useful methodology in attempting to address the main aim of this study. 
Qualitative research however, is not a homogenous speciality.  There are a variety of 
qualitative approaches that gather under the umbrella term of “qualitative methodology”.  
Methods such as grounded theory (Glaser & Strauss, 1967), interpretative phenomenological 
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analysis (IPA: Smith, 1996) thematic analysis (Braun & Clark, 2006) and discourse analysis 
(Potter & Wetherell, 1987) each have their own theoretical and methodological commitments.  
Although diverse in their application, there are some important recurrent themes within all 
qualitative research methodologies which suggest that significant similarities exist.  Miles and 
Huberman (1994) summarise these recurrent features which include: the commitment of 
qualitative research to study phenomenon in naturalistic settings; the fact that the method is 
inductive, with the participant often leading the process of data generation; the fact that most 
analyses are conducted on words (e.g., written accounts or interview transcripts); and the fact 
that the researcher is viewed as an “instrument” within the study who plays a central role in 
making sense of and interpreting the phenomenon under investigation. 
Whilst a number of qualitative approaches are available, it will be argued that the GTM is 
the most suitable approach for the purpose of this research. 
2.2.2 Description of the Grounded Theory Method 
The term “Grounded Theory” relates both to the result of an overall methodological 
approach to research (i.e., a way of developing a theory that has been generated and is therefore 
“grounded” in data) and a specific set of methods, principles and procedures used for data 
analysis that was first advocated by sociologists Barney G. Glaser and Anhelm L. Strauss in the 
1960’s (Henwood & Pidgeon, 2006).  Although the above distinction may appear relatively 
straightforward, this explicit difference between “methodology” and a “set of methods” is often 
absent within the literature and can lead to confusion, particularly for those relatively new to the 
subject (Charmaz, 2008). 
Qualitative methods were viewed with suspicion in the 1960’s and criticised for being 
unsystematic, anecdotal and biased (Charmaz, 2006).  Glaser and Strauss’s seminal text – The 
Discovery of Grounded Theory (1967) – is often described as “cutting-edge” because it 
challenged that view and the dominance of sophisticated quantitative methodologies that were 
rooted in positivism (i.e., assuming a belief in scientific objectivity, logic and truth) and very 
much favoured by the scientific community at that time (Charmaz, 2008).  The book aimed to 
legitimise rigorous qualitative research and support its own intrinsic value and integrity that was 
distinct from quantitative research (Bigus, Hadden, & Glaser 1982).  Denzin & Lincoln (1994) 
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argue that their book was a key force that helped to spearhead the “qualitative revolution” that in 
the latter part of the twentieth century was gaining momentum. 
 Since the publication of The Discovery of Grounded Theory (1967) the authors have 
seemingly evolved and developed the GTM in divergent directions; Glaser (1978) arguing for a 
strict positivist approach to data with the researcher remaining entirely objective compared to 
Straus who, along with later collaborator Juliet Corbin (Straus & Corbin, 1990), suggested that 
data needed to be reduced into more manageable forms with some level of researcher 
interpretation a necessity.  Further diversification occurred with the development of Charmaz’s 
(1990; 2000) Constructivist GTM.  Her version emphasises how “data, analysis, and 
methodological strategies become constructed, and takes into account the research contexts and 
researchers’ positions, perspectives, priorities, and interactions” (Bryant & Charmaz, 2007, pg. 
10).  Although debates as to the relative merits of a Glaserian, Straussian or Constructivist 
approach continue (e.g., Boychuk-Duchscher & Morgan, 2004), some argue that dividing the 
GTM into these rigid categories is not particularly helpful (Annells, 1996; Birks & Mills, 2011). 
Heath and Cowley (2004) agree and suggest that researchers – particularly those new to 
the GTM – should select the approach that best suits their style and enables them to achieve an 
appropriate and useful grounded theory.  Birks & Mills (2011) concur with this position and 
argue that methodologically “there are no right or wrong approaches to using grounded theory 
methods” (pg. 8).  Bryant and Charmaz (2007) have suggested that instead of viewing grounded 
theory methods as detailed, rigid prescriptions for research practices and procedures, researchers 
should treat them as heuristics and guidelines which provide tools to use as opposed to recipes to 
follow. 
2.2.3 Rationale for using the Grounded Theory Method 
In considering some of the background, debates and processes associated with the GTM, 
one can appreciate its position as a popular and useful qualitative approach to research.  Birks & 
Mills (2011) argue that an integrated and comprehensive grounded theory that explains a process 
associated with a given phenomenon is the final product of a grounded theory study.  They 
suggest that it is suitable to use when little is known about the area of study and when the desired 
outcome is the generation of a theory with explanatory power.  It is for these main reasons that 
the GTM has been selected as the most appropriate to utilise for the purpose of this study. 
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Although other qualitative methodologies were considered – in particularly IPA (Smith, 
1996) and thematic analysis (Braun & Clark, 2006) – they did not enable the development of a 
theoretical formulation which assisted in enhancing the understanding of the process of adhering 
to aerosol therapy from a patient and parent perspective.  Furthermore, the chief investigator has 
a preference for the GTMs emphasis on taking a systematic, step-by-step approach to analysing 
data.  As the chief investigator had prior knowledge of the adherence literature, this systematic 
approach was particularly helpful in reducing potential bias.  
2.3 Ethical Considerations 
2.3.1 Ethical Approval 
The study was originally reviewed by an independent academic panel at The University 
of Leeds in November 2010.  A full ethics application was then submitted to the NHS National 
Research Ethics Service (NRES).  This was reviewed by the NRES Yorkshire and the Humber 
committee in July 2011.  Following the satisfactory completion of some minor amendments, the 
study was granted ethical approval on 12th September 2011 (see Appendix 1).  The amendments 
included some minor details being added to the participant information sheets, the inclusion of a 
standardised letter to be sent to the participants’ general practitioner and for boxes that enabled 
the participants to initial each question answered to be added to the consent form.  NHS 
Research and Development approval was obtained from the Leeds Teaching Hospitals NHS 
Trust on 10th October 2011 and from Alder Hey Children's NHS Foundation Trust on 17th 
September 2011. 
2.3.2 Informed Consent 
It was important that the participants were able to give informed consent to take part in 
the study.  Participants were approached by the CF specialist physiotherapist during routine 
outpatient appointments, not the chief investigator.  Interested participants were provided with 
information sheets appropriate to their age.  One was for those participants aged 11 to 13 (see 
Appendix 2), one was for those aged 14 to 16 (similar to Appendix 2), and one was for the parent 
(see Appendix 3).  Participants had the opportunity to ask questions about the study at this time 
and again when the chief investigator contacted them.  If they agreed to take part, then the 
written consent form (see Appendix 4) was completed at their follow-up outpatient appointment. 
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2.3.3 Anonymity 
The dignity, rights, safety and well-being of participants was an absolute priority 
throughout the process of conducting the research.  This included the assurance of anonymity.   
Participants were informed that the seven-day retrospective PLS data downloaded from the I-
neb™ device would be fully anonymised and sent via secure e-mail correspondence by the 
specialist CF physiotherapist to the chief investigators NHS Net mail account ahead of the semi-
structured interview.  In addition, an I.D. number was given for each participant and used on all 
interview recordings and transcripts.  Any identifiable person or place name was removed from 
the transcript.  During the process of analysis, pseudonyms were used to ensure that any quotes 
selected to feature as part of the results would not easily identify the participants. 
2.4 Sampling 
The study used aspects of “purposeful sampling” (i.e., whereby the researcher actively 
seeks participants who offer a rich source of information that will likely help to meet the overall 
research aim) in that only those who had experience of using the I-neb™ device for at least the 
last 12 months as part of their treatment regimen were invited to take part.  However, the CF 
physiotherapist approached these potential participants in order of their attendance at routine 
appointments to reduce bias.  In this way, a selection of patients typically encountered within 
routine clinical practice (and their parents) was selected to take part in the study. 
2.4.1 Participants 
Participants were adolescents and parents recruited from two regional paediatric CF 
centres: Leeds General Infirmary (LGI) and Alder Hey Children’s Hospital (AHCH), Liverpool.  
A total of six adolescent participants aged 11 – 16 were recruited (three from each centre).  
Parents of the participants were also recruited, resulting in a total sample of N=12.  Those 
identified as the primary caregiver, most commonly mothers (Timko, Stovel & Moos, 1992) 
were invited to take part.  Adolescents were eligible for participation if they were 11-16 years of 
age, had a confirmed diagnosis of CF via sweat testing and had been using the I-neb™ device for 
at least the last 12 months as part of their treatment regimen.  Participants were excluded from 
the study if they were under 11 years or over 16 years of age.  They were also excluded from the 
study if they were not deemed clinically stable (i.e., if they had had an FEV1 reading <50% over 
the last 12 months). 
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2.5 Recruitment of participants 
After ethical approval was granted, a list of patient names who met the inclusion criteria 
was compiled by the specialist CF Physiotherapists at LGI and AHCH.  Potential participants 
(adolescent patient and their parent) who met the inclusion criteria were approached about the 
study by the CF physiotherapists during their routine outpatient appointment.  This was done on 
a first-come, first-served basis (i.e., the patients who had their outpatient clinics scheduled at the 
earliest date were the first to be approached).  Interested patients and their parent received an 
information sheet (one for the patient using age appropriate language and one for the parent) 
regarding the study and were encouraged to ask questions.  At this point, the next outpatient 
appointment was arranged for approximately 6 weeks time by the CF Physiotherapists as 
standard.  Interested participants were informed that the chief investigator would telephone 
potential participants to answer any further questions they may have about taking part in the 
study and to arrange a convenient time for the potential interview to take place (i.e., within 7 
days after the next outpatient appointment).  The chief investigator also telephoned the 
participants the day before their next scheduled outpatient appointment to remind them both of 
the importance of bringing along the I-neb™ to their appointment and of the date and time of the 
pre-arranged semi-structured interview. 
Participants attended their next scheduled outpatient clinic appointment as planned and 
were again provided with the original participant information sheet in order to reiterate that their 
PLS data routinely downloaded within the outpatient clinic appointment would be sent via secure 
e-mail correspondence by the specialist CF physiotherapist to the chief investigators NHS net e-
mail account ahead of the semi-structured interview.  Participants were then asked to sign a form 
which consented to their anonymised adherence data being sent to the chief investigator and 
which consented to them taking part in the study.  The anonymised PLS data downloaded from 
the I-neb™ at the outpatient clinic appointment was then sent via secure e-mail correspondence.  
The chief investigator met the participants at the scheduled time in order to conduct the semi-
structured interview.  Participants predominantly requested that home interviews were conducted 
as these were the most convenient. 
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2.6 Data collection 
2.6.1 Interview schedule 
Two interview schedules were used; one for the adolescent patient (see Appendix 5) and 
one for their parent (see Appendix 6).  Although both were similar, the interview schedule that 
was devised for the adolescent patient used language that was slightly easier and more 
appropriate for the participants’ level of development.  Each interview schedule was based upon 
the recommendations made by Charmaz (2006) and consistent of 11 open-ended questions that 
were simple, clear, brief, forthright and jargon-free (see Appendix 5 and 6).  Each of the 11 
questions had associated prompts that were designed to elicit full and rich accounts from the 
participants.  The interview schedule for the adolescents was designed to elicit a description of 
the experience of adhering to aerosol therapy.  For the parents, the schedule was designed to 
elicit a description of their experiences of their child adhering to aerosol therapy. 
The development of the interview schedule took place over a number of weeks.  Charmaz 
(2006 pgs. 30-31) provides a series of sample grounded theory interview questions and many of 
these were adapted and used to develop the initial interview schedule for the current study.  The 
draft questions were discussed and revised during a pre-arranged supervision session.  The 
resulting draft interview schedule was piloted on a trainee clinical psychology colleague and an 
adolescent family member, with the resulting suggestions for improvements in the phrasing of 
the questions being made.  Further information about how the interview schedule was used 
alongside the Patient Logging System data is provided in section 2.6.3. 
2.6.2 Patient Logging System data 
The third generation AAD system nebulizer – the I-neb™ (see Figure 4) has a built-in 
Patient Logging System (PLS) capability which consists of a memory chip that can record up to 
4000 treatments.  Every nebulised dose of medication is recorded as an individual line of data 
and includes the time and date, drug code, dose delivered (either Full, <12.5%, or between 
>12.5% and <100%), breathing mode (Tidal Breathing Mode [TBM] or Target Inhalation Mode 
[TIM]) and duration of treatment.  The I-neb™ deice is able to transmit this recorded PLS data to 
a PC via an infrared interface. 
It was the most recent seven days worth of this PLS data (downloaded as standard within 
the outpatient appointment) that was anonymised and sent via secure e-mail to the chief 
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investigator ahead of the pre-arranged semi-structured research interview.  This information was 
then transferred onto a more easy-to-read sheet that resembled a seven-day diary (see Appendix 
7).  This information was presented to the parents and adolescents to assist them in reflecting on 
their recent experiences of adherence to aerosol therapy and to guide some of the questions on 
the interview schedule. 
 
Figure 4: The I-neb Adaptive Aerosol Delivery (AAD) System 
2.6.3 Semi-structured interviews 
For their convenience, the participants decided who was to be interviewed first.  Based on 
the guidelines suggested by Fylan (2005, pp. 69-74), the chief investigator attempted to establish 
and maintain rapport with participants throughout the interview process.  The use of the 
interview schedules allowed sufficient structure to focus the interview although the use of “topic 
prompts” allowed for flexibility and ensured that an over-reliance on fixed questions was 
avoided.   The order of questions was changed on an ad hoc basis depending on the specific 
idiosyncrasies of each interview.  The PLS data was used to guide some of the open-ended 
interview questions which allowed participants to reflect on their recent experiences of adhering 
to aerosol therapy over the previous week.  As the interviews progressed, it was noticeable that 
the chief investigator attempted to ensure that the PLS data was introduced earlier on in the 
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interview process as this was proving to offer valuable insight into the participants lived 
experiences and encouraged interesting reflections on specific adherence situations.  The 
majority of interviews lasted approximately one hour each, and were all conducted in private. 
2.7 Data analysis 
The data analysis process was guided in particular by the models used by Straus and 
Corbin (1990) and Charmaz (2006).  The coding process began with transcription of all the 
interviews which were then subjected to the structured process of open, axial and theoretical 
coding.  These coding methods will be outlined in the following section along with a worked 
example to illustrate the process more fully.  Data analysis was supported by a number of other 
techniques commonly used within the GTM including constant comparison, memo writing and 
diagramming.  These techniques will also be outlined before moving on to describe the tools 
used to ensure that the overall quality of the data analysis process was maintained. 
2.7.1 Transcribing 
All of the digitally recorded interviews were transcribed by a trained third party.  All 
recorded interviews and subsequent interview transcripts were password protected.  The chief 
investigator listened back to all of the recorded interviews alongside the transcript to ensure 
accuracy and to enable familiarity with the participants’ narrative accounts (Henwood & 
Pidgeon, 2006). 
2.7.2 Coding 
Bryant and Charmaz (2007) offer a very straightforward definition of coding in the GTM: 
“Coding is the process of defining what the data is about” (pg.605).  In the GTM, this defining of 
data is done in a series of stages.  The open coding process begins by analysing the transcripts 
line-by-line and assigning a code to each.  Axial coding is a method of grouping these open 
codes into a series of emerging categories.  Finally, theoretical coding attempts to identify the 
possible relationships between these categories which are then used as hypotheses to be 
integrated into a theoretical formulation of the overall process.  The constant comparison of 
incidents within the data, incidents with categories, categories with other categories and 
categories with emerging theoretical propositions is a method used throughout the lifetime of the 
project.  Memos of the researcher’s thoughts (from initial and basic to more advanced and 
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theoretical) are used alongside coding and constant comparison with the explicit aim of taking 
conceptual development forward.  Closely related is the use of diagrams which create a visual 
display that helps to conceptually map analysis throughout the entire process. 
Before moving on to describe each of these methods in more detail, a diagram of the 
overall process outlined above is shown for the current study in Figure 5.  
 
 
 
 
 
 
 
 
 
Figure 5: The GTM data analysis process 
2.7.2.1 Open coding 
The initial process of open coding is used to “fracture the data” (Glaser & Strauss, 1967) 
so as to compare incident with incident, name emerging patterns or apparent phenomena and 
instigate the practice of comparison between the codes applied.  When coding, Charmaz (2006) 
agues for the use of gerunds (i.e., verbs used as nouns that always finish with ‘ing) as a way of 
discovering process in the data in addition to focussing on the participant’s experiences as a 
source of conceptual analysis.  In this way, codes are prevented from being used simply as a 
descriptive summary of an event; enabling the first level of interpretation to begin by assigning a 
label to a unit of meaning (Strauss & Corbin, 1990). 
The chief investigator began the open coding process by working through a transcript, 
and assigning a code to each line of text.  Glaser (1978) poses three questions to be asked of the 
data, with Charmaz (2006) adding a forth: what is this data a study of?; what category does this 
incident indicate?; what is actually happening in the data?; and from whose point of view?  The 
chief investigator utilised these questions throughout which helped to preserve the data analysis 
process and allowed different theoretical possibilities to remain open (Charmaz, 2006).  
Although parent and adolescent transcripts were analysed separately, they were also analysed 
concurrently (i.e., a parent transcript was analysed and then an adolescent transcript was 
Raw Data 
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Open Coding 
 
Parent: 436 
 
 Adolescent: 362  
Axial Coding (stage 2) 
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Axial Coding (stage 1) 
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Constant Comparison 
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Constant Comparison 
Diagramming Memos 
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analysed and vice versa).  This enabled the process of constant comparison both within and 
between transcripts and helped to prevent the forcing of data into a preconceived framework 
(Glaser, 1992).  The line-by-line open codes for each transcript were written on post-it notes 
(with the associated page number) and transferred to the back pages (see Appendix 8).  The chief 
investigator regularly returned to the open codes, using the above questions to ensure that the 
meaning captured was accurate.  Those codes that did not were re-categorised or removed.  The 
initial stage of open coding produced 436 codes for the parent analysis and 362 codes for the 
adolescent analysis.  An example of the open coding process is shown in Table 1. 
Table 1: Example of the open coding process 
2.7.2.2 Axial coding 
Data analysis continues with axial coding, which was described by Strauss and Corbin (1990, 
pg.96) as “a set of procedures whereby data are put back together in new ways after open coding, 
by making connections between and within categories”.  Stage one of axial coding is where open 
codes are compared and reviewed both within and between transcripts in order to find 
similarities in meaning.  In the current study, all of the generated open codes were written onto 
the back of each transcript (see Appendix 8) to enable this comparison to take place. 
Strauss & Corbin (1998) suggest that similar codes are then grouped together into 
emerging subcategories that begin to form the initial analytic framework.  These axial code 
subcategories (and associated open codes) in the current study, were written onto the back of 
each transcript (see Appendix 9).  At this stage, 436 open codes for the parent data were reduced 
Quote from participant Example of open coding 
Parent 3: “I like to know she’s done it [aerosol 
therapy] because if she hasn’t done it I worry and 
again it’s, she’ll say I’m a control freak and I 
probably am a bit but having had all the years where I 
had complete control over her treatments to almost 
having no control at all now, erm yeah  
I like to remind her, just check in my own 
mind that she’s done it.    
Monitoring adherence 
Feeling worried 
Child’s frustration 
Behaviour has an impact 
Having control over treatments 
Feeling out of control 
Supervising strategy 
Reminding reduces parental anxiety 
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to 112 axial code subcategories.  For the adolescent data, 362 open codes were reduced to 87 
axial codes. 
The second stage of axial coding aims to link the subcategories to the emerging core 
categories and asks how they are related (Charmaz, 2006).  In the current study, this was 
achieved by transferring each axial code subcategory onto a post-it note and arranging them 
diagrammatically on large pieces of card (see section 2.8.3).  Memo writing was used alongside 
this process to capture analytical thoughts and to help drive the development of theoretical ideas 
(see section 2.8.2).  Strauss and Corbin (1990) advocate the use of diagrams such as these from 
the commencement of a study in tandem with the writing of memos.  In this second stage, 112 
axial code subcategories for the parents were reduced and organised hierarchically underneath 42 
final subcategories and 9 core categories.  For the adolescents, 87 axial code subcategories were 
reduced and organised into 37 final subcategories which sat under 9 core categories.   
The process of regular supervision at this stage helped to provide a more objective view 
of the emerging conceptual organisation of subcategories.  To provide an illustrative example of 
the progression from open to axial coding, the open codes from Table 1 have been used to show 
how the coding process developed (see Table 2). 
Table 2: Example of the axial coding process 
2.7.2.3 Theoretical coding 
Although the core categories and subcategories had been developed, they lacked an 
overall theoretical structure.  Glaser (2005) suggests that this is not uncommon and argues that 
Open code Axial code subcategory 
Monitoring adherence 
Feeling worried 
Child’s frustration 
Behaviour has an impact 
Having control over treatments 
Feeling out of control 
Supervising strategy 
Reminding reduces parental anxiety 
Reminding 
Anxiety and worry 
Child feeling emotional 
Responsibility, independence and the developing child 
Feelings of control 
Feelings of control 
Reminding 
Reminding / Anxiety and worry 
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theoretical coding, although difficult, helps to form a theory which explains how categories 
relate to each other.  He goes on to say that theoretical codes can be drawn from existing theories 
to assist in theoretical integration.  In using this method, Birks and Mills (2011) suggest that 
“explanatory power is added to the final product of a grounded theory study by situating it in 
relation to a theoretical body of knowledge.” 
In the current study, the post-it note diagrams were used alongside theoretical memos to 
arrange the core categories into a coherent story which best reflected the experiences of the 
participants.  This enabled the development of a theoretical formulation which described the 
process of adhering to aerosol therapy from both a parent and adolescent patient perspective.  
Table 3 provides an illustrative example of how the open and axial code subcategories relate to 
the core categories and processes described in the theoretical formulation for the parent data. 
To reduce subjectivity, research supervision was used to check that the theoretical 
formulation best represented the participants’ narrative accounts.  This enabled the formulation 
to be openly discussed and refined. 
2.8 Other procedures in the methodology 
2.8.1 Constant Comparison 
 As previously highlighted, constant comparison is an important feature of the GTM and 
was used throughout the process of analysis in the current study.  Bryant and Charmaz (2007) 
define constant comparison as a “method of analysis that generates successively more abstract 
concepts and theories through inductive processes of comparing data with data, data with 
category, category with category, and category to concepts” (pg.607). 
At the level of open coding, parent and adolescent data were compared both within and between 
transcripts and coded repeatedly, enabling any new codes to be checked against existing ones.  
At the level of axial coding, constantly comparing potential subcategory codes enabled them to 
be checked to see if they were describing the same phenomena.  At the level of theoretical 
coding, comparing the emerging theoretical formulation with the participant accounts within the 
raw data helped to ensure that the resulting grounded theory best represented the experiences of 
the parents and adolescents.
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Table 3: Example of the overall data analysis coding process 
 
 
Open code Axial code subcategory Core Category Process described 
Monitoring adherence 
Feeling worried 
Child’s frustration 
 
Behaviour has an impact 
 
Having control over treatments 
Feeling out of control 
Supervising strategy 
Reminding reduces worry 
Reminding 
Anxiety and worry 
Child feeling emotional 
 
Responsibility, independence 
and the developing child 
Feelings of control 
Feelings of control 
Reminding 
Reminding / Anxiety and worry 
Strategies and behaviours 
Emotional drivers 
Parent’s experience of their 
child’s adherence behaviour 
Parent and adolescent 
relationship 
Emotional drivers 
Emotional drivers 
Strategies and behaviours 
Strategies and behaviours 
and Emotional drivers 
Cognitive, affective and behavioural 
Cognitive, affective and behavioural 
Parent’s interaction with their child 
 
Parent’s interaction with their child 
 
Cognitive, affective and behavioural 
Cognitive, affective and behavioural 
Cognitive, affective and behavioural 
Cognitive, affective and behavioural 
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2.8.2 Memo writing 
Memos have been described by Clarke (2005) as “intellectual capital in the bank.”  
Memos are a written record of a researchers thinking throughout the process of undertaking a 
GTM study.  The chief investigator found that numerous memos were stimulated during the 
different stages of coding.  Henwood & Pidgeon (2006) suggest that the content of memos 
should not be constrained in any way and can include hunches and insights, comments about 
specific codes and categories, deliberations about refinements and explanations of 
modifications to categories.  Memos were kept on post-it notes and used to record exactly the 
types of content recommended above.  There were used as both a helpful memory aid during 
the analytic process and as an essential tool in the development of the overall theoretical 
formulation.  An example of a memo is shown in Figure 6.  In addition to using memos, the 
researcher kept a reflective research journal which was used primarily to capture thoughts 
immediately after conducting the semi-structured interviews.  These journal entries were a 
valuable source of data when compiling the participant pen portraits (see section 3.2).  
 
 
 
 
 
 
 
Figure 6: Example of a memo 
2.8.3 Diagramming 
 Strauss and Corbin (1990) advocate the use of diagrams from the beginning of a study 
in tandem with the writing of memos.  Birks and Mills (2011) suggest that diagramming 
whilst concurrently analysing data enables a greater sense of organisation of ideas.  They go 
on to say that although initial coding may result in messy and intricate diagrams, more neat 
and simple diagrams will evolve as the researcher moves through axial and theoretical coding 
Memo date: 13.04.12 
Parent 3: “I like to know she’s done it because if she hasn’t done it I worry and 
again it’s, she’ll say I’m a control freak and I probably am a bit but having had all 
the years where I had complete control over her treatments to almost having no 
control at all now, erm yeah I like to remind her, just check in my own mind that 
she’s done it” (Page 21: 907-913) 
 
Anxiety and worry is present and appears to be driving reminding behaviour?  Her 
daughters account suggest that reminders can help but are frustrating (pg. 13 356-
562) 
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stages.  Diagramming was used in the current study throughout the three main stages of 
analysis.  The fact that axial codes were kept on small post-it notes enabled large A1 size card 
diagrams to constantly evolve throughout the coding process.  The process of diagramming 
was particularly helpful during axial and theoretical coding as a way of visually representing 
how the categories related to each other and how the processes described by the participants 
interacted with one another.  Appendix 10 shows a picture of a diagram used during the axial 
coding stage of the parent data analysis. 
2.9 Quality control 
2.9.1 Supervision 
Regular research supervision was arranged throughout the entire study.  Supervision 
was particularly helpful during the process of data analysis.  The systematic and visual 
approach adopted during data analysis enabled supervision to be used in a variety of ways to 
ensure adequate quality controls were in place.  This included, for example, the checking of 
line-by-line initial codes, making comments and observations about axial codes and ensuring 
that the theoretical formulation could be further developed and refined.  Minutes of the 
research supervision sessions were kept so as to provide a record of detailed discussions.  
This approach enabled the maintenance of an “audit trail” which Burns (1989) argues is a 
major factor in ensuring methodological and procedural rigour.  Furthermore, being able to 
bring examples of the A1 sized card diagrams and copy’s of memos into supervision helped 
the research supervisor to make comments and suggestions that were based upon a visual 
representation of the chief investigators thought processes throughout the various stages of 
data analysis. 
The chief investigator also attended a peer supervision group facilitated by an 
academic supervisor with decades of experience in qualitative methodologies.  The peer 
supervision group provided additional support and helped to ensure that the data analysis 
process could be openly discussed and commented upon. 
Although the use of supervision helped to reduce subjectivity, it is recognised that 
some form of researcher interpretation of the data is inevitable.  This is discussed in more 
detail in section 2.9.3.    
2.9.2 Consideration of other methods of quality control 
 There were other methods of quality control that were considered for use within the 
current study including inter-rater reliability and respondent validation.  Although some 
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argue that estimates of inter-rater reliability (i.e., whereby different observers attempt to 
replicate the process of coding and calculate a percentage of agreement) should be included 
in qualitative studies (e.g., Lincoln & Guba, 1985) others suggest that the method is 
inappropriate for qualitative inquiry because the concept is based on positivist assumptions 
(Bogdan & Biklen, 1992; Marshall & Rossman, 1995).   Goodwin and Goodwin (1992) 
further argue that although reliability and validity are relevant to qualitative research, 
“empirical estimation is difficult to impossible" (pg.416) and make concepts which rely on 
these techniques (such as inter-rater reliability) meaningless, particularly when one considers 
the ontological and epistemological foundations of qualitative methodology.  Although 
estimates of inter-rater reliability were considered as a method of quality control in the 
current study, it was decided that efforts would be directed at ensuring adequate 
methodological and procedural rigour was maintained as opposed to utilising a technique that 
may not prove to be helpful or appropriate. 
     Respondent validation (i.e., whereby participants are asked to comment upon and 
critically analyse the coding process and/or the overall study findings) has received support 
as a helpful method of ensuring the overall validity of qualitative research (Smith, 2008).  
However, time constraints and the disparate geographical locations of the chief investigator 
and the participants did not make this technique a viable proposition.    
2.9.3 Potential researcher bias 
Numerous commentators have highlighted the need for researchers to be aware of 
their own potential biases and the way in which these can influence the overall research 
process (Bryant & Charmaz, 2007; Smith, 2008).  Birks and Mills (2011) argue that the use 
of memos, reflective writing and the overall maintenance of an audit trail promote reflexivity 
and help the researcher to remain alert to the influence of potential biases.  These techniques 
were used throughout the study and have been described in detail above.  In addition, the 
following section will provide a brief description of the chief investigator and potential 
sources of bias.  These biases are further considered in section 4.8.1. 
2.9.3.1 Introducing the chief investigator 
 The chief investigator is a 35 year old, white, male psychologist in clinical training 
from Northern Lincolnshire.  Prior to entering clinical psychology training, he worked within 
a large public health department where he became interested in health behaviour research and 
the wider determinants of health.  These interests led to further academic study and he 
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completed an MSc in Health Psychology in 2009.  Although he had prior knowledge of the 
adherence literature, this understanding was not in-depth and he was keen to delay a thorough 
review of the existing literature (so as to prevent existing theories and knowledge impacting 
on the study processes and outcomes) until after the data analysis was complete.  While this 
was not entirely possible, due to the submission of an earlier researcher proposal, he returned 
to the literature to review this more thoroughly following the completion of the results 
chapter. 
 The chief investigator’s recent clinical work has focussed on providing psychological 
support for adult patients with chronic physical health conditions such as heart disease, 
cancer and diabetes.  He takes a person-centred approach to his clinical work and is 
influenced (and utilises) the ideas in cognitive behavioural, psychodynamic and systemic 
approaches.  Prior to beginning the research study, he had never met anyone diagnosed with 
CF.  He reflected both in his research journal and within supervision about his feelings 
towards the parent and adolescent participants.  These primarily focussed on the admiration 
felt towards the participants for coping with the very real demands of living with CF.  He also 
felt very privileged to hear the participants’ accounts and was humbled by their experiences.  
This led to a passion for the research and a hope that the study findings would add to the 
existing research on adherence in CF. 
 The chief investigator has conducted a number of previous qualitative studies but had 
no prior experience of using the GTM. 
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3.0 RESULTS 
3.1 Sample 
 12 participants (six child-parent dyads) took part in this study.  The adolescent 
participants were all between the ages of 11 and 16 years.  The parents taking part were 
predominantly mothers, with only one of the participants being a father.  As explained in the 
methodology section, it was anticipated that more mothers than fathers would respond to the 
invitation to take part.  Table 4 provides basic demographic details of the child-parent dyad 
participants along with information relating to the child’s aerosol therapy regimen.  
Pseudonyms have been given to each participant in order to maintain confidentiality. 
   
Table 4: Participant demographic information (N=12) 
Participant* Gender  Age at 
interview 
Number of 
aerosolised 
treatments 
prescribed 
Average 
7-day 
adherence 
rate (%) 
Average 7-
day doses 
fully 
administered 
(%) 
Mode of 
administration 
** 
Average 
treatment 
administration 
time 
(minutes) 
         
Karen 
 
Female  16 1 28.57 14.29 TBM 10 
Mary 
 
Female  43 - - - - - 
         
Tom 
 
Male  11 1 100 100 TIM 1 
Pippa 
 
Female  39 - - - - - 
         
Amanda Female  14 1 71.43 42.86 TIM 12.2 
         
Carla Female  45 - - - - - 
         
Elizabeth 
 
Female  13 2 100 92.86 TIM 2.64 
Greg 
 
Male  46 - - - - - 
         
David Male  12 2 85.71 85.71 TIM 1 
         
Lindsey Female  37 - - - - - 
         
Simon Male  13 2 92.86 92.86 TIM 4.23 
         
Pam Female  42 - - - - - 
         
 
Note: 
* Names have been changed to maintain confidentiality 
** Mode of administration: TBM = Tidal Breathing Mode; TIM = Target Inhalation Mode 
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3.2 Pen Portraits 
 The purpose of providing a pen portrait of each parent-adolescent dyad is to introduce 
the reader to the sample of participants by providing some more detailed background 
information.  By including a description of some demographic details, background and 
interests and the parent and adolescent experiences of CF it is hoped that a more complete 
picture is provided.  This section also includes some of the author’s own impressions which 
were formed throughout and immediately after the semi-structured interview and written 
down within a reflective research journal.  The participants’ interactional style – including 
non-verbal aspects of the process – along with the richness and quality of their narrative 
account are reflected upon here.  There will also be a summary of the emerging main themes 
that the analysis of each individual transcript uncovered in addition to some reflections on the 
parent and adolescent relationship. 
 
Karen and Mary 
Karen 
Karen was aged 16 at the time of the interview and was studying at a local community 
college.  She was diagnosed with CF shortly before her second birthday.  She described not 
being affected particularly badly by CF but found the treatment regimen a burden and said 
that she goes through stages of not taking her treatment.  Approximately three years ago she 
was diagnosed with CF related diabetes and this caused her significant emotional distress.  
She struggled to effectively manage the diabetes in the initial stages following diagnosis and 
was recently fitted with an insulin pump which she says has helped her to feel more in control 
of her treatment. 
 Karen described leading a very active social life.  She was keen to be interviewed 
before her mother as she was due to go out and meet with her boyfriend and friends that 
evening.  She had commented before the interview started that she really did not know why 
she often failed to take her aerosol therapy and was concerned that she would have little to 
say.  However, as the interview progressed she was able to speak quite openly about CF and 
her treatment.  Although at times she was unable to maintain eye contact and appeared a little 
distracted, she was not particularly difficult to engage in conversation and provided some 
detailed responses to the interview questions. 
 Karen did not like the fact that she had to sit and concentrate in order to effectively 
take her aerosol therapy.  She described it being different to her tablets, inhaler and insulin 
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pump because it took longer to do and was inconvenient.  She described often forgetting to 
take her aerosol therapy and when she did remember she would get distracted quite easily by 
the television, mobile phone or puppy which resulted in lengthier and less optimum treatment 
administration.  On the one hand she said that she needed to be reminded to take her 
medication but on the other hand she found being prompted frustrating and at times this was a 
source of conflict with her mother. 
 
Mary 
Mary is a single mother of two and was aged 43 at the time of the interview.  She 
lives with her eldest son (19) and Karen.  Mary found it difficult to hide her frustration 
relating to her daughters non-adherence and at times got quite emotional in the interview.  
She was hopeful for Karen’s future but was holding on to a great deal of worry and anxiety 
regarding the very serious potential health consequences of her not taking her treatment.  My 
initial impressions were that she was exasperated by the daily process of taking responsibility 
for her daughter’s treatment and the constant struggle to attempt to encourage her to adhere. 
The analysis of the transcripts confirmed these initial impressions.  Mary seemed to 
have got to a point where she recognised the need for her daughter to start taking greater 
responsibility for her treatment but was reluctant to relinquish control.  She described the 
burden of guilt she carried when she knew that Karen had not been taking her aerosol therapy 
and this could sometimes lead to conflict with her daughter.  Karen’s recent request to take 
more responsibility of her treatment was welcomed on the one hand but not taken particularly 
seriously on the other.  Karen’s busy lifestyle and the impression she gives that taking her 
treatment is not an important priority seemed to be preventing her mother from trusting her 
with more responsibility.  However, when tensions in the house were high, Mary said that she 
had begun to stand back and at times disengage from the treatment process as she feels that 
she has tried her best and failed. 
 
Tom and Pippa 
Tom 
 At age 11, Tom was the youngest participant to be interviewed.  He had recently 
moved up from his Primary School and said he was enjoying the increased responsibility of 
High School.  He described in detail his busy school days which he said started early because 
of his CF treatment.  Although he was diagnosed with CF at age 7, he said he could not really 
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remember this and commented that living with CF was “a bit of a pain”.  He said that his 
friends did not really understand his illness and throughout the interview it was apparent that 
he saw CF as making him different from others. 
 Tom really enjoyed playing on his Xbox and watching TV but also said he spent a lot 
of time playing outside and meeting up with his friends at the skatepark to ride on his scooter.  
He described resenting his treatments, particularly his physiotherapy and his nebuliser 
because they took up so much of his time.  Although he said that his nebuliser was quick and 
easy to take, he did not like the fact that he had to take this alongside his physiotherapy.  He 
described being in a consistent routine with his treatments but that this sometimes changed at 
the weekend depending on what activities he or his family was engaged with. 
 Overall, Tom was a pleasant character who spoke with maturity about his aerosol 
therapy treatment.  He was uncertain as to the actual purpose of his aerosol therapy treatment 
but had a sense that it “kept him healthy”.  Although he appeared a little under-confident at 
the beginning of the interview, he became much more engaged in the process as the interview 
progressed. 
 
Pippa 
 Pippa lived with her two daughters (7 and 9), Tom and her husband.  She was aged 39 
at the time of the interview.  She described a very busy daily routine which at times she said 
she felt overwhelmed with.  Similarly to Tom, she described having some resentment towards 
his aerosol therapy treatment.  This ill feeling was mainly directed at the amount of time it 
took to effectively clean the aerosol therapy device and the fact that she was unsure whether 
the treatment was actually having any beneficial effect.  A number of recent hospital 
admissions for her son coupled with the burdensome nature of the daily treatment regimen 
appeared to be contributing to her current state of mind.  However, it was clear that she 
would do whatever it took to attempt to keep her son healthy and described feelings of guilt 
even at the thought of not adhering because of her own frustrations. 
 Pippa was engaged throughout the interview and provided a rich and detailed account 
of her and her son’s experiences of living with CF.  I got the sense that she really wanted to 
help me to understand the daily struggle of living with the condition and some of the 
associated worry and anxiety.  I came away from the interview with a genuine sense of 
admiration for Tom, Pippa and their family. 
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Amanda and Carla 
Amanda 
 Amanda was aged 14 at the time of the interview.  She described enjoying school with 
her favourite subject being art.  She was keen to show me some of her favourite drawings and 
engage in general conversation reflecting her warm and friendly approach throughout the 
interview.  Although she had a busy social life within and outside of school, at times she 
came across as quite a shy girl who was very modest about her own abilities. 
 Amanda described finding her CF a “bit annoying” but said that she had never lived 
without it so had just got used to living with the condition.  She said she found it frustrating 
that her family and friends did not really understand what it is like living with CF and having 
to take treatments, including her aerosol therapy.  She was very computer literate and said she 
spent a lot of time on Facebook.  She had developed a friendship on Facebook with another 
girl her age that had CF and she said that it was good to be in regular contact with someone 
who understood what it was like to live with the condition. 
 Amanda said she did not particularly like having to take her aerosol therapy as it got 
in the way of her doing other things and found it a particular burden when she was prescribed 
more than one aerosolised treatment.  She said she often got distracted whilst taking her 
aerosol therapy by the computer, mobile phone or the TV and that this often frustrated her 
mum.  However, she said she was reasonably consistent when it came to adhering to her 
aerosol therapy treatment.  There was some uncertainty about whether she found it easier to 
take her aerosol therapy during the school week or at the weekend, but said that it was 
probably easier when she was at school because she was in a consistent routine. 
 
Carla 
 Carla was aged 45 at the time of the interview and lived together with her husband 
and Amanda’s brother who was 17.  She worked part-time and although she did not 
particularly enjoy her job, she was very grateful that they were flexible with her hours when 
it came to caring for Amanda.  She enjoyed exercising and had to start the day very early to 
ensure she could incorporate an early morning work-out before beginning the process of 
helping Amanda with all of her treatments. 
 Carla was a very straight-talking, practical woman who discussed the importance of 
establishing a regular routine when it came to Amanda’s CF treatment.  She said she felt she 
did everything she could to make the process of Amanda adhering to her treatments as simple 
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as possible and described finding it frustrating when her daughter procrastinated with taking 
her aerosol therapy or forgot to take it altogether.  She said she often worried about 
Amanda’s CF and was keen to monitor her daughter’s adherence to aerosol therapy; often 
using frequent daily reminders in an attempt to provide some peace of mind. 
 Carla described her and her daughter being very similar.  She said they had a good 
relationship and were very close.  Although she would sometimes get frustrated with Amanda 
when it came to taking her aerosol therapy, she described having a lot of empathy for her 
daughter about having to take so many treatments.  She was very engaged throughout the 
interview and provided some very helpful insights.  However, it was clear that she was keen 
to press on with the discussion as she had a number of treatment-related tasks to complete 
that evening in addition to cooking the family meal perhaps reflecting the daily effort 
involved with caring for a child with CF. 
 
Elizabeth and Greg 
Elizabeth 
 Elizabeth was 13 at the time of the interview and attended the local comprehensive 
school.  She was a friendly and intelligent girl who enjoyed sporting activities and led a very 
active life.  She took a very practical approach towards her CF and seemed keen to dismiss 
any of the potentially emotional aspects of living with the disease.  She was prescribed two 
aerosolised treatments per day which she said she usually took in the evening.  She had been 
diagnosed with CF related diabetes approximately two years ago and although she said that 
this was an inconvenience, she again described taking a pragmatic approach to the 
management of the illness.  Her parents separated approximately 6 years ago and she spent 
roughly an equal amount of time living between the two homes during the week.  She kept 
one I-neb™ device at her father’s house and one at her mother’s. 
 Elizabeth described her school week as very planned and organised.  She said that 
taking her I-neb™ had been part of her daily routine for a number of years and felt that this 
had enabled her to treat adhering to her aerosol therapy as a “part of life”.  Analysis revealed 
a strong sense of knowing what her treatments were for and feeling that her aerosol therapy 
kept her well.  There were themes of her two aerosolised therapy treatments being dependent 
upon each other and the necessary planning that was needed in order to reduce the 
inconvenience that this caused.  Her sense that her aerosol therapy was usually taken in the 
evenings was confirmed by the downloaded data.  Analysis revealed a very busy morning 
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routine which she said prevented the I-neb™ from being taken at this time.  Evenings were 
seen as more relaxing, but there was still a very clear structure in place which involved her 
adhering to her treatments. 
Although Elizabeth took on most of the responsibility for preparing and cleaning the 
I-neb™, support from her family was a consistent theme.  It was clear that she valued 
occasionally being prompted if her father had noticed that she may have forgotten to take her 
I-neb™.  However, I got the sense that Elizabeth was something of a perfectionist and she did 
comment that she gets frustrated with herself if she forgets to take her aerosol therapy.  
Although she said that she prefers not to take her I-neb™ in front of her friends, she 
described a consistent and supportive friendship group who knew about her CF. 
 
Greg 
 Greg was the only father taking part in the study and was aged 46 at the time of the 
interview.  Elizabeth spent three to four nights a week living with her father and his partner in 
their home, with the rest of the week being spent living with her mother.  My initial 
impressions were that he was a very welcoming man who had a great deal of involvement 
with his daughter’s treatment regime and life in general.  He also appeared to be a very 
practical man and it was perhaps unsurprising that he placed a great deal of value on 
routinised behaviour when taking into account his ex-forces background.  Although this 
straightforward and practical approach perhaps led to his accounts being less in-depth than 
some of the other participating parents, he was a very articulate man and engaged well with 
the interview process. 
 The analysis revealed substantial positivity toward the I-neb™ device with Greg 
referring to it as “a great piece of kit”.  There were strong beliefs about the value of the 
aerosol therapy and the way that it prevented pseudomonas and hospital admissions.  So 
strong were these beliefs that he said that he would “fight hammer and nail” to ensure the 
hospital staff continued to prescribe it.  The TIM mouthpiece was a welcomed addition to the 
I-neb™ and he was in no doubt that this had reduced his daughter’s administration times and 
given her back some free time during the evening.  He valued being able to see the 
downloaded data and was clearly very impressed both with his daughters 100% adherence 
rate over the preceding week and the short administration times.  He said that this represented 
a typical week and said that it would be more uncommon if his daughter had missed her 
treatment. 
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 There were strong themes around viewing aerosol therapy as a part of life and 
allowing his daughter the responsibility of being able to get on with it and “not make a fuss 
about it”.  Although he felt that there were few issues with adherence, he did say that 
mornings were too busy to effectively take the I-neb™, preferring evenings when things were 
more relaxed.  He also felt that school days were easier to take the I-neb™ than weekends 
because the consistency of the routine during the week allowed for effective planning.  The 
same was true for term-time versus holidays and he added that it was much more difficult to 
effectively prepare and clean the I-neb™ when on holiday.  However, he did say that efficient 
planning could usually overcome these difficulties perhaps representing his strong beliefs that 
his daughter’s aerosol therapy was an essential part of life that could not be compromised.   
 
David and Lindsey 
David 
 David had been admitted to hospital for a routine procedure at the time of the 
interview, so I agreed to meet with him on the ward as this was more convenient for the 
family.  He was 12 at the time of the interview.  He was very easy to engage in conversation 
although he sometimes found it difficult to stick to the topic under discussion.  He would 
often provide very succinct answers to open questions that were relevant to the study.  He 
was very passionate about his guitar playing and said that he enjoyed school. 
 David appeared to be a very confident and independent boy who took an impressive 
amount of responsibility for his treatments.  He said that he frequently prepared and 
administered the aerosol therapy treatment himself and then cleaned the I-neb™ device 
afterwards.  He said that he did not mind taking his aerosol therapy as it tasted quite nice.  He 
understood the purpose of taking his I-neb™ and said that he would usually adhere to the 
treatment every day.  He enjoyed playing outside with friends and said that the sooner he got 
his aerosol therapy “out of the way” the quicker he could go out to play. 
 
Lindsey 
Lindsey was 37 at the time of the interview.  She lived with her husband, her daughter 
who was 11, and David.  She worked within the NHS and was very knowledgeable about her 
son’s condition.  Although she was not currently at work, she said that she enjoyed her job.  
She came across as very outgoing and seemed keen at the beginning of the interview to 
engage me in conversation about the role of a psychologist.    
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 Lindsey said that she felt that David did not really have a problem with adhering to 
his aerosol therapy as he usually took it every day.  She described feeling guilty if her son did 
not take his treatment and was aware that he did not adhere to his aerosol therapy on the 
weekend before the interview.  She said that it had been difficult to prioritise his treatments 
over the weekend because they had family staying with them at the house.  She described 
herself as a “control freak” and said that she reminded David numerous times throughout the 
day to remember to take his I-neb™.  She said that it was often very difficult to manage the 
daily competing demands of family life alongside a complicated treatment regimen.  She 
described this as often leading to feelings of frustration but was keen to point out that she did 
not view David’s treatments as burdensome as they were there to keep him well. 
 Lindsey was very complimentary about the design and functionality of the I-neb™ 
device and said that she much preferred this to the older types of nebuliser.  She described 
finding it difficult when less experienced doctors did not seem to appreciate the daily struggle 
of trying to manage a complicated treatment regimen but said that she had a positive 
relationship with her son’s care team in general and in particular, the hospital consultants.   
This reflected my impression of her as someone who was very knowledgeable and capable, 
but who also appreciated empathy and support. 
 
Simon and Pam 
Simon 
 Simon was 13 at the time of the interview.  He was very creative and was keen to 
show me one of his recent paintings after the interview had stopped.  He said that he would 
like to become an art teacher when he was older.  He enjoyed watching TV and playing 
computer games in his spare time.  Although he liked the outdoors, he said that he was unable 
to participate in sporting activities because of his implanted ‘Portacath’ (portable catheter 
appliance) and the fact that he often got out of breath.  He described being used to his CF 
treatment and said that in addition to his daily regimen he also had overnight gastronomy 
feeds and received intravenous antibiotics at home once every three to four months.  He said 
that he preferred his tablets to his other treatments because they were the easiest and quickest 
to take.  He was able to articulate his thoughts well and although he appeared a little nervous 
towards the beginning, he appeared to develop more confidence as the interview progressed.  
 Simon said that he did not really mind taking his aerosol therapy.  He said he has 
noticed that his nebuliser administration times had reduced significantly since using the TIM 
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mouthpiece and that this was positive because he ‘got to do more stuff’.  He had a good 
understanding of the purpose of his treatment and said that he was just beginning to take 
more responsibility for the preparation of aerosol therapy.  He said that he did not take his 
aerosol therapy when he was at his dad’s house because his mum did not want him to forget 
to bring his nebuliser home with him.  He said that he did not really mind missing his 
treatment because it gave him a night off and enabled him to ‘relax’.  
Pam 
 Pam was aged 42 at the time of the interview.  She separated from her husband 
approximately seven years ago and lived at home with her older son (17) and Simon.  She 
was coming to the end her degree course and was thoroughly engaged in the process of 
writing up her dissertation.  She was interested in the process of the Clinical Psychology 
Doctorate; asking questions and enjoying exchanging stories about the challenges of 
academic study.  This seemed to put her at ease and she went on to explain the difficulties 
associated with caring for a child with CF alongside numerous other commitments. 
 Pam outlined a busy CF treatment regimen which took up a lot of her and Simon’s 
time together.  There was a theme around encouraging Simon to become more independent 
both generally and in taking greater responsibility for his treatment.  This became more 
evident during the process of analysis with consistent themes about Simon’s age and stage of 
development and his mum’s belief that it was important to gradually start to ‘push him’ to 
take on more responsibility.  She did not feel that her son’s adherence to aerosol therapy was 
particularly problematic.  She was actually of the belief that Simon’s adherence would be 
100% nearly every week but for the fact that he did not take his aerosol therapy when he 
stayed over at his father’s house on a Saturday night.  This was mainly because she did not 
want her son to forget to bring his aerosol therapy device back with him, but it still caused 
her some frustration as she felt that he was only able to get a break from his aerosol therapy 
treatment and therefore his CF, when he stayed with his father.  Although she reflected that 
she felt ‘silly’ saying this, it was clear that this topic was emotionally charged. 
 Overall, Pam came across as a very supportive and caring mother who had a very 
good relationship with her son.  She discussed numerous challenges in relation to Simon’s 
aerosol therapy treatment but seemed to overcome these very effectively perhaps reflecting 
her reported beliefs in the necessity for the treatment. 
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3.3 Parent group analysis 
This chapter will begin by outlining the theoretical formulation of the parent group 
data, which consists of 9 core categories.  The parent group data will be reported first as the 
accounts are richer and more detailed and provide helpful context to the child group analysis 
where the accounts are – perhaps unsurprisingly – less comprehensive.  Each of the core 
categories will then be expanded upon by describing the associated subcategories.  Quotes 
taken directly from the parent interviews will be used to further illustrate the subcategories.  
3.3.1 Theoretical formulation 
The detailed process of coding provided 436 open codes and 112 axial codes.  These 
were then revised to produce 9 core categories, and 42 subcategories.  The theoretical 
formulation comprises a number of interacting processes described by the parents and can be 
seen as a diagram in Figure 7.  The formulation illustrates the process of their child adhering 
to aerosol therapy, as experienced by the six parents interviewed for this study.  The 4 
process areas which contain the 9 core categories are shown in Table 5.   
Table 5: Arrangement of the core categories into a theoretical formulation 
Process Areas 
Core Category 
 
Parent’s interaction with the aerosol therapy 
Category 1: Regimen characteristics 
Category 2: Device characteristics 
 
Parent’s cognitive, affective and behavioural processes 
Category 3: Beliefs about aerosol therapy 
Category 4: Emotional drivers 
Category 5: Strategies and behaviours 
 
  
Parent’s interaction with their child 
Category 6: Parents experience of their child’s adherence 
Category 7: Parent and adolescent relationship 
 
The context of adherence 
Category 8: Everyday life  
Category 9: Environmental influences  
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Figure 7: Overall theoretical formulation - Parent group data  
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Figure 7: Overall theoretical formulation – Parent group data 
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3.3.1.1 Description of theoretical formulation 
 
Parent’s interaction with the aerosol therapy 
Parents reported on the process of interacting with the aerosol therapy treatment 
regimen and the I-neb™ device itself.  Many of the various characteristics of the regimen and 
some of the features of the device were seen as demanding and burdensome with parents 
reporting on the way in which these characteristics influenced their experiences, thoughts, 
feelings and behaviour around adherence.  The experiences of the parents interacting with 
some of the more positive aspects of the I-neb™ device were described as helping to 
facilitate their child’s adherence. 
 
Parent’s cognitive, affective and behavioural processes 
 The cognitive, affective and behavioural processes of the parents refers to the 
complex way in which their salient thoughts and beliefs about aerosol therapy interact with a 
number of strong feelings concerning their child’s adherence to aerosol therapy.  These 
interactions were seen as influencing a series of behaviours and strategies which had their 
relative strengths and weaknesses in facilitating the process of adherence.  The linked, 
circular arrows within this section of the diagram represent the fact that these interactions are 
multifaceted and non-linear. 
 
Parent’s interaction with their child  
 This process area encompasses both the parent’s experience of their child’s adherence 
behaviour and the way in which the parent and adolescent relationship influences the overall 
process of adherence.  Many of the experiences reported by the parents regarding their child 
adhering to aerosol therapy were a potential source of frustration.  The arrows pointing 
outwards from category seven within the diagram represents the way in which the parent and 
adolescent relationship mediates the impact of the parent’s experience of their child’s 
adherence on their cognitive and behavioural processes and vice versa.  
 
The context of adherence 
  Parents reported that the context in which adherence to aerosol therapy was taking 
place was important.  Adherence did not exist in a vacuum and parents reported on the way in 
which everyday life and aspects of the environment interacted and influenced the process of 
adherence. 
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3.3.2 Summary 
  Overall, the accounts of the parents suggest a complex series of cognitive, emotional 
and behavioural processes which interact with the way in which they experience their child’s 
adherence behaviour and are mediated largely by the relationship they have with their child.  
The above processes are further influenced by the interactions with the aerosol therapy 
regimen and device characteristics and the context in which adherence is taking place.   
3.3.3 Core Categories 
 This section elaborates on each of the 9 core categories and 42 associated 
subcategories which have all been directly derived from the data.  In order to demonstrate 
this, the number of parents who contributed to the categories is provided along with 
illustrative quotes taken directly from the transcripts.  Whilst space prohibits the reporting of 
the full coding hierarchies – which illustrates diagrammatically the open and axial codes that 
contribute to each core category – an example of the full coding hierarchy used to generate 
core category 1 will be provided.  In addition, the subcategories that contribute to the each of 
the remaining core categories will be also be represented diagrammatically. 
 
Category 1 – Regimen characteristics 
Number of sources: 6 
Description: The experiences of the aerosol therapy treatment regimen were discussed by all 
of the participating parents.  The parents reported on the multi-faceted nature of the aerosol 
therapy treatment regimen and these have been organised into six subcategories.  The full 
coding hierarchy used to generate Core Category 1 can be seen in Figure 8. 
 
Subcategory 1a: Multiple treatments 
Number of sources: 6 
Description: Parents reported that the aerosol therapy treatment was only one part of a 
complex and demanding CF treatment regimen that placed significant strains on the parent 
and adolescent: 
“I think it’s very easy to look at things isolated, if you just had your 10 minute 
nebuliser every day or if you just had this tablet or if you just had that, but if you put 
the whole lot together it all gets too much sometimes because it’s all a big, it’s a 
whole, it’s just something on top of everything else.” (Carla) 
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Figure 8: Coding hierarchy for parent data - Category 1
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Figure 8: Coding hierarchy for Category 1 – “Regimen characteristics” 
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Subcategory 1b: Treatments are interdependent 
Number of sources: 5 
Description: Parents reported that the nature of certain treatments having to be administered 
in a time sensitive manner alongside other treatments placed further demands on the parent 
and adolescent: 
“Erm, but it can’t be too close to his nebuliser either erm if you’re doing his physio it 
has to be at least an hour after his nebuliser.” (Pippa) 
 
“As long as there’s a 2 hour period between his Colomycin and his DNase it’s ok.” 
(Pam) 
 
Subcategory 1c: Treatments are time consuming 
Number of sources: 6 
Description: Parents reported that in general, the treatment regimen was time consuming 
with some parents specifically highlighting the time consuming nature of the aerosol therapy 
treatment:  
“And I think, sometimes it, yeah you do resent how things are because it does take up 
so much time.” (Mary) 
 
“I’d say it’s probably her physio and nebulisers that are the ones that she hates 
because they’re time consuming.” (Carla) 
 
Subcategory 1d: The changing nature of the aerosol therapy regimen 
Number of sources: 4 
Description: Parents reported that the quantity and type of medication prescribed as part of 
the aerosol therapy treatment regimen often dictated the associated burden:  
“When he first started with it I thought great. And then sometimes like when he’s had 
pseudomonas, he has three a day.  He has like promixine twice a day and then he has 
his DNase.  That’s pure evil.  It’s like torture!” (Pippa) 
 
“I say a lot of it depends on the drugs that they’re on and how time consuming erm 
and when they’re on you know two or three of them it’s all very well for [child’s 
name] at the minute because she’s only on one.” (Carla) 
 
Subcategory 1e: Side effects 
Number of sources: 3 
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Description: Some of the parents (2/3) reported that there were often side effects associated 
with certain nebulised treatments which negatively impacted on their child’s experience of 
taking aerosol therapy:  
“She was on tobramycin and that was horrible, it took such a long time to go through 
and apparently tasted horrible as well you know I take her word for it, I wasn’t going 
to try it.” (Carla) 
 
This subcategory is also supported by statements made by one parent who did not feel that 
the aerosol therapy treatment had associated side effects: 
“It’s a treatment that they need to have you know, erm it doesn’t take long, it’s not 
painful, it’s not time consuming.  Erm there’s no real reason why you wouldn’t do it.” 
(Lindsey) 
 
Subcategory 1f: Feeling understood 
Number of sources: 4 
Description: Some of the parents (3/4) reported that the hospital doctors do not always seem 
to understand the impact that the aerosol therapy treatment regimen places upon parents and 
that this sometimes led to frustration and resentment: 
“It is tough and I think when the doctors are saying you need to do this, this and this, 
they don’t realise the day to day struggle of what it’s really like to live with it.  You 
know it’s alright for them to sit there and say he needs this nebuliser every day, this 
tablet every day, that tablet every day, they’re not dishing them up, administering all 
the medicine.” (Pippa) 
 
This subcategory is also supported by statements made by a parent who did feel that the 
doctors understood the impact of the aerosol therapy treatment regimen and allowed some 
flexibility with adherence: 
“They’ve always said like for the matter of a week or two weeks if you’re going 
abroad, it doesn’t really matter about the nebuliser, you can afford to lose that period 
of time.” (Greg) 
 
Category 2 – Device Characteristics 
Number of sources: 6 
Description: All of the parents interviewed reported on their experiences of using the I-
neb™ device.  These positive and negative device characteristics were all experienced as 
important for the parents and have been organised into four subcategories (see Figure 9). 
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Figure 9: Subcategories contributing to parent data - Category 2 
 
Subcategory 2a: Being able to compare technological advances 
Number of sources: 5 
Description: Parents reported that they were able to compare the older nebulisers to the 
newer I-neb™ device.  They commented upon the technological advancement of the I-neb™ 
device and the associated benefits: 
“The I-neb is, oh it’s so much easier than what it was because we used to have to set 
everything up and it’s mad, I can’t even remember how we used to set the old one up 
there was that many pieces erm and the I-neb is just fabulous.” (Pam) 
 
Subcategory 2b: Target Inhalation Mode (TIM) mouthpiece makes it easier 
Number of sources: 5 
Description: Parents reported that the intelligent design of the TIM mouthpiece in providing 
users with immediate feedback on positive breathing technique had noticeably reduced 
aerosol therapy administration times: 
“Since we’ve got the TIM, I’ve not had one argument out of him as to the fact that 
he’s got to do it.” (Pippa) 
 
 
Subcategory 2c: Using the downloaded data 
Number of sources: 4 
Description: Parents reported that the data downloaded from the I-neb™ was interesting and 
helped to provide an objective measurement of adherence.  This was the case both for the 
data used within the interviews and more generally with some (2/4) suggesting that it would 
be useful to discuss the data within clinic appointments more than it was currently:    
“[Looking at the downloaded data] It’s really interesting actually because I just 
assume that she’s done it and she’s done it properly and she’s had the full dose erm 
but no that’s quite useful, it’s actually really interesting.” (Carla)  
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This subcategory is also supported by statements made by a parent who did not feel that the 
downloaded data was particularly helpful and viewed it in a more punitive way: 
“The downloaded information?  This is where Big Brother looks at you and points the 
big finger!” (Lindsey) 
 
Subcategory 2d: Cleaning 
Number of sources: 5 
Description: Parents reported that cleaning the I-neb™ device thoroughly was of vital 
importance.  However, the frequency and thoroughness of cleaning was experienced as 
burdensome: 
“That’s another thing, you have to boil the damn thing once a week, you have to boil 
it for about 10, 15 minutes.” (Pippa) 
 
Category 3 – Beliefs about aerosol therapy 
Number of sources: 6 
Description: All of the parents reported experiencing thoughts and beliefs specifically 
relating to the process of their child adhering to aerosol therapy.  These salient thoughts and 
beliefs were experienced as part of a complex relationship between emotional and 
behavioural responses.  This category has been organised into three subcategories (see Figure 
10). 
 
 
 
 
 
 
 
 
 
Figure 10: Subcategories contributing to parent data - Category 3 
 
Subcategory 3a: Beliefs about the effectiveness of the aerosol therapy 
Number of sources: 5 
Description: Parents reported that their belief about the positive benefits gained from their 
child taking aerosol therapy was a factor which motivated them to encourage their child to 
adhere to the treatment: 
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“Anyway, as soon as they took her off the Neb, about a month after she was in 
hospital.  Then they put her back on the Neb now ever since she’s been on the Neb, 
touch wood, right, she’s never been, she’s never had a stay in hospital so there’s got 
to be something in it as far as I’m concerned.” (Greg) 
 
This subcategory is also supported by statements made by two parents who were still 
uncertain as to the benefit gained from their child taking aerosol therapy: 
“I can understand why some parents would think ‘stuff it, it’s making no difference’ 
because in some ways I feel like that.” (Pippa) 
 
Subcategory 3b: Beliefs about the reality of adherence 
Number of sources: 4 
Description: Parents reported that they thought it was unrealistic to expect 100% adherence 
to aerosol therapy every single day:   
“But there are times when you can’t.  You know, we’ve either been out for the day 
and it’s far too late or we’re all feeling under the weather, there are times where he 
doesn’t have it every day.” (Pippa) 
 
Subcategory 3c: Beliefs about the consequences of non-adherence 
Number of sources: 4 
Description: Parents reported their thoughts and beliefs about the limited negative impact 
resulting from their child failing to adhere to their aerosol therapy treatment over a short 
period of time:   
“You tend to think, ‘well you’ll be alright for a few days’ or whatever, ‘it’s only one 
treatment’.” (Lindsey) 
 
This subcategory is also supported by statements made by a parent who believed that the 
ultimate consequence of her child failing to adhere to her treatment was a shortened life: 
“The way she’s carrying on erm is very upsetting, ‘cos she won’t, she’ll be in her 
20s.” (Mary) 
 
Category 4 – Emotional drivers 
Number of sources: 6 
Description: All of the parents reported experiencing a number of emotions relating to the 
process of their child adhering to aerosol therapy and have been organised into 4 
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subcategories (see Figure 11).  These emotions were often described in relation to the way 
they influenced certain behavioural patterns that the parents had noticed. 
 
 
 
 
 
 
 
 
 
 
Figure 11: Subcategories contributing to parent data - Category 4 
 
Subcategory 4a: Feelings of control 
Number of sources: 4 
Description:  Parents reported that relinquishing the control they have over their child’s 
adherence to aerosol therapy feels very difficult and often influenced a number of complex 
and interacting cognitive processes, emotional reactions and behavioural strategies: 
“I like to know she’s done it because if she hasn’t done it I worry and again it’s, 
she’ll say I’m a control freak and I probably am a bit but having had all the years 
where I had complete control over her treatments to almost having no control at all 
now, erm yeah I like to remind her, just check in my own mind that she’s done it.” 
(Carla) 
 
Subcategory 4b: Anxiety and worry 
Number of sources: 4 
Description: Parents reported that at any given point, they were experiencing multiple 
worries relating to their child’s CF.  Parents also reported a number of worries specifically 
relating to their child’s aerosol therapy:  
“It’s just something that’s in the back of your mind all the time is ‘what she’s got in 
where she’s going to be’ and err you know and to ‘make sure she’s got it [i-neb] with 
her’.” (Carla) 
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Subcategory 4c: Feeling guilty 
Number of sources: 3 
Description:  Parents reported that they experienced significant feelings of guilt when their 
child had not adhered to their aerosol therapy, particularly if the parent had forgotten to 
prepare the medication or failed to remind their child: 
“I feel really, really guilty if he doesn’t have it.  Every now and again he might miss 
his nebuliser but I do feel really guilty when he does.” (Pippa)  
“It makes me feel guilty when he hasn’t done his neb, that you’re failing him in a 
way.” (Lindsey) 
 
Subcategory 4d: Feeling frustrated 
Number of sources: 5 
Description:  Parents reported that there were numerous potential sources of frustration 
involved with the process of their child adhering to aerosol therapy.  Some were related to the 
regimen and the device (see category 1 and 2), but many feelings of frustration stemmed from 
their child’s behaviour and relate to the later core category ‘Parents experience of their 
child’s adherence’ (Core category 6): 
“[Looking at the downloaded data] I suppose she spent all morning in bed ‘cos she 
usually does as the weekend.  In fact there’s absolutely no reason why she shouldn’t 
have done it.” (Carla) 
 
Category 5 – Strategies and behaviours 
Number of sources: 6 
Description:  The use of certain strategies in relation to the process of their child adhering to 
aerosol therapy was reported by all of the parents.  Many of these strategies were 
interconnected to the thoughts and feelings outlined above with parents describing some of 
these strategies and behaviours as helpful and others as less helpful.  In addition, there was 
some variation in the way that different parents experienced the same behaviours and 
strategies as either positive or negative in encouraging their child to adhere to their aerosol 
therapy.  This category has been organised into seven subcategories (see Figure 12). 
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Figure 12: Subcategories contributing to parent data - Category 5 
 
Subcategory 5a: Being in a routine 
Number of sources: 6 
Description: Parents reported on the importance of developing a well organised routine 
which helps to facilitate adherence.  Although all of the parents discussed the importance of 
sticking to the established routine, some (2/6) also highlighted the necessity of allowing some 
flexibility within the routine to accommodate a busy lifestyle: 
“You’ve got your routine of getting up, getting ready, going to school, coming home 
having your tea, having your Neb, having your physio, having your DNase, going to 
bed.” (Greg) 
 
Subcategory 5b: Reminding 
Number of sources: 6 
Description: Parents reported that reminders were one of the main ways in which they 
monitored and supervised their child’s adherence.  Most (4/6) parents suggested that they 
were a constant and repetitive feature of everyday life which sometimes led to conflict and 
did not necessarily encourage adherence: 
“I should just record my voice and just play it continuously ‘[Name of child] do your 
blows, [Name of child] do your blows.  Have you took your medicines?  Have you 
done your neb?’” (Lindsey) 
 
“She’s said if she doesn’t get reminded, she won’t take it but if she does get reminded, 
she resents being reminded to take it.” (Mary) 
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This subcategory is also supported by statements made by two of the parents who felt that the 
gentle and individualised way in which reminders were used and communicated to their child 
were a key factor in ensuring that this strategy encouraged adherence: 
“You have to prompt her like and say ‘you should be doing something by now 
shouldn’t you?’.  She’ll think ‘oh yeah’ and she’ll go and do it like you know.” (Greg) 
 
Subcategory 5c: Normalising and accepting 
Number of sources: 5 
Description:  Parents reported that trying to make the process of adhering to aerosol therapy 
as much a part of normal everyday life as possible was something that helped parents and 
their children accept the treatment and ‘get on with it’: 
“I know it sounds peculiar but it’s just become part of normal life for us.” (Pam) 
 
Subcategory 5d: Explaining the purpose of aerosol therapy to the child 
Number of sources: 5 
Description:  Parents reported that it was of vital importance that their child understood the 
purpose of taking their aerosol therapy: 
“If they’ve got no rationale about whether it’s beneficial to them, they just see it as 
an intrusion on their day to day life.” (Lindsey) 
 
Subcategory 5e: Rewarding and incentivising adherence 
Number of sources: 4 
Description:  Parents reported on the value of providing rewards and incentives for their 
child adhering to the aerosol therapy: 
“[Looking at the downloaded data] She’d been told to get it done before dinner erm 
and she’ll have been doing it earlier here because she wanted to watch ‘I’m a 
celebrity’ and I told her to get it done.” (Carla) 
 
Subcategory 5f: Simplifying the process 
Number of sources: 4 
Description:  Parents reported that it was important to try to ensure that the process of 
adhering to aerosol therapy was made as simple as possible for their child. Some parents (2/4) 
reported feeling irritated if their child had failed to adhere despite them trying to make the 
process as easy as possible and relates to their earlier subcategory ‘Feeling frustrated’ (4d):  
“I make it as easy as I can make it for her to do it.” (Mary) 
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Subcategory 5g: Having a break 
Number of sources: 4 
Description:  Parents reported the mixed emotions involved with having a break from 
adhering to treatments.  All of the parents said it was a relief to have a break but some (2/4) 
said that they experienced accompanying feelings of guilt as a result.  In addition, one parent 
described feelings of resentment towards her ex-husband because her child did not adhere to 
his aerosol therapy when he stayed with him:   
“I feel guilty that I’m putting the onus on somebody else to do his treatment when he’s 
not here but at the same time I’m really pleased that I don’t have to just be doing it 
every single day.” (Pippa) 
 
“But I’d rather if he was, he could not have his treatment here as well rather than just 
at his dad’s.  I can’t erm explain properly but erm it’s like he hasn’t got CF at his 
dad’s, he can have a night off from having CF and his treatments.” (Pam) 
 
Category 6 – Parent’s experience of their child’s adherence behaviour 
Number of sources: 6 
Description: Parents reported on the numerous experiences encountered as a result of the 
process of their child taking aerosol therapy.  Many of these experiences were a potential 
source of frustration for the parents.  This category comprises six subcategories (see Figure 
13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Subcategories contributing to parent data - Category 6 
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Subcategory 6a: Child forgetting 
Number of sources: 6 
Description: Parents reported that their child often forgot to take their aerosol therapy.  
Although parents reported that this was frustrating, there was an acknowledgment that this 
forgetting was often accidental: 
“It gets forgotten sometimes.  She doesn’t mean to forget it but you know she does 
forget it sometimes.” (Carla) 
 
Subcategory 6b: Child getting distracted 
Number of sources: 5 
Description: Parents reported that their child often got distracted by various things and that 
this lack of concentration negatively impacted on adherence.  This was often experienced as a 
source of frustration for the parents: 
“She’ll be on her computer or something and then something comes up on Facebook 
and she’ll put it down for a second and she’ll ‘ooh yeah’ and pick it back up again.” 
(Carla) 
 
Subcategory 6c: Child procrastinating 
Number of sources: 4 
Description:  Parents reported that their child procrastinating about taking their aerosol 
therapy led to them feeling irritated: 
“He would like prefer to sort of wait and wait and wait and wait and do it as late as 
possible.  He’s trying to put it off.” (Pippa) 
 
Subcategory 6d: Child’s breathing technique 
Number of sources: 6 
Description: Parents reported that their child’s poor breathing technique resulted in longer 
and less adequate aerosol therapy administration.  Although parents experienced this as 
frustrating they described how the newer mouthpiece has improved their child’s breathing 
technique and relates to the earlier subcategory ‘TIM mouthpiece makes it easier’ (2b):  
 “He wasn’t trying hard enough to do really, really good breaths, it was taking a 
long, long time and a lot of the medicine was getting wasted.” (Pippa) 
 
Subcategory 6e: Child feeling emotional 
Number of sources: 4 
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Description:  Parents reported that it was not uncommon for their child to feel upset and 
emotional.  They reported that occasionally their child would get upset about actually having 
CF but more often they would become emotional about a whole variety of more normal, 
everyday concerns.  Parents reported that their child’s emotional state sometimes had an 
impact on the process of adhering to their treatments: 
“When she’s upset, she will not do any of her medication, her neb or anything.  She 
won’t take it.” (Mary) 
 
Subcategory 6f: Child feeling different 
Number of sources: 6 
Description:  Parents reported that their child was often reluctant to take their aerosol 
therapy in front of others through fear of embarrassment.  Parents also reported that taking 
their aerosol therapy in front of other people was a reminder to their child that they had CF 
and were different to other people: 
“[Looking at the downloaded data] He wouldn’t have taken it with him to his friend’s 
house ‘cos I think [Name of child] would be embarrassed if he ever took his nebs with 
him.  Don’t know if it’s ‘cos of his age but he doesn’t like to talk to his friends about 
having CF.” (Pam) 
 
This subcategory is also supported by statements made by one parent who said that from her 
perspective, she did not think that their child was embarrassed about taking their treatments 
in front of other people: 
“I don’t think, he’s never feels embarrassed about any of his treatments or anything 
like that.” (Lindsey) 
 
Category 7 – Parent and adolescent relationship 
Number of sources: 6 
Description: The complex and changing nature of the parent and adolescent relationship was 
reported by all of the parents.  The relationship was seen as influencing and mediating the 
process of adhering to aerosol therapy.  Perhaps unsurprisingly, aspects of the relationship 
that were categorised as constructive were reported to have a more beneficial impact on 
adherence than less positive aspects. This category comprises four subcategories (see Figure 
14). 
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Figure 14: Subcategories contributing to parent data - Category 7 
 
Subcategory 7a: Responsibility, independence and the developing child 
Number of sources: 6 
Description:  Parents reported the importance of ensuring that increased responsibility 
around the aerosol therapy was gradually introduced as their child got older and developed 
greater independence: 
“I think when they’re younger, you have more control and that responsibility is then 
passed onto them.  Like the I-neb, that’s up to her to do it you know I can’t make her 
do it and and whatever.  The responsibility is on her now you know.” (Mary) 
 
This subcategory is also supported by statements made by many of the parents (4/6) who said 
that although introducing greater responsibility was important, it was difficult to do.  This 
relates to the earlier subcategory ‘Feelings of control’ (4a): 
“I think it’s hard to let go, he’s like nearly coming up to 13 and he’s had his nebuliser 
from day 1 so it’s hard not to have those erm those thoughts.” (Lindsey) 
 
Subcategory 7b: Cooperating and negotiating 
Number of sources: 5 
Description:  Parents reported that it was necessary to cooperate effectively with their child 
around their aerosol therapy in order to avoid potential conflict and encourage and maintain 
adherence: 
“[Looking at the downloaded data] I said ‘while I’m in the shower, you make up your 
colomycin for me’ so that’s what he done.” (Pam) 
 
“But yeah the more you fight things the more she’ll just dig her heels in.  You’ve just 
got to make it as calm as possible erm” (Carla) 
 
Subcategory 7c: Recognising preferences 
Number of sources: 5 
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Description:  Parents reported that it was important to recognise that their child had their 
own preferences concerning their CF treatment and more specifically had preferences when it 
came to the process of adhering to aerosol therapy.  They reported that it was also important 
to acknowledge that these preferences may well be different to their own: 
“I think his physio, he’s more inclined not to want to do that than his aerosol therapy 
because he knows that’s only going to take him a very short amount of time.” (Pippa) 
 
“Whereas I would always do things straight away and get it out of the way, [Name of 
child] will always leave everything to the last minute.” (Carla) 
 
Subcategory 7d: Empathising and supporting 
Number of sources: 4 
Description:  Parents reported they could really empathise with their child about how hard it 
must be to adhere to a difficult treatment regimen and more specifically, adhering to the 
aerosol therapy.  They reported that it was important to support their child as much as 
possible to help them deal with the daily struggle of treatment: 
“I do tell [Name of child] as he does, what he has to go through ‘cos I am proud of 
him and he knows that erm and I do tell him so maybe that’s helped.” (Lindsey) 
 
“I think that’s why I let him do it in front of the TV to try and make things a little bit 
more easier for him but I think it must be hard.” (Pam) 
 
Category 8 – Everyday life 
Number of sources: 6 
Description: Parents reported on the way in which everyday life impacted on the process of 
adhering to the aerosol therapy treatment regimen and vice versa.  This category has been 
organised into four subcategories (see Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Subcategories contributing to parent data - Category 8 
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Subcategory 8a: The juggling act (fitting everything in) 
Number of sources: 6 
Description:  Parents reported that trying to fit everything in during a typical day was similar 
to a juggling act which sometimes resulted in the child’s aerosol therapy being dropped: 
[Name of health professional] once asked us ‘what gets in the way?’ And we said 
‘life’.  Life gets in the way because if you want to go out and do something or you 
want to go to a show or the cinemas, and you come back and it’s 10 o’clock at night, 
you don’t want to do your neb.” (Mary) 
 
This category was also supported by two parents who reported that despite having a busy 
lifestyle, it was important to try to ensure that the aerosol therapy treatment was incorporated 
into daily life and relates to the earlier subcategory ‘Being in a routine’ (5a): 
“You go ‘right ok, well how do we slot this into our lifestyle?’  So you look at it then 
and you develop that routine and you stick to that routine.” (Greg) 
 
Subcategory 8b: School days vs. weekends 
Number of sources: 6 
Description: Parents reported that patterns of adhering to aerosol therapy were noticeable 
with half (3/6) suggesting that adhering during the school week was more straightforward:  
“Weekdays are probably easier than weekends and school days are probably easier 
than when she’s off school because you’ve got your routine haven’t you?  You’ve got 
your routine of getting up, getting ready, going to school, coming home having your 
tea, having your Neb, having your physio, having your Dornase, going to bed.  
Whereas on weekends, you’re busy doing other things aren’t you?” (Greg) 
 
This subcategory is also supported by the other half of the parents who suggested that that 
weekend adherence was easier: 
“I’d say the weekend when he’s more chilled out ‘cos school erm he does it again 
sitting on the couch but of a weekend he’s more chilled and he’ll just have his neb and 
he, I don’t know if it’s my perception but he seems to be more relaxed to take it of a 
weekend.” (Pam) 
 
Subcategory 8c: Mornings vs. evenings 
Number of sources: 6 
Description: Parents reported that there were further noticeable patterns of adhering to 
aerosol therapy with most (5/6) suggesting that taking the medication in the evening was 
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easier than in the morning.  Mornings were thought to be too busy, whereas evenings were 
said to be more relaxed: 
“[Looking at the downloaded data] We never do his Ineb in a morning.  Because it’s 
just too much, when we’re getting three kids ready for school, ourselves ready for 
work.” (Pippa)  
 
This subcategory is also supported by statements made by two parents who suggested that 
patterns of morning or evening adherence were also dependent on how many aerosolised 
therapies were prescribed and relates to the earlier subcategory ‘The changing nature of the 
aerosol therapy regimen’ (1d): 
“If it was only once a day we’d always do it at night, if it’s twice a day obviously 
she’d have to do it in the morning as well.” (Carla) 
 
However, this subcategory is also further supported by a parent who suggested that neither 
morning nor evening adherence was easier with both presenting difficulties: 
“And we’ve tried, we’ve tried all the ways, we’ve tried doing it on a morning, we’ve 
tried doing it on a night, on a teatime when she came home from school. I don’t think 
there’s any good time for her.” (Mary)  
 
Subcategory 8d: Parties, events and celebrations 
Number of sources: 4 
Description: Parents reported that special occasions often impacted on adherence to aerosol 
therapy with adherence often taking on less of a priority when there was an event or a 
celebration: 
“Erm and it’s like when she goes to parties and things and when she’s going away 
with school and we try to let her drop as much as we can.” (Carla) 
“[Looking at the downloaded data] That day was my birthday.  I made [name of 
husband] do it [laughs].  ‘It’s my birthday, I’m not doing it, you can do it.” (Pippa) 
 
Category 9 – Environmental influences 
Number of sources: 6 
Description: All of the parents reported on the significant impact that certain aspects of the 
environment had on the process of adherence.  The majority of accounts focussed on 
interactions with different and less familiar environments and the way in which they 
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influenced experiences of using the I-neb™ device.  There are four subcategories that 
contribute to this core category (see Figure 16). 
  
 
 
 
 
 
 
 
 
 
Figure 16: Subcategories contributing to parent data - Category 9 
 
Subcategory 9a: Going on holidays and school trips 
Number of sources: 5 
Description: Parents reported that being away on holiday in an unfamiliar environment made 
it difficult for their child to adhere to the aerosol therapy because storing and preparing the 
medication and then cleaning the I-neb™ device was experienced as problematic: 
“If we’re going away, if like we went camping, we didn’t take it with us, there’s 
nowhere to keep the medicine it’s got to be in a fridge.  That’s a pain in the bum, 
because it’s got to be in a fridge all the time” (Pippa)  
 
“When we’ve been on holiday or erm you know if she’s not had the facility for erm 
cleaning it, then obviously you might be only able to take it the once and then you 
can’t do it again because you can’t boil a kettle to you know clean the equipment 
properly and stuff.” (Greg)  
 
Subcategory 9b: Staying over in a different house 
Number of sources: 5 
Description: Parents reported that staying over at someone else’s house made it more 
difficult for their child to adhere to their aerosol therapy.  This included staying over at a 
friend’s house for a sleepover and also staying over at another parent’s house when the 
child’s parents were separated.  Many of the reasons focussed again on the problem of 
storing, preparing and cleaning the I-neb™ device in an unfamiliar environment, but others 
included the child forgetting to bring the device back home and the child not wanting to take 
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the medication in front of their friends – which relates to the earlier subcategory ‘Child 
feeling different to others’ (6f): 
“[Looking at the downloaded data] ‘Cos it looks like she hasn’t taken any of her 
treatments there.  She was on a sleepover at her friend’s that night that would be the 
reason why.” (Mary) 
 
“[Looking at the downloaded data] He goes to his dad’s on a Saturday night erm, I 
don’t let him take the Ineb with him ‘Cos he’ll forget to bring it back.” (Pam) 
 
Subcategory 9c: Being in hospital 
Number of sources: 2 
Description:  Parents reported that when their child was admitted to hospital, the lack of 
adequate facilities for preparing and cleaning the I-neb™ device made it difficult for them to 
adhere to the aerosol therapy: 
 “And interestingly, the worst time is when you’re in hospital with her and she’s 
obviously still using it but there’s no washing facilities there ‘cos you’ve got no plug 
that you can put into things.” (Carla) 
 
Subcategory 9d: The visibility of the device 
Number of sources: 4 
Description: Parents reported that ensuring the I-neb™ device and associated equipment was 
visible in the home environment was something which helped to normalise aerosol therapy 
treatment but did not necessarily facilitate adherence: 
“‘Cos it’s there, it’s in the kitchen, it’s there on view, I never put it away, it’s on view 
there and like when she has her supper, she must see it, but it just I just don’t think 
she just doesn’t think about it.” (Mary) 
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3.4 Adolescent group analysis 
The analysis of the adolescent group data provided nine core categories.  Each of the 
core categories will be expanded upon by describing the associated subcategories with quotes 
taken directly from the adolescent interviews being used to further illustrate these.  Many of 
the themes within the adolescent group analysis were similar to the parent data – unsurprising 
given they are discussing their experiences of the same process – though the perspective 
expressed was often different. 
3.4.1 Theoretical formulation 
The process of coding provided 362 open codes and 87 axial codes.  These were then 
revised to produce 9 core categories, and 37 subcategories.  The theoretical formulation 
comprises a number of interacting processes described by the patients and can be seen as a 
diagram in Figure 17.  This compliments the formulation described for the parent data and 
illustrates the process of adhering to aerosol therapy, as experienced by the six adolescent 
patients.  Although there are differences at the level of content, the visual depiction of the 
theoretical formulation of the core categories is very similar to that presented on the parent 
data.  Though some similarities were expected, the extent of the overlap was unexpected. 
This was led by the data, however, and represents the best fit for the reports provided by the 
adolescent participants. The 4 process areas which contain the 9 core categories are shown in 
Table 6.   
Table 6: Arrangement of the core categories into a theoretical formulation 
Process Areas 
Core Category 
 
Adolescent patient’s interaction with the aerosol therapy 
Category 1: Regimen characteristics 
Category 2: Device characteristics 
 
Adolescent patient’s cognitive, affective and behavioural processes 
Category 3: Beliefs about aerosol therapy 
Category 4: Emotional drivers 
Category 5: Strategies and behaviours 
 
  
Adolescent patient’s interaction with their parent 
Category 6: Adolescent patient’s experience of their parent’s behaviour 
Category 7: Parent and adolescent relationship 
 
The context of adherence 
Category 8: Everyday life  
Category 9: Environmental influences  
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Figure 17: Overall theoretical formulation - Adolescent group data  
Aerosol Therapy 
Category 1 
  
Regimen 
characteristics 
Category 2 
  
Device 
characteristics 
Context 
Category 8 
  
Everyday life 
Category 9 
  
Environmental 
influences 
Category 7 
  
Parent and 
adolescent 
relationship 
Adolescent 
Category 5 
  
Strategies 
and behaviours 
Category 3 
  
Beliefs about  
aerosol therapy 
Category 4 
  
Emotional 
drivers 
Parent 
Category 6 
  
Adolescent patient’s 
experience of their 
parent’s behaviour 
Cognitive, affective and behavioural processes 
  
   
 
 
Adolescent patient’s interaction with their parent 
  
   
 
 
Figure 17: Overall theoretical formulation – Adolescent group data 
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3.4.1.1 Description of theoretical formulation 
Adolescent patient’s interaction with the aerosol therapy 
Patients reported on the process of interacting with the aerosol therapy treatment 
regimen and the I-neb™ device itself.  The accounts were similar to those of their parents  
with many of the regimen characteristics and some of the features of the device experienced 
as demanding.  There was a particular emphasis on the lack of immediate feedback from the 
aerosol therapy medication.  The feedback gained from the device itself was often 
experienced as positive.  The way in which the above characteristics influenced the 
adolescents’ experiences, thoughts, feelings and behaviour around adherence was very 
similar to the processes described by the parents. 
 
Adolescent patients’ cognitive, affective and behavioural processes 
 The cognitive, affective and behavioural processes of the adolescent patients were 
described in a less overt way than in the accounts of their parents.  However, the data 
suggested that the complex way in which the patients’ beliefs about adherence interacted with 
a series of emotional and behavioural responses was actually very similar to the processes 
described by the parents.  The adolescents were obviously describing these from a patient 
perspective and this helped to provide valuable insight into the origins of some of the 
behaviours that negatively impacted upon adherence that their parents found confusing or 
frustrating.  Again, the circular arrows within this section of the diagram represent the fact 
that these interactions are multifaceted and non-linear. 
 
Adolescent patients’ interaction with their parent  
 This process area is similar to the one outlined within the parent data section but this 
time describes the adolescent patient’s experience of their parent’s behaviour and the way in 
which the parent and adolescent relationship influences the overall process of adherence; this 
time discussed from a patient perspective.  Interestingly, the reports concerning their parent’s 
behaviour were often commented upon indirectly and those accounts that were more direct 
were largely positive.  It is possible that this may have reflected the nature of the interview 
process and the adolescent patients’ reluctance to be overly critical of their parents’ 
behaviour to someone they had only just met.  However, the accounts appeared to be very 
genuine and provided helpful insight from a patient perspective into the way in which the 
adolescent’s interactions with their parent influenced the complex processes associated with 
adhering to aerosol therapy. 
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The context of adherence 
  Similarly to their parents, the adolescents reported that the context in which 
adherence to aerosol therapy was taking place was important.  The way in which aspects of 
everyday life and features of the lived environment influenced the process of adherence was 
discussed from a patient perspective. 
3.4.2 Summary 
  Overall, the accounts of the adolescents suggested that the interacting phenomena 
that were identified within the reports from the parents were also present as factors 
influencing adherence within the young patients.  The adolescent patient accounts provided 
additional insight into the way in which the processes identified by the parents influence 
adherence to aerosol therapy. 
3.4.3 Core Categories 
 This section elaborates on each of the 9 core categories and 37 associated 
subcategories which have all been directly derived from the data. 
 
Category 1 – Regimen characteristics 
Number of sources: 6 
Description: The adolescent patients all reported on their experiences of the aerosol therapy 
treatment regimen.  Although many of the regimen characteristics that were highlighted as 
impacting on the process of adhering to aerosol therapy were similar to their parents, there 
were some subtle differences in experience and perspective.  The immediacy of the effect 
gained from taking the aerosol therapy was an additional area that the adolescent patients 
identified.  This category has been organised into five subcategories (see Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Subcategories contributing to adolescent data - Category 1 
Category 1 
  
Regimen 
Characteristics 
(6) 
Subcategory 1a 
  
Multiple 
treatments (6) 
Subcategory 1b 
  
Treatments are  
time consuming (5) 
Subcategory 1c 
  
Treatments are  
interdependent (5) 
Subcategory 1d 
 
Immediacy of  
effects (3) 
 
Subcategory 1e 
  
Side 
effects (4) 
 
 85 
Subcategory 1a: Multiple treatments 
Number of sources: 6 
Description: Adolescent patients reported that they take numerous treatments for their CF.  
Similarly to the parents, many of the adolescents (4/6) reported that their aerosol therapy was 
just one further treatment to take as part of a burdensome daily regime: 
“I have my IV’s about every three or four months which, it stays in for two weeks.  
Err, I have erm quite a lot of erm checkups, about six a year maybe.  I have a 
nebuliser.  Erm a physio with inhaler.  I take about, probably about 10 normal tablets 
a day.  Me enzymes, I probably have about 15 of them.  There’s quite a lot really.” 
(Simon) 
 
“The nebuliser, it’s just another thing to do.  It’s like, most people are just like ‘oh it’s 
just one thing, it just takes five minutes’ but it’s ANOTHER thing so.” (Amanda) 
 
“Some days you get up and you have to do it but you just get bored of having to do 
them because you have to do so much like every day. (David) 
 
Subcategory 1b: Treatments are time consuming 
Number of sources: 5 
Description: Adolescent patients reported that the treatments taken to manage their CF are 
time consuming.  Some (3/5) specifically highlighted the aerosol therapy treatment regimen 
as being more time consuming than other treatments, particularly if they were prescribed 
more than one nebulised medication: 
“The nebuliser, you have to sit and concentrate and breathe for a while and it takes 
time.  Like your tablets you can take them and they’re done and inhalers you can take 
them and they’re done but it’s a bit longer and inconvenient.” (Karen) 
 
Subcategory 1c: Treatments are interdependent 
Number of sources: 5 
Description: Adolescent patients reported that some of their treatments are dependent upon 
each other; with physiotherapy and aerosol therapy being discussed in particular.  Some (3/5) 
said that the process of taking their aerosol therapy is often influenced by their physiotherapy 
and vice versa: 
“Erm it’s not the actual taking them it’s just time so if when I’m taking the first one 
which is normally promixin, I’ve got to leave an hour in between them and it’s got to 
be the last thing I do before I go to bed.” (Elizabeth) 
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“[Looking at the downloaded data] It depends on how long it’s taken me to do my 
blows.  Like, if it takes me about 10 minutes or 15 minutes I end up doing my Neb 
about quarter past 7.” (David) 
 
Subcategory 1d: Immediacy of effects 
Number of sources: 3 
Description: Adolescent patients reported that the lack of immediate benefits gained from 
taking aerosol therapy can negatively impact on adherence: 
“Another thing is it, you don’t feel the immediate effects. Like an inhaler, more so 
with your inhaler, you just do it and you immediately, your lungs feel better but 
nebuliser it doesn’t, it’s over a long period of time you’d feel damage.  It’s not like an 
immediate thing.” (Karen) 
 
“The thing is it’s like erm Dornase it’s not an immediate dose kind of thing, it’s like a 
long term thing.  I’ve been doing Dornase for so long so I figure I’ve built up enough 
to probably miss a couple of days.” (Amanda) 
 
In contrast to the above reports, this subcategory is also supported by statements made by one 
patient who felt that the effects of his aerosol therapy were more immediate and that this 
encouraged him to adhere to the treatment: 
“It can reduce the coughing quite a lot sometimes.  I can be like quite chesty 
sometimes and after that I’m fine for a bit.” (Simon) 
 
Subcategory 1e: Side effects 
Number of sources: 4 
Description: Adolescent patients reported that there were sometimes unpleasant side effects 
associated with taking their aerosol therapy: 
“When I went into hospital we had to do this thing, this salty nebuliser.  I didn’t like it 
‘cos it made me cough loads.” (Tom) 
 
“I always feel like it doesn’t take enough air into it as well, it feels like you’re 
suffocating a bit, I hate it.” (Amanda) 
 
This subcategory was also supported by one patient who said that his prescribed aerosol 
therapy treatment had quite a pleasant taste which made it easier to take: 
“I don’t mind it.  I think it’s got quite a nice taste to be honest, Promixin.  You can’t 
really describe it, it just tastes nice, it’s not a nasty taste.  I don’t mind having to take 
that one.” (David) 
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Category 2 – Device Characteristics 
Number of sources: 6 
Description: Similarly to the parents, the adolescent patients identified a number of positive 
and negative characteristics of the I-neb™ device which they experienced as important in 
terms of influencing the process of adherence.  The adolescent patient reports suggest a 
significant degree of importance is placed on the ability of the I-neb™ device to provide 
useful feedback.  This category has been organised into five subcategories (see Figure 19). 
 
 
 
 
 
 
 
 
 
Figure 19: Subcategories contributing to adolescent data - Category 2 
 
Subcategory 2a: The I-neb™ device provides feedback 
Number of sources: 6 
Description: Adolescent patients reported that the I-neb™ device was intelligent in the way 
that it provided feedback to help with accurate administration: 
“Erm it buzzes and then I keep doing that until it like beeps once more and a face 
comes on the screen.  It’s just a smiley face that tells you that you’ve done it.” 
(David) 
 
“Sometimes if I haven’t got the nebs in the right position it makes a little alarm.” 
(Simon) 
 
Subcategory 2b: Target Inhalation Mode (TIM) mouthpiece makes it easier 
Number of sources: 5 
Description: Adolescent patients reported very similar findings to their parents in terms of 
the way in which the TIM mouthpiece provided specific feedback around accurate breathing 
technique resulting in quicker administration times.  This relates to the above subcategory 
‘The I-neb™ device provides feedback’ (2a): 
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“We changed to this thing called the TIM mouthpiece.  The new one shakes when you, 
err, when the breath has finished.  So the old one took like five to ten minutes and the 
new one takes like half a minute to two minutes.” (Tom) 
 
Subcategory 2c: Using the downloaded data 
Number of sources: 5 
Description: Adolescent patients reported mixed opinions about the data that is downloaded 
from the I-neb™ device both in terms of the current interview process and when this is done 
within their outpatient appointments.   Most (4/5) said that they felt it was helpful as it 
provided a more accurate view of their adherence: 
“[Looking at the downloaded data] I think it does help, like ‘cos you can see what its 
really like, I mean I’ve never thought of it like that.  I never really looked at it like this 
before, just the times and like minutes that I’ve taken it in.  12 minutes.  See when I’m 
on it, it doesn’t feel like 12 minutes.” (Elizabeth) 
 
This subcategory also contains comments by two patients who felt that the downloaded data 
was not discussed within their outpatient appointments with one of them saying that it would 
probably not encourage adherence even if it was: 
“I’m not sure why they always download it ‘cos they don’t really use it.  I don’t know 
that it would make much difference.” (Amanda) 
 
This subcategory is further supported by one patient who had mixed views about the value of 
seeing the downloaded information within her outpatient appointment but who went on to say 
that the approach taken by the health professional discussing it was important: 
“I think I’ve done well and then you see it and I haven’t done as well as I thought.  It 
does encourage me a little bit but it’s kind of disheartening.  I don’t like going to the 
diabetic clinic at all, they’re always like ‘you can do better’.  They never appreciate 
what I have done whereas [Name of health professional at the CF clinic] says ‘oh 
well, you’ve done it this many times but if you can, just try and do a bit better’. She 
doesn’t shout at you.” (Karen) 
 
Subcategory 2d: Preparation and Cleaning 
Number of sources: 6 
Description: Adolescent patients reported that there was a necessary process of preparing the 
aerosol therapy medication and device in order for the treatment to be taken.  Most (4/6) 
patients said that they were usually responsible for this preparation.  There was an awareness 
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of the burdensome nature of cleaning the I-neb™ device but most (5/6) said that this was 
usually done by their parents: 
“I put the medication in and take it and take it apart and then mum usually washes 
it.” (Amanda) 
 
“I prepare it but I don’t wash it.” (Tom) 
 
This subcategory is also supported by one child who said that they take responsibility for 
cleaning the I-neb™ device now that they are older: 
“Yeah, I wash it.  I never used to when I was little ‘cos I didn’t understand how to.” 
(Elizabeth) 
 
Subcategory 2e: The I-neb™ device is not portable 
Number of sources: 4 
Description: Adolescent patients reported that the I-neb™ device was very rarely taken 
anywhere outside of their own house.  Patients reported a number of device characteristics 
influencing this lack of portability including the necessity for storing all the associated 
aerosol therapy medication in the fridge and viewing the device as expensive and fragile:   
“My tablets as well I can put them in my bag and take them with me.  Or my inhaler I 
can take it with me but I don’t take my I-neb.  I don’t tend to take it out, I usually 
leave it here.  It’s because I’m a bit, ‘I’ll lose it!’.  That’ll be my thing ‘cos it’s quite 
expensive, I wouldn’t want to lose it.” (Karen) 
 
“I took it to a friend’s house erm but I don’t think I’d ever do it again because it was 
hard to keep track of where all my stuff was.” (Amanda) 
 
Category 3 – Beliefs about aerosol therapy 
Number of sources: 6 
Description: All of the adolescent patients reported experiencing thoughts and beliefs that 
were specifically related to the process of adhering to their aerosol therapy.  Although some 
of these thoughts and beliefs were discussed from a different perspective to their parents, the 
actual process of these beliefs interacting with a series of emotional and behavioural 
responses was very similar.  In addition, the way in which the preferences for certain 
treatments influenced the process of adherence was also identified.  This category has been 
organised into four subcategories (see Figure 20). 
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Figure 20: Subcategories contributing to adolescent data - Category 3 
 
Subcategory 3a: Beliefs about the effectiveness of the aerosol therapy 
Number of sources: 6 
Description: Adolescent patients reported a number of beliefs about the effectiveness of the 
aerosol therapy.  Most (4/6) believed that their aerosol therapy was important to take because 
it helped to keep them physically healthy: 
“It’s really important because it obviously helps your health and looks after you.  I 
haven’t been in hospital since I’ve been on them so.” (Elizabeth) 
 
“I know it helps me quite a lot so I keep taking it.” (Simon) 
This subcategory is also supported by statements made by two patients who reported mixed 
beliefs about their aerosol therapy, feeling that at times they were unsure as to the benefit 
gained from taking it.  This relates to the earlier subcategory ‘Immediacy of effects’ (1d): 
“I don’t feel like it does much but I know like when I don’t take it, I do notice that my 
chest feels a bit worse, but like for a day if I didn’t take it then I wouldn’t notice.  I 
went through a phase of not taking it because I didn’t think it was doing anything.” 
(Karen) 
 
Subcategory 3b: Beliefs about necessity 
Number of sources: 3 
Description: The adolescent patients reported specific beliefs concerning how necessary they 
felt it was to adhere to their aerosol therapy.  Many of these beliefs related to the way in 
which they perceived their symptoms, often linking a greater necessity to adhere to aerosol 
therapy with feeling unwell: 
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“When I’m well it kind of slides a bit.  It’s less of a priority, well it’s still a priority 
but it’s just not as important as when I’m unwell ‘cos when I’m unwell I want to get 
better but when I’m well it’s not as much of an incentive.” (Karen) 
 
Subcategory 3c: Beliefs about consequences 
Number of sources: 4 
Description: The adolescent patients reported having specific thoughts and beliefs 
concerning the potential consequences of not adhering to their aerosol therapy treatment:   
“I saw this programme once and it was about how things rot and I saw these erm like 
there were pseudomonas and that and erm it showed you how it looked through a 
microscope and stuff and proper bugs so ever since then like I’ve just been a bit more 
keen to do it.” (David) 
 
This category was also supported by one of the adolescent patients who reported that even 
though she understood at a cognitive level the potential consequences associated with not 
adhering to her aerosol therapy it did not necessarily encourage adherence:  
“’Cos like I’ve been told the consequences and stuff of not taking it and I still didn’t 
listen.” (Karen) 
 
Subcategory 3d: Beliefs about treatment preference 
Number of sources: 6 
Description: The adolescent patients reported that they were influenced by a number of 
different internal beliefs about the preferences they had for certain treatments.  Tablet 
medications, physiotherapy and aerosol therapy were the three main treatments that were 
often compared to each other with most (5/6) reporting that they preferred taking their tablets 
because these were more straightforward and took less time. 
“To be honest, I probably out of all of them I’d rather have me tablets.  They’re 
easier and they have less of an effect really.  Like I can do them really quick whereas 
all me other ones I can’t really do much while I’m having them.” (Simon) 
 
Many (4/6) reported that physiotherapy was the least favourite treatment because it was time 
consuming and often relied upon other people to help with the process. 
“Doing me accapella, it takes me about an hour sometimes two hours.  I just hate 
doing them, boring as well.  So that’s pretty much the only treatment like that I don’t 
really like having.” (David) 
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Some (3/6) said that they did not necessarily dislike taking their aerosol therapy but only one 
reported having a preference for this over other treatments: 
“I don’t mind having my Neb but it’s just the rest of them.” (David) 
 
Two patients reported disliking their aerosol therapy in comparison to other treatments, citing 
as reasons the time taken to administer it and the fact that it made them feel different to 
others:  
“I don’t mind taking my tablets or doing my insulin, it’s just that I wouldn’t sit there 
and do it [nebuliser] for five minutes when my mates are here.” (Karen) 
 
Category 4 – Emotional drivers 
Number of sources: 6 
Description: The adolescent patients reported experiencing a number of emotions relating to 
the process of adhering to aerosol therapy.  These emotions were quite different to those 
experienced by their parents.  However, the way in which they seemed to influence certain 
behavioural patterns was very similar but appeared to be less conscious than the processes 
described by their parents.  This category has been organised into four subcategories (see 
Figure 21). 
 
 
 
 
 
 
 
 
 
 
Figure 21: Subcategories contributing to adolescent data - Category 4 
 
Subcategory 4a: Fearing the consequences 
Number of sources: 4 
Description: Adolescent patients reported that they were afraid of the numerous physical and 
social consequences associated with not taking their CF treatments and more specifically, not 
taking their aerosol therapy.  Although this strongly relates to the earlier subcategory of 
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‘Beliefs about consequences’ (3c), the previous subcategory detailed a more cognitive 
engagement with thoughts and beliefs about the potential consequences of non-adherence 
whereas the current subcategory relates to the emotional fear concerning the potential 
consequences: 
“At the end of the day if I don’t take them I could die because I would become ill and 
that but it’s keeping me alive but I don’t like doing them. If I don’t attack them [The 
pseudomonas] they’ll just erm kill part of my lung.” (David) 
 
“I know that if I maybe stop taking it then I’ll grow pseudomonas again so it does 
encourage me to take them.  I’m just frightened of missing school at the minute ‘cos 
it’s an important stage now in high school.” (Elizabeth) 
 
Subcategory 4b: Feeling different to others 
Number of sources: 6 
Description: Adolescent patients reported that there were particular difficulties associated 
with taking their aerosol therapy in front of other people because it sometimes made them 
feel different and is related to the earlier subcategory ‘Beliefs about treatment preference’ 
(3d).  Some of the patients (3/6) reported that aerosol therapy was harder to take in front of 
others than treatments in tablet form because it took longer.  Two patients also talked about 
taking aerosol therapy in front of others, feeling that it was harder than physiotherapy 
because it was isolating, whereas certain types of physiotherapy could involve friends.  
Furthermore, some of the adolescent patients (2/6) reported that in addition to the difficulties 
associated with taking their aerosol therapy in front of friends, taking it in front of family 
members also singled them out.  
“[Looking at the downloaded data] I’m allowed to do my Dornase during TV but I 
always feel quite bad ‘cos I just sit there and feel silly cos it buzzes, well not me 
buzzing, it just buzzes and it’s quite loud and dad just sits and looks at me.” 
(Amanda) 
 
The language used by some of the participants emphasised the importance of keeping CF 
treatment separate form their social life:  
“You could go on the trampoline and that, you could do that with a mate but you 
couldn’t take your nebuliser with a friend obviously.” (Tom) 
 
 
 
 94 
Subcategory 4c: Not feeling understood 
Number of sources: 3 
Description: The adolescent patients reported that not feeling understood by family and 
friends was something that led to feelings of frustration and isolation, particularly when it 
concerned a lack of understanding about having to take treatments for CF:  
“‘Cos it’s like, no one else understands really, it’s like my brother, he doesn’t 
understand at all, he’s just like ‘oh why can’t you just do this, it’s not a big problem’ 
but it’s like, adds up.  And it’s like, like with my nebulisers it’s like I know mum thinks 
it isn’t much to do and I suppose it isn’t but it’s just another thing.” (Amanda) 
 
Subcategory 4d: Feeling tired and upset 
Number of sources: 4 
Description: The adolescent patients reported that adhering to their CF treatments became 
even more difficult when they were feeling in a ‘bad mood’ or were feeling particularly tired: 
“I just wouldn’t do them.  It depends what mood I’m in really.  Sometimes I don’t 
mind doing them but sometimes I do mind doing them.  Erm sometimes when I’m 
tired, erm, or just don’t feel like doing them.  I just get them over and done with 
quicker if I’m happy.” (David) 
 
“That isn’t just a nebuliser thing, I do it with my tablets sometimes I just think, oh I’m 
too tired.” (Karen) 
 
Category 5 – Strategies and behaviours 
Number of sources: 6 
Description:  The adolescent patients reported engaging in a number of strategies and 
behaviours concerning the process of adhering to their aerosol therapy.  Similarly to their 
parents, some of the reported strategies and behaviours were described as helping to facilitate 
adherence whereas others were describing as barriers to adherence.  Perhaps unsurprisingly, 
they were less able than their parents to discuss in detail the ways in which their thoughts, 
beliefs and emotions about aerosol therapy influenced their behavioural patterns but they still 
provided some very useful insights.    This category has been organised into five 
subcategories (see Figure 22). 
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Figure 22: Subcategories contributing to adolescent data - Category 5 
 
Subcategory 5a: Being in a routine 
Number of sources: 6  
Description: Adolescent patients reported that having a consistent routine helped to 
encourage adherence.  Many (3/6) of the patients reported that there was more of an 
established routine with their treatments during weekday term-times: 
“[Looking at the downloaded data] In the weekday I have much more of a routine I 
couldn’t describe my routine at the weekend, everything kind of just goes so I don’t 
know when I’m doing what, so I just try and fit it in when I can.” (Amanda) 
 
“[Looking at the downloaded data] I take it, me first one which is just normally 
Promixin, I take after my dinner which is about half 5, quarter to 6 so sometimes I’ll 
be sitting here and it will hit 6 o’clock and I’ll be sitting here watching telly and I’ll 
go ‘Oh no’ so then I have to run into the kitchen and do it.” (Elizabeth) 
 
Subcategory 5b: Getting it done vs. putting it off 
Number of sources: 5 
Description: The adolescent patients reported that they often engaged in two very separate 
strategies when it came to taking their aerosol therapy.  Although some (3/5) appeared to 
have a preference for getting their aerosol therapy done quickly in order to free up their spare 
time, others (2/5) noticed a tendency to delay taking their aerosol therapy.  While the data 
suggested that there were preferences, reports also indicated that these were not necessarily 
clear cut with adolescent patients sometimes alternating between the two strategies:  
“’Cos you can get it over and done with and you can do what you want then.” (Tom) 
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“[Looking at the downloaded data] I just leave it too late, that’s the only reason ‘cos 
I leave it too late and then I can’t be bothered so I just got to bed.  But if I’ve got 
something to do I think ‘I’ll do it straight away’ and then I can go and do this.”  
(Karen) 
 
Subcategory 5c: Breathing technique 
Number of sources: 6  
Description: Adolescent patients reported that appropriate breathing technique was essential 
when using the I-neb™ device with all saying that it was important to take slow, deep breaths 
to ensure accurate administration.  Although many (5/6) said that the TIM mouthpiece helped 
to facilitate an accurate breathing technique, some of these patients (3/6) also reported that 
trying to breathe quickly in order to speed up the process was still sometimes tempting: 
“To make it easy you just have to breathe in like slowly instead of like fast because it 
like, it like it goes ‘HMMMMM’ and then it goes quiet and then it does a little shaking 
thing.  So if you do that fast, then, it’s going to be harder. But if you do it slow then it 
gets to it.” (Tom) 
 
“When I’m taking me Neb and I’ll be breathing, when I’m rushing I’ll be breathing 
faster to try and get it done and obviously that’s not the way to go about it because 
you’re not waiting for the buzz, so it takes longer.” (Elizabeth) 
 
Subcategory 5d: Forgetting 
Number of sources: 6 
Description: Adolescent patients reported that they sometimes forgot to take their aerosol 
therapy.  Although forgetting was largely accidental, two patients reported that forgetting to 
take their aerosol therapy also provided them with the opportunity to forget that they were ill:  
“‘Cos I forget (laughs), I know it’s nice, not remembering I suppose.  But it’s kind of 
hard to forget so I don’t really manage it.  It’s nice to forget you’re ill, that’s good.” 
(Amanda) 
 
The above patient went on to further explain that the regularity involved with taking aerosol 
therapy over a long period of time actually serves to facilitate forgetting and that this causes 
her parents some confusion: 
“That’s what mum and dad never understand they say ‘How can you forget? You’ve 
been doing it all your life’.  It’s just I don’t know, maybe it’s ‘cos of that I just 
forget.” (Amanda) 
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Subcategory 5e: Planned vs. spontaneous non-adherence 
Number of sources: 6 
Description: The adolescent patients reported that there were occasions when they had either 
planned to not take their aerosol therapy or when the decision to not adhere had occurred 
more spontaneously.  The reported explanations for spontaneous non-adherence were 
multiple and included being too busy, being late for something (e.g., catching the school bus, 
attending an out of school activity) and leaving it too late.  Reasons for planned non-
adherence included going away on holiday, staying over in a different house or having an 
event or celebration planned.  Some (4/6) reported that having a break from adherence was 
welcomed.  Three patients reported that planned non-adherence was often discussed more 
openly: 
“Most people know about it.  I think the people at the hospital know as well.  They 
don’t seem too bothered that I have a night off.  I quite like it because I can do a lot 
more.  I can do what I want really.” (Simon) 
 
Category 6 – Adolescent patients’ experience of their parent’s behaviour 
Number of sources: 6 
Description: The adolescent patients reported on their experiences of the behaviour of their 
parent; largely the behaviour of the mothers.  As discussed earlier, many of the reports 
concerning their parent’s behaviour were commented upon indirectly and those accounts that 
were more direct were largely positive.  This category comprises three subcategories (see 
Figure 23). 
 
 
 
 
 
 
 
 
 
 
Figure 23: Subcategories contributing to adolescent data - Category 6 
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Subcategory 6a: Being reminded 
Number of sources: 6 
Description: Adolescent patients reported on the complicated relationship between 
reminders and adherence with most (5/6) saying that reminders were helpful: 
“[Looking at the downloaded data] Erm on Sunday morning my mum reminded me, 
she said ‘Have you took your Neb?’, then I says ‘Oh God no!’.  Erm, so I’ve gone and 
done it.” (David) 
 
However, despite it being helpful this subcategory was also supported by statements from 
two adolescent patients who said that being reminded was still a source of frustration: 
“I don’t like being reminded but I know that if I don’t get reminded then I won’t do 
it.” (Karen) 
 
This subcategory is also supported by statements made by one of the adolescent patients who 
felt that the supportive way in which reminders were communicated helped to encourage 
adherence and was consistent with her father’s earlier account: 
“Erm, my dad and [Name of Dad’s partner], they really help me a lot.  They kind of, 
say if I’ve forgot and they say ‘Is there anything you need to do?’ and I immediately 
know.” (Elizabeth) 
 
A statement made by one of the younger adolescent patients suggested that he is not afforded 
the luxury of being reminded to take his aerosol therapy treatment: 
“I don’t get reminded, I just get told to do it.” (Tom) 
 
Subcategory 6b: Being rewarded 
Number of sources: 5 
Description: The adolescent patients reported that their parents often rewarded and 
incentivised their adherence to aerosol therapy.  This strategy was reported to have a 
motivating impact which encouraged adherence: 
“Then after my dinner all my physio and I-neb and everything, after I’ve done all 
that, I can go back on my Xbox for like 10 or 20 minutes.” (Tom) 
 
“[Looking at the downloaded data] I just like the kind of Saturday night TV stuff and 
my mum and dad don’t like me doing it [nebuliser] during TV so I have to get it done 
before TV.” (Amanda) 
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Subcategory 6c: Being Supported 
Number of sources: 5 
Description: The adolescent patients reported that their parents offered much needed support 
when it came to taking their CF treatments and more specifically, adhering to their aerosol 
therapy.  The main types of support were practical (e.g., ordering the medication, cleaning the 
device) and emotional (e.g., empathising about treatment burden and providing comfort): 
“I don’t know what I’d do without them ‘cos they’re a big part of it I suppose.  They 
just help me in massive ways like sometimes I’ll feel a bit down about it and upset and 
they comfort me and stuff like that.” (Elizabeth) 
 
 
Category 7 – Parent and adolescent relationship 
Number of sources: 6 
Description: The adolescent patients reported on their experiences of the relationship with 
their parents.  Although many of the reports concerning the parent and adolescent relationship 
were again commented upon indirectly, the relationship was seen as influencing and 
mediating the process of adhering to aerosol therapy.  This was very similar to the process 
reported by the parents with a more beneficial impact on adherence being associated with 
more positive aspects of the relationship.  This category comprises four subcategories (see 
Figure 24). 
 
 
 
 
 
 
 
 
 
Figure 24: Subcategories contributing to adolescent data - Category 7 
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“I’ve just got to remember, but most of the time my mum’s in so I just do it when she 
gives it to me.” (Simon) 
 
“If my mum probably wasn’t around then I probably wouldn’t do them.” (David) 
 
The parent data reports suggested that relinquishing this responsibility and control as the 
child grew older was difficult.  Some (2/6) adolescent patients reported that they recognised a 
need to take on greater responsibility as they got older: 
“I’m going to have to learn to order it myself aren’t I?  If I get into a routine of doing 
my neb every night it will help when I’m older won’t it?” (David) 
 
This category is also supported by one adolescent patient who reported both recognising the 
need for taking on greater responsibility and who demonstrated an impressive ability to 
largely manage the process of adhering to the aerosol therapy herself.  However, having the 
safety net of support offered by her parents was seen as reassuring and relates to the earlier 
subcategory ‘Being supported’ (6c):   
“When I moved up to senior school and erm obviously I needed to start taking 
responsibility because my dad’s not always in the house so obviously I had to learn 
kind of how to do it.” (Elizabeth) 
 
“I mean if I’m tired and I want to go to bed, sometimes they’ll wash my neb for me or 
make it up if I’m not well or whatever.” (Elizabeth) 
 
Subcategory 7b: Clear and consistent communication 
Number of sources: 6 
Description: The adolescent patients reported that when it came to the process of adhering to 
aerosol therapy, having clear and consistent instructions and expectations from their parents 
was experienced as helpful.  Patients also reported that they often became frustrated when 
this was not the case: 
“She doesn’t, like, ‘cos if she were messing me around, like saying, ‘come and do 
your physio’, I do it.  Then I go back up and then when I’ve just got back up to my 
room she says ‘come and do your nebuliser’, it would be quite annoying.  But she says 
it as soon as I’ve finished my physio.” (Tom) 
 
Subcategory 7c: Cooperating and problem solving 
Number of sources: 4 
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Description: The adolescent patients reported that problems often got in the way of adhering 
to aerosol therapy.  The successful negotiation of these problems was often achieved by the 
parent and adolescent working together to decide upon a solution:   
“[Looking at the downloaded data] We had a conversation that we couldn’t leave too 
late because I hadn’t done my Neb and erm obviously the party was going to go ‘til 
like one, two in the morning.  I think I just said that I hadn’t had my Neb and we said 
that we couldn’t leave too late then.” (Elizabeth) 
 
Subcategory 7d: The potential for conflict 
Number of sources: 4 
Description: The adolescent patients reported that the process of adhering to aerosol therapy 
sometimes had the potential to cause conflict between the adolescent and their parent.  The 
main sources of frustration for the adolescents came from parents ‘nagging’ or failing to 
recognise the burden of having to adhere to the aerosol therapy.  The main frustrations for the 
parents were their child forgetting to take their aerosol therapy:   
“My mum like nags me.  Like mum says ‘take your neb’ and sometimes I like argue 
and say that I don’t want to.” (David) 
 
Category 8 – Everyday life 
Number of sources: 6 
Description: Adolescent patients reported very similar findings to their parents in terms of 
the way in which everyday life impacted on the process of adhering to the aerosol therapy 
treatment regimen and vice versa.  Patients reported an additional emphasis on the way in 
which aerosol therapy gets in the way of fun hobbies and activities.  This category has been 
organised into four subcategories (see Figure 25).  
 
 
 
 
 
 
 
 
 
 
Figure 25: Subcategories contributing to adolescent data - Category 8 
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Subcategory 8a: School days vs. Weekends 
Number of sources: 6 
Description: Similarly to their parents, adolescent patients reported that there were 
differences in school day and weekend adherence.  Some (3/6) reported that it was easier to 
adhere to their aerosol therapy during schooldays because of the consistent routine and relates 
to the earlier subcategory ‘Being in a routine’ (5a).  When referring back to the parent data, 
this seemed to match their perceptions also but only for two out of the three patients: 
“[Looking at the downloaded data] Erm I think it’s better in school time because I’ve 
got a routine that’s going on in school time.” (Elizabeth) 
 
In contrast, one patient reported that weekends were harder to adhere to because she felt she 
had less time.  This was actually inconsistent with her parent’s view: 
“[Looking at the downloaded data] I think I find it harder at weekends ‘cos we’re 
strapped for time a bit at weekends.” (Amanda) 
 
This subcategory is also supported by some (2/6) patients who said that weekend adherence 
was easier and one patient who did not feel there were any differences between schooldays 
and weekends: 
“I prefer doing it when I’m off school because I have more time.” (David) 
 
“I find them the same on weekends and weekdays.” (Simon) 
 
Subcategory 8b: Mornings vs. Evenings 
Number of sources: 6 
Description: Adolescent patients reported that there were times during the day that adhering 
to aerosol therapy was easier with some (3/6) suggesting that evening adherence was more 
straightforward: 
“Probably in the evening ‘cos I’ve got more energy whereas in the morning I’ve just 
woke up so I’m a bit drowsy.” (Simon) 
 
“I was like missing registration so I’d have to go and explain why I was late and 
things like that and so then we just decided to do it of a night time because it was 
easier and we had time on the night time.” (Elizabeth) 
 
Interestingly, this subcategory was also supported by statements made by half (3/6) of the 
adolescent patients who reported that they felt morning adherence was easier despite the 
downloaded data suggesting that they took their aerosol therapy in the evening.  One patient 
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said that he realised he took it at night but just thought it would probably be easier in the 
morning whereas the other two were more surprised when presented with the downloaded 
information.  This relates to the earlier subcategory ‘Using the downloaded data’ (2c): 
“[Looking at the downloaded data] I don’t know.  It might be ‘cos I lie in sometimes, 
when I don’t have college.  I have a lie in, so I don’t get up ‘til dinner time so then 
I’m a bit out of the routine.  That could be why actually.” (Karen) 
 
Subcategory 8c: Aerosol therapy gets in the way of fun 
Number of sources: 5 
Description: Adolescent patients reported that having to take aerosol therapy is often 
experienced as inconvenient and can get in the way of enjoyable hobbies and activities: 
“Like when I’m in the middle of something and I’m like doing really good on my Xbox 
or something.  Like in a match and my Mum says to me to come down and do it and I 
say I’ll just finish this match and I say it like 10 times and she keeps calling me 
down.” (Tom) 
 
“It’s not particularly fun and it’s just, I don’t know it kind of gets in the way of me 
playing on the computer endlessly or erm like if I’m going to my friends.” (Amanda) 
 
This subcategory was also supported by two patients who said that although the I-neb can get 
in the way, the prospect of fun activities can also be used to motivate adherence and relates to 
the earlier subcategories ‘Getting it done vs. putting it off’ (5b) and ‘Being rewarded’ (6b): 
“If I get it done quicker I can do more stuff like play me guitar, go on my Xbox, watch 
telly or play out like.  If I get it done quick, I can just make the most of the day.” 
(David) 
 
Subcategory 8d: Parties, events and celebrations 
Number of sources: 4 
Description: The adolescent patients reported that celebrations and special occasions often 
impacted on adherence to aerosol therapy.  Similarly to their parents, the adolescent patients 
reported that adherence took on less of a priority at these times and relates to the earlier 
subcategory ‘Planned vs. spontaneous non-adherence’ (5e): 
“Going to the pub with my family or going to a party and being late or family coming 
erm when my family comes and stay over for the night I just want to spend time with 
family and forget about it.” (David) 
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Category 9 – Environmental influences 
Number of sources: 6 
Description: All of the adolescent patients reported on the impact that certain aspects of the 
environment had on the process of adherence.  Many of the patient accounts were similar to 
those reported by their parents, particularly in terms of the way in which less familiar 
environments acted as a barrier to adhering to their aerosol therapy.  In addition, the 
adolescent patients highlighted the negative impact that easy access to technological devices 
within their environment had on the process of adherence.  There are three subcategories that 
contribute to this core category (see Figure 26). 
 
 
 
 
 
 
 
 
 
 
Figure 26: Subcategories contributing to adolescent data - Category 9 
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Description: The adolescent patients reported that it was more difficult to adhere to their 
aerosol therapy when they were staying over at someone else’s house.  There were a number 
of reasons for this with explanations relating to the earlier subcategories ‘I-neb™ device is 
not portable’ (2e), ‘Feeling different to others’ (4b) and ‘‘Planned vs. spontaneous non-
adherence’ (5e): 
“[Looking at the downloaded data] I don’t normally take me neb to me dad’s err I 
think like it’s like a bit of a night off it.  Saturday I was staying at me friend’s house.  
If I’m staying at me mates I don’t really bring it either.  I think that’s also a bit of a 
night off I think sometimes as well.  It’s just relaxing really and I can just talk to me 
mates and that.” (Simon)  
 
Subcategory 9c: Getting distracted by technological devices 
Number of sources: 5 
Description: Adolescent patients reported that they would frequently get distracted when it 
came to taking their aerosol therapy.  Becoming distracted was often reported by the 
adolescent patients in terms of them being passively influenced by aspects of their 
environment as opposed to them actively engaging in distractions as some kind conscious 
behaviour.  Technological distractions (e.g., television, social networking sites and mobile 
phones) were the main sources with patients reporting that these things were often 
responsible both for forgetting to take the aerosol therapy altogether and for partial 
administration: 
“[Looking at the downloaded data] I came back down to watch telly and [Name of 
boyfriend] said ‘Do your I-neb’.  Then someone could have rang, it does that a lot, 
someone rings me and I put it down.  It could have been my dad that rang me’. 
(Karen) 
 
“[Looking at the downloaded data] I was probably on my computer, I might have 
been texting someone.  If I’m on Facebook and I see something interesting, I’ll put it 
down to type something or if I’m like on a game I’ll put it down to do something 
quickly and I’ll forget about it.” (Amanda)
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4.0 DISCUSSION 
The aim of the discussion chapter is to relate the findings of the current study to the 
existing literature.  This chapter will begin by revisiting the research aim before providing a 
summary of the results.  The main findings of the study will then be discussed in terms of the 
contribution they make to the existing knowledge base before moving on to summarise a 
number of methodological considerations, clinical implications and suggestions for future 
research.  
4.1 Revisiting the research aim 
 The primary research aim of the current study was to qualitatively explore how the 
process of adhering to aerosol therapy in CF is experienced by both an adolescent patient and 
their parent.  Although there were secondary research questions (e.g., the differences and 
commonalities in the experience of aerosol therapy compared to other therapies used in CF; 
and whether the use of the data downloaded from the I-neb™ device helped to qualitatively 
explore the process of adhering to aerosol therapy) the main focus of the discussion will 
centre around the primary research aim. 
 12 participants (six parent-adolescent dyads) were interviewed about their experiences 
of adhering to aerosol therapy.  A seven-day retrospective download of data from the I-neb™ 
device was used to help guide part of the semi-structured interview.  The Grounded Theory 
Method was used to analyse the interview transcripts and a theoretical formulation describing 
the participants’ experiences of the process of adhering to aerosol therapy was developed.  It 
is hoped that this will contribute to the wider literature concerning adherence to treatment in 
adolescents with CF. 
4.2 Summary of results 
The analysis revealed a complex interaction of cognitive, emotional and behavioural 
processes around adherence, with the parent and adolescent experience of one another at the 
core, and the parent and child relationship mediating the interactions.  The above processes 
are further influenced by the interactions with the aerosol therapy treatment regimen, device 
characteristics and context in which adherence is taking place. 
Participants were cued by the data downloaded from the I-neb™ device which helped 
to offer a window into their lived experience and enabled rich and open accounts of the 
numerous processes that influence adherence to aerosol therapy treatment to be gained.  
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Parents and adolescents often compared aerosol therapy to other forms of treatment, with an 
internal hierarchy of preference often favouring those treatments that were quick and less 
intrusive.  Although the overall theoretical formulation was very similar for adolescent and 
parent, the analysis highlighted the way in which the same phenomena could be experienced 
from different viewpoints and provided valuable insight into the process of adherence from 
both perspectives.  
The current study supports the view of Dziuban et al (2010) who suggested that 
treatment adherence is likely to be influenced by deep and complex psychosocial processes 
that are often difficult to ascertain.  There is also support for the developmental, 
biopsychosocial model proposed by Barker & Quittner (2010), with the current study 
identifying a series of interacting biological (i.e., aerosol therapy regimen characteristics 
which are often dependent on disease management and progression), psychological (i.e., 
cognitive, emotional and behavioural processes alongside specific developmental challenges 
in the context of the parent-child relationship) and social influences (i.e., the environment in 
which adherence takes place and the demands of everyday life) on adherence to aerosol 
therapy treatment. 
4.3 The aerosol therapy 
 Parents and adolescents reported on the impact of both aerosol therapy regimen 
characteristics and device characteristics on the process of adherence. 
4.3.1 Regimen characteristics 
 The analysis revealed that parents and adolescents found that many of the 
characteristics of the aerosol therapy treatment regimen had a negative influence on the 
process of adhering to treatment.  Particular areas highlighted were the fact that aerosol 
therapy was only one aspect of an already time consuming and demanding treatment regimen.  
Treatment regimens that are time consuming and burdensome have consistently demonstrated 
an association with poorer adherence in children and adolescents with a chronic health 
condition (Hayford & Ross, 1988; Lemanek et al., 2001; April et al., 2008) and more 
specifically for those living with CF (Passero, Remor, & Salomon, 1981; Modi & Quittner, 
2006; Williams, Mukhopadhyay, Dowell, & Coyle, 2007; Bucks et al., 2009). 
 Related to the above was the novel finding that adolescents and parents felt that the 
interdependent nature of certain treatments – particularly between aerosol therapy and 
physiotherapy – added an additional layer of complexity to the process of adhering to 
 108 
nebulised treatments, something not previously explored in the literature.  This could be 
because interdependence is something specifically related to the process of adhering to the 
CF treatment regimen.  However, it could also reflect the fact that interdependence of certain 
treatments (e.g., the necessity of waiting an hour after doing physiotherapy before being able 
to take aerosol therapy) is more commonly described within the research literature under the 
general heading of complexity.  Indeed, the complexity of a given treatment regimen and the 
way in which this negatively impacts on rates of adherence is a widespread finding for those 
children and adolescents living with a chronic health condition (Glasgow, McCaul, & 
Schafer, 1986; Feldman et al., 2007; April, et al., 2008) and more specifically for those living 
with CF (Passero et al., 1981; Dziuban et al., 2010; George et al., 2010).    
The quantity and type of medication prescribed as part of the aerosol therapy 
treatment regimen was reported as an additional factor which negatively impacted on the 
process of adherence.  Previous research supports this observation with lower adherence 
being found in three times daily vs. two times daily medication regimens (Van Dyke, Lee, 
Johnson, Wiznia, Mohan, & Stanley 2002) for example.  Related to this issue is the finding 
that some of the parents felt that the hospital doctors did not appreciate and empathise with 
the burden associated with increasing the prescribed number of aerosolised therapy 
treatments.  Clearly, the quality of the provider-patient interaction is important with many 
studies suggesting that practitioners’ ability to make empathic, affective contact with patients 
improves satisfaction with the consultation and increases the commitment to a treatment plan 
and overall adherence to the regimen (Becker & Maiman 1975; Squier, 1990).  However, 
perhaps surprisingly the participants did not place much emphasis on the impact of the health 
providers’ behaviour on the process of adherence, a finding which echoes Hall et al’s (Hall, 
Roter & Katz, 1988) influential meta-analysis which concluded that overall, provider 
behaviour is relatively weakly related to adherence.  This does not mean, of course that health 
providers do not have the potential to influence adherence, but it does indicate that other 
factors are far more salient to the families in this study.   
Several parents and adolescents described specific unpleasant side effects associated 
with taking aerosol therapy.  The concept that regimens which produce more negative side 
effects should be associated with lower adherence makes intuitive sense.  Research 
examining this hypothesis in patients with asthma for example, found that unpleasant tasting 
medications were related to lower adherence (Slack & Brooks, 1995; Celano et al., 1998).  
However, fewer studies have investigated this factor in CF and those more recent studies 
which have identified a series of barriers to adherence in adolescents with CF have failed to 
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identify unpleasant side effects as a major difficulty (Dziuban et al., 2010; George et al., 
2010; Bregnballe et al., 2011).  One potential explanation for this is that the above studies 
examined potential barriers to adherence for the overall regimen as opposed to specific 
treatments.  It could be argued that studies examining barriers to specific aspects of the 
treatment regimen are more likely to focus on participants’ responses and provide more 
detailed information about the barriers and facilitators associated with the particular treatment 
under investigation.  Indeed, the current study was specifically designed to attempt to achieve 
that aim. 
One patient identified that he actually liked the taste of a particular aerosolised 
antibiotic that another patient found unpalatable.  This was an interesting finding.  However, 
previous studies have found that although children and adolescents may have taste 
preferences for different antibiotics, there is no differentially related adherence associated 
with these preferences (El-Charr, Mardy, Wehlou, & Rubin, 1996; Matsui, Barron, & Rieder, 
1996). 
Adolescent patients said that the lack of immediate benefits gained from taking 
aerosol therapy can negatively impact on adherence.  This is a common finding within the 
research literature as the immediacy of benefits gained from treatments prescribed to children 
and adolescents living with a chronic health condition are often delayed (Lovell, Giannini, & 
Brewer, 1984; Rapoff, 2010).  
4.3.2 Device characteristics 
 Parents and adolescents identified a number of characteristics of the I-neb™ device 
itself which had an impact on the process of adherence to aerosol therapy.  Many of these 
characteristics were related to technological advances that were experienced as having a 
positive influence.  Parents for example, highlighted that they were able to compare the 
advances of the newer I-neb™ device to those more cumbersome and demanding devices that 
were previously used.  Parents described the associated relief of not having to endure some of 
the difficulties that accompanied the older devices (e.g., larger devices with more 
components that had to be administered with the window open to aid ventilation).  Whilst the 
adolescents did not specifically highlight this as a motivating factor – perhaps reflecting their 
inability to remember the burden associated with the older devices – parents clearly felt 
fortunate that the I-neb™ device was smaller, less demanding and easier to use.  Although 
nebulisers have been used for administration of inhaled medications for the treatment of a 
number of chronic health conditions (e.g., pulmonary infections, asthma) since the 1920s, it 
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was the recognition of exactly the types of limitations of conventional nebulisers that were 
identified by the parents that led to the development of newer devices – such as the I-neb™ 
which utilises AAD technology – over the last two decades (Denyer, Nikander & Smith, 
2004). 
The recency of the topic concerning the ways in which technological advances may 
influence adherence to treatment in CF serves to limit the existing research investigating the 
relationship.  However, there have been a number of studies examining devices that utilise 
the AAD system compared to conventional nebulisers.  These studies indicate that more 
complete doses are taken with the newer devices when compared with conventional 
nebulisers (Marsden, Conway, Dodd, & Weller, 2002), they are easier to use, administration 
times are reported to be significantly reduced when compared with conventional nebulisers 
(Mulrennan, Moon, & Morice, 2004) and patients found it better to use than their older 
nebuliser device (Marsden, Conway, Dodd, Edenborough, Rigby, Taylor, & Weller, 2002).  
In addition, there were a number of promising studies that presented initial findings at the 
recent European Cystic Fibrosis Society conference (Journal of Cystic Fibrosis, 2012) which 
indicated the potential usefulness of newer technologies in encouraging and motivating 
adherence to treatment (Pollard, Watson, Conway, Etherington, Ollerton, & Peckham, 2012). 
   The ability of TIM to provide specific feedback on breathing technique through the 
use of a vibrating mouthpiece was identified by both the parents and adolescents as having a 
positive impact on accurate breathing technique, resulting in quicker administration times.  
Some parents and adolescents thought the reduction in administration times were so 
significant that it had led to greater motivation to adhere to the I-neb™ and a reduction in 
oppositional behaviour and arguments.  These findings are certainly in keeping with previous 
research with a number of studies suggesting that TIM is acceptable to patients (Denyer, 
Black, Nikander, Dyche, & Prince, 2010; Denyer, Prince, Dixon, Agent, Pryor, & Hodson, 
2010; Goodman, Morgan, Nikander, Hinch, & Coughlin, 2010) and a more recent study 
finding that TIM significantly reduces treatment administration times and may positively 
influence adherence to treatment (McCormack, McNamara, & Southern, 2011). 
Adolescents also highlighted the ability of the I-neb™ to provide specific feedback on 
correct positioning of the device (e.g., the use of an alarm) and completion of treatment 
administration (e.g., the use of an auditory beep and a visual LED smiling face).  Denyer & 
Dyche (2010) argue that the role of feedback signals throughout nebulisation with the I-neb™ 
is essential to a successful drug delivery.  From a psychobiological perspective, positive and 
negative feedback mechanisms regulate a huge amount of human physiological processes 
 111 
(Carlson, 2007; Kalat, 2007).  The human body is therefore not only naturally programmed to 
seek out and understand feedback but traditional behavioural theories such as operant 
conditioning (Skinner, 1948; 1953) further suggest that when a particular action has good 
consequences (such as positive feedback), the action will tend to be repeated whereas an 
action associated with bad consequences (such as negative feedback) will tend not to be 
repeated.  A number of clinical studies have examined the use of feedback on the compliance 
with the correct use of devices that utilise AAD technology (Conway, Dodd, Marsden, Paul, 
& Weller, 2002; Nikander, Arheden, Denyer, & Cobos, 2003; Goodman, Morgan, Nikander, 
Hinch & Coughlin, 2010).  These studies found that over 80% of patients administered the 
AAD device until the feedback cascade informed them that they had come to the end of 
nebulisation.  In the current study, adolescents highlighted the role of feedback both in terms 
of the way it encouraged adherence to aerosol therapy and how it improved the overall 
accuracy of the treatment.  
       Related to the above issue of device feedback was the finding that parents and 
adolescents had mixed opinions as to the usefulness of the patient logging system (PLS) data 
downloaded from the I-neb™ device.  Many felt that it was extremely useful whereas some 
were more ambivalent.  This was true both for within outpatient appointments and within the 
current research interview process itself.  In terms of clinical settings, PLS data can be 
actively used by clinicians to monitor their patients and identify those who are not adhering 
to their aerosol therapy treatment or failing to use the I-neb™ device correctly (Denyer & 
Dyche, 2010).  A number of studies utilising this PLS data found that rates of adherence to 
nebulised antibiotics were generally low (50%) in adults (Latchford et al., 2009) and slightly 
better in children and adolescents (between 60 and 70%) (McNamara et al., 2009).  The 
authors concluded that whilst AAD system technology may improve medication 
administration, rates of adherence may still be sub-optimal.  They went on to suggest that 
clinicians can utilise PLS data to routinely monitor adherence within an outpatient setting but 
that they should be mindful of the pattern of non-adherence for each individual patient and 
the multiple factors which may be influencing this. 
The way in which this data is used and communicated to patients and their parents is 
clearly important.  The current study found that one patient had a preference for the gentle 
and encouraging way that her CF clinician utilised the PLS data in her outpatient appointment 
compared to the pejorative way in which her diabetes clinician utilised similar data 
downloaded from her attached insulin pump.  Some approaches within the literature favour 
the former approach.  Motivational Interviewing (MI) (Miller, 1983; Miller & Rollnick, 
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1981) for example, is a directive, patient-centred counselling style that aims to help patients 
explore and resolve their ambivalence about behaviour change.  MI has been used in medical 
settings for a number of years and a recent review suggests that MI is well-received by 
patients and is an effective framework for guiding CF outpatient consultations particularly in 
order to encourage and improve adherence (Duff & Latchford, 2010). 
 Parents and adolescents also reported that certain characteristics associated with the 
device were burdensome.  The adolescents reported that it was common for them to prepare 
the medication and device ready for administration whereas parents tended to be responsible 
for cleaning the device afterwards.  Although this preparation was not specifically 
highlighted as problematic for the adolescents, the process was clearly very detailed and 
represented an additional degree of complexity when compared to treatments such as oral 
medications.  In contrast, the process of cleaning was identified as very burdensome, 
particularly by the parents.  It is vitally important to adequately clean the device in order to 
prevent harmful bacteria growing and to ensure optimal efficacy of medication delivery.  The 
process of cleaning is quite complex (Koninklijke Philips Electronics, 2010).  Parents were 
clearly aware of the importance of cleaning but said that it was onerous and negatively 
impacted on the portability of the device which made adhering to aerosol therapy outside of 
the home problematic.  The issues highlighted may go some way to explaining why recent 
research indicated that approaching 40% of patients do not clean their nebuliser at all (Boyle 
& Hall, 2012).  Patients also highlighted additional reasons for the lack of portability of the 
device including experiencing the device as fragile and expensive and they discussed how 
this negatively impacts on the process of adherence.  This was an important point as on the 
one hand, many of the devices technological advances appeared to encourage the process of 
adherence but on the other hand, the resulting complications of additional cleaning and the 
anxiety associated with the fear of losing or damaging a device perceived as very expensive 
seemed to act as barriers.      
4.4 Cognitive, affective and behavioural processes 
Analysis revealed the complex way in which parents’ and adolescents’ thoughts and 
beliefs about aerosol therapy interacted with a series of emotional and behavioural responses 
which all had their relative strengths and weaknesses in facilitating the process of adherence. 
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4.4.1 Beliefs about aerosol therapy 
 Parents and adolescents reported a number of salient thoughts and beliefs concerning 
aerosol therapy.  This is a common finding within the research literature with many studies 
suggesting that patients hold complex beliefs about medications and that these might 
influence adherence to treatment (Conrad, 1985; Britten, 1994; Horn, 1997).  Although 
variation exists across studies in terms of the specific type of beliefs that are associated with 
adherence, findings indicate that certain cognitive variables included in the Theory of 
Planned Behaviour (TPB: Ajzen, 1988) and the Health Belief Model (HBM: Rosenstock, 
1974; Janz & Becker, 1984) appear to predict adherence in certain situations.  Adherence 
decisions for example, may be influenced by a cost-benefit analysis whereby the perceived 
benefits of treatment are weighted against the perceived barriers (Nelson, Stason, Neutra, 
Soloman, & McArdle, 1978; Cummings, Becker, Kirscht, & Levin, 1981; Brownlee-Duffeck, 
Peterson, Simonds, Goldstein, Kilo, Hoette, 1987).  The main benefit associated with 
adhering to aerosol therapy as identified by both the parents and the adolescents in the current 
study was that the treatment is effective.  However, the above research suggests that these 
beneficial effects are likely to be considered alongside the numerous barriers – many of 
which have already been discussed in detail above – and it is this cost-benefit analysis which 
can influence adherence.   
Although it would appear that for many of the participants, the belief in the positive 
benefits gained from taking aerosol therapy outweighed the associated costs, some 
participants were less sure as to the benefit gained, arguably making the cost-benefit analysis 
less clear cut.  In addition, patients also reported that they were influenced by the beliefs they 
had about preferences for different treatments.  They described wide variation in the costs 
and benefits associated with different treatments and it was clear that this internal hierarchy 
of treatment preference was often responsible for influencing the process of adherence.  For 
some patients, it is also possible that their own preferences for a particular treatment might 
not match their parents’ preferences leading to additional complications, potential 
disagreements or conflict.    
 Further variables of the HBM and TPB are reflected in research that found higher 
rates of adherence in those patients who believe that failure to take the treatment could result 
in adverse consequences that they are personally susceptible to (Nelson et al., 1978; 
Cummings et al., 1981; Kelly, Mannon & Scott, 1987).  The parents and adolescents in the 
current study reported specific beliefs about the potential consequences of not adhering to 
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aerosol therapy.  It is likely that these thoughts and beliefs about consequences were 
influencing the feelings and behaviour of many of the participants and helping to encourage 
the process of adherence.  One patient however (Karen) said that although she was aware of 
the consequences at a cognitive level, it did not particularly encourage her to adhere to the 
aerosol therapy.  It is possible that for this patient, the cost-benefit analysis described was not 
convincing enough to drive adherence behaviour.  Although it is likely that a myriad of 
additional biopsychosocial influences were impacting on this patient’s adherence behaviour, 
it is interesting that her adherence rate was the lowest of all participants, at 28%.  
 Many of the above concepts relate to more systematic research by Horne and 
colleagues (Horne, 2003; Horne, Weinman & Hankins, 1999) that suggest that four core 
themes – specific necessity, specific concerns, general harm and general overuse – underlie 
commonly held beliefs about medications.  The first two factors describe people’s beliefs 
about their prescribed medicines and were found to be more strongly related to adherence 
reports than the second two factors which describe people’s beliefs about medicines in 
general.  Specific necessity describes beliefs that people have around the perceived need of 
the prescribed medication for maintaining health.  Adolescents in the current study reported 
beliefs they held about the necessity of adhering to the aerosol therapy medication.  Many of 
these beliefs related to the way in which they perceived their symptoms, often linking a 
greater necessity to adhere to aerosol therapy with feeling physically unwell.  Previous 
studies have shown that those with stronger beliefs in the necessity of their prescribed 
medication reported greater adherence to the regimen (Horne, 2003; Horne et al., 1999).  This 
research also showed that, although illness perceptions (such as the way the adolescents 
perceived the severity of their symptoms) can explain variance in adherence, they may play a 
more important role in determining beliefs about treatment.  In a study of factors influencing 
adherence to preventative treatments for patients with asthma for example, stronger beliefs 
about the necessity of taking these medications were found in those who perceived their 
condition as more chronic with greater negative consequences (Horne & Weinman, 2002). 
 There are other theories with a focus on cognitive approaches to non-adherence.  
Kendall (1993) argues that thoughts or self-generated rules can influence adherence 
behaviour in two general ways.  Firstly, patients and parents can fail to generate thoughts or 
rules about the health condition and associated treatment regimen when it would be helpful to 
do so (e.g., “I need to take my treatment consistently in order to give the medication a chance 
to work.”).  Secondly, patients and parents may actually generate counterproductive thoughts 
or rules (e.g., “I’ll take my treatment so long as I’m not too busy”).  The current study 
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provided examples of both the failure to generate cognitions (e.g., Karen: “I’ve been told the 
consequences and stuff of not taking it and I still didn’t listen) and the generation of unhelpful 
cognitions (e.g., Lindsey: “You tend to think, ‘well you’ll be alright for a few days’ or 
whatever, ‘it’s only one treatment ) that were related to the process of adhering to aerosol 
therapy. 
Leventhal’s self-regulatory model (Leventhal, 1993; Leventhal et al., 1984) is a 
further example of a dynamic cognitive approach which has been utilised in the explanation 
of non-adherence.  Marteau & Weinman (2004, pg.287) suggest that the model 
“acknowledges the importance of symptom perception in influencing illness representations 
which, in turn, direct coping responses, including adherence behaviour.”  Research has linked 
illness perceptions with a variety of behaviours that influence the process of adherence.  In a 
study examining the role of illness perceptions and treatment beliefs in adolescents with CF 
for example, Bucks and colleagues (Bucks et al., 2009) reported that doubts about the 
necessity of antibiotics and a belief that CF is not able to be controlled by treatment were 
both related to non-adherence. 
 The above theories and models have been formulated and tested mostly within adult 
populations so, by necessity, many of the studies referred to above have been extrapolated 
from the adult literature in order to apply these theories to children and adolescents.  The 
main exception to this is the HBM, which has been adapted for use within paediatric 
populations.  The Children’s Health Belief Model (CHBM: Bush & Iannotti, 1990) not only 
includes very similar variables as the traditional HBM (e.g., perceived benefits and perceived 
barriers) but also places additional emphasis on the role of parental influences on children’s 
health beliefs and actions (e.g., parental perceived benefit of the child taking prescribed 
medication).  What was clear within the current study was that parents (as well as 
adolescents) held complex thoughts and beliefs about aerosol therapy and that these not only 
had an influence on their own emotions and behaviour, but those of their children. 
Although not adapted specifically for paediatric populations, the TPB also emphasises 
that the perceived views of significant others, such as family and friends (normative beliefs) 
may also influence adherence (Cochrane & Gitlin, 1988; Conner & Sparks, 2005).  This 
would suggest that the adolescents in the current study were more likely to adhere to the 
aerosol therapy where parental beliefs in the benefit of taking the treatment were strong.  
However, it was clear from the parental reports that their beliefs were not necessarily static as 
some parents expressed having doubts about the effectiveness of aerosol therapy from time-
to-time, particularly when their child became unwell. 
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Even where beliefs in the treatment were consistently strong, many of the parents also 
held beliefs about the unlikelihood that adherence to aerosol therapy would always be one 
hundred percent.  They felt that there were times when the many daily barriers to adherence 
(e.g., lack of time, having to clean the device or their child feeling tired) outweighed the 
benefits.  Rapoff (2010) argues that this reality of non-adherence reflects “part of a mosaic of 
patient and family struggles” (pg.184) which makes the prospect of consistently perfect 
adherence rates very unlikely.  Whilst advances in the efficacy of treatment for CF may have 
encouraged patients and parents to believe in the value of taking medications such as aerosol 
therapy, there are broader psychosocial contexts that are likely to continue to impact on non-
adherence. 
4.4.2 Emotional drivers 
 Parents reported a number of emotions associated with the process of their child 
adhering to aerosol therapy.  These were often described in relation to the way that they 
interacted with thoughts and beliefs and subsequently initiated certain behavioural patterns.  
One area that caused parents particular concern was the uncomfortable feelings generated at 
the thought of relinquishing the control they had over their child’s adherence to CF 
treatments.  Most of the parents, for example, described having taken full responsibility for 
their child’s adherence to aerosol therapy for many years (e.g., ordering the medication, 
preparing the treatment, handing their child the device, supervising them taking it and then 
cleaning the device afterwards) and said that the idea of this responsibility being passed over 
to their child was experienced as difficult.  The struggle to find a balance between greater 
autonomy for the adolescent and assurance that daily CF treatments will be adhered to has 
been previously reported in the literature (Delambo, Ievers-Landis, & Drotar, 2004; Fiese & 
Everhart, 2006; Smith & Wood, 2007).  What was clear within the current study was that 
attempts to relinquish control over adherence to aerosol therapy caused significant anxiety for 
some parents and led to increased monitoring and supervision through the use of frequent 
daily reminders.  Linked to this issue was the finding that some parents often had feelings of 
guilt when their child had not taken their aerosol therapy, particularly if they had failed to 
remind their child to take it.  It would appear that the use of certain behavioural strategies 
(such as frequent reminders), were not only employed to encourage their child to adhere to 
aerosol therapy so that they secured the associated health benefits, but also to relieve their 
own uncomfortable feelings of anxiety and guilt.   
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 Difficulties in relinquishing control were not the only sources of anxiety and worry 
reported by the parents.  Being anxious about the disease itself, the child’s health status and 
general treatment concerns (e.g., worrying whether enough medication had been ordered) 
were all potential causes of negative affect.  Increased levels of anxiety are not uncommon in 
those parents caring for a child with CF (Barker & Quittner, 2010) and greater levels of 
parental stress and anxiety have been associated with lower levels of adherence to treatment 
in other chronic health conditions (Hazzard et al., 1990; Brownbridge & Fielding, 1994; 
Gerson et al., 2004).  There were parents in the current study who also described feelings of 
frustration towards some of their child’s behaviour in relation to the process of adhering to 
aerosol therapy.  The child forgetting to take the aerosol therapy, getting distracted, 
procrastinating or failing to breathe correctly when using the I-neb™ device were all 
examples of sources of frustration which had the potential to impact negatively on their day-
to-day interactions with their child.  Although understandable, these types of negative parent-
child interactions have been associated with lower adherence to treatment regimens for renal 
disease (Gerson et al., 2004), diabetes (Miller & Drotar, 2007) and CF (Quittner, Drotar, & 
Ievers-Landis, 2004). 
 It is clear from the findings of the current study that parents caring for a child with CF 
are under significant pressure.  It is perhaps unsurprising therefore, that higher rates of 
depression have been found in those parents caring for a child with CF (Snell, Barker, & 
Marciel, 2008; Yilmaz, Sogut, & Gulle, 2008).  In addition, emerging evidence suggests that 
parents may experience “burnout” in their role as caregiver during adolescence which 
highlights the importance of monitoring both children and parents’ psychological and 
emotional distress and providing additional support to parent caregivers where appropriate 
(Snell et al., 2008; Barker & Quittner, 2010; Smith, Modi, Quittner, & Wood, 2010).  
Intervening in this way is particularly important when taking into consideration that a higher 
level of parental stress and depression is associated with lower levels of adherence to 
treatment (Quittner, Barker, & Geller, 2007; Ward, Massie, & Glazner, 2009).   
 The adolescents in the current study described the consequences resulting from some 
of the more negative aspects of the parent-child relationship.  Patient experiences of their 
parent or other members of their family getting frustrated as a result of them forgetting to 
take the aerosol therapy contributed to feelings of not being understood.  Reports indicated 
that this contributed to their own feelings of frustration and a sense of being different to 
others.  Lower levels of adherence in CF have been linked to increased conflict with parents, 
time spent outside of the home and away from parental monitoring and a heightened desire to 
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be similar to friends and peers who are healthy (DeLambo et al., 2004; Badlan, 2006; Smith 
& Wood, 2007; Modi et al., 2008).  A reluctance to disclose their illness to peers and an 
associated unwillingness to take their treatment in front of others have all been previously 
reported in the literature (D’Auria, Christian, & Richerdson, 1997; George et al., 2010; 
Bregnballe et al., 2011).  However, the finding that adolescents in the current study felt 
embarrassed taking their aerosol therapy in front of their parents as well as their peers in 
certain situations (e.g., when parents are watching the TV) and the finding that adolescents 
experienced adhering to some types of treatment harder than others when in public (e.g., 
nebulisers were harder than tablets because tablets were less time consuming and more 
portable) were novel.  Although few studies have examined how close friends and peers can 
influence adherence, it was clear that for some of the adolescents certain types of 
physiotherapy (e.g., trampolining) were more amenable to involving friends, therefore 
serving to encourage adherence, than treatments such as aerosol therapy.      
 Managing the burden of living with a chronic health condition can take its toll on 
children and adolescents.  Children experiencing emotional difficulties are less likely to 
adhere to treatments prescribed for diabetes, cancer and renal disease (Brownbridge & 
Fielding, 1994; Kennard, Stewart, Olvera, Bawdon, Ailin, & Lewis, 2004; Greening, et al., 
2007).  The simple fact that adolescents may feel tired and decide to not take their treatments 
was reported in a study which examined the barriers to adherence in CF (George et al., 2010).  
The adolescents in the current study echoed the above findings in describing how feeling 
upset or tired negatively impacted on the process of adherence to aerosol therapy.  Whilst 
fearing the consequences of non-adherence was not a pleasant experience, the adolescents 
reported that this often helped to encourage adherence and is consistent with recent findings 
that investigated facilitators of adherence behaviour in CF (George et al., 2010). 
Although none of the adolescents in the current study reported feelings of significant 
depression, the impact of negative affect on adherence is a growing area of research interest.  
The International Depression and Anxiety Epidemiological Study (TIDES) was established to 
conduct the first international systematic research investigating anxious and depressive 
symptoms in young patients with CF and their parent caregivers (Quittner, 2012).  The 
TIDES data indicates that 25% of adolescents with CF reported depressive symptoms above a 
clinical cut-off, with 20% reporting anxious symptomology.  These are important findings 
when considered alongside recent evidence which indicates that more depressive symptoms 
in children and adolescents with CF are related to poorer rates of adherence (Smith et al., 
2010).  Although the routine monitoring of depression and anxiety is not commonplace 
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within CF outpatient clinics (Barker & Quittner, 2010), the routine monitoring of aerosol 
therapy adherence data has become much more frequent (McNamara et al., 2009).  Through 
careful and sensitive exploration of objectively poor levels of adherence to aerosol therapy, 
clinicians have the opportunity to help to ascertain if negative affect – experienced by either 
adolescents or parents – is impacting on the process of adherence.  If so, offering appropriate 
levels of support or more specialist psychological interventions may help to address these 
issues and improve adherence behaviour. 
4.4.3 Strategies and behaviours 
 Several strategies and behaviours related to the process of adherence were reported by 
the parents and adolescents.  The way in which a well defined and regular routine – 
particularly during the school-week – helped to facilitate adherence to aerosol therapy was 
highlighted as important by virtually all of the participants.  Even when people hold positive 
beliefs about treatment and have intentions to adhere, Abraham and colleagues (Abraham, 
Sheeran & Johnston, 1998) acknowledge that intentions do not automatically translate into 
action and suggest that it is prior planning and subsequent rehearsal that can help to enhance 
individual control of action and facilitate the routinisation of health-related behaviour.  The 
participants in the current study were clear that a well planned and rehearsed routine was 
vitally important, with some saying that a lack of routine was a barrier to adhering to aerosol 
therapy.  This finding is very common in the literature, with a number of studies consistently 
highlighting that a lack of routine is a barrier to adherence in CF (Dziuban et al., 2010; 
George et al., 2010).  Routinisation of adherence was further reflected in the parental reports 
of normailsing and accepting that adhering to aerosol therapy was part of life and needed to 
be effectively planned and managed.  Adolescent reports of “getting it done and out of the 
way” were an additional behavioural strategy that related to routine and acceptance. 
One strategy for improving the planning and rehearsal necessary to facilitate the 
routinisation of health-related behaviour is to devise and agree upon an implementation plan 
(Gollwitzer, 1999).  Implementation intentions are self-regulatory strategies which utilise an 
if-then-plan (i.e., “If situation X arises, I will perform response Y”) and are used to increase 
the likelihood of attaining goals.  A meta-analysis showed that implementation 
intentions had a positive effect (d = .65) on goal attainment and were effective in promoting 
the initiation of goal striving and the shielding of goal pursuit from unwanted influences.  
Although not specifically investigated for use in the encouragement of adherence to treatment 
in CF, implementation intentions are clearly helpful and could be utilised in clinical settings 
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for this purpose.  Research which examines the effectiveness of implementation intentions 
used to encourage adherence in CF may be warranted. 
 Parents said that they frequently used reminders as a way of monitoring and 
supervising their child’s adherence to aerosol therapy.  There are studies which found that 
lack of parental monitoring of treatment behaviour and activity can contribute significantly to 
non-adherence, particularly to chronic disease regimens (Wiebe, Berg, Korbel, Palmer, 
Beveridge, & Upchurch, 2005; Rapoff, 2010).  One study examining the management 
strategies of children with diabetes found that parental monitoring and supervision had all but 
ended by the time the children had reached 15 years of age (Ingersoll, Orr, Herrold, & 
Golden, 1986).  In CF, Modi and colleagues (Modi et al., 2008) found better adherence in 
adolescents who spent greater amounts of their treatment time supervised by their parents, 
particularly mothers. However, there was evidence in the current study that the patients may 
not appreciate having to spend increased periods of time being supervised by their parents, 
particularly with the older adolescents who enjoyed an active social life outside of the family 
home.  These conflicted views and resulting behaviour may have the potential to negatively 
impact on the parent-adolescent relationship. 
Whilst reminding their child to take their CF treatments appears to be a popular 
strategy for parents (Cowlard, Yorke & Carr, 2010) and can sometimes help to facilitate 
adherence (George et al., 2010) it is not necessarily the most effective way of monitoring 
behaviour and patients in the current study had mixed views about how helpful they found 
them (i.e., on the one had they helped to prompt adherence behaviour but on the other hand, 
they were experienced as frustrating).  General reminders about treatment were described by 
some of the parents in the current study as a way of attempting to alleviate the anxiety 
associated with fears about their child’s non-adherence.  A study by Ellis and colleagues 
(Ellis, Yopp, Templin, Naar-King, Frey, & Cunningham, 2007) found that comprehensive 
diabetes-specific, rather than more general parental supervision and monitoring was 
associated with higher adherence.  Rapoff (2010) suggests that the use of monitoring charts 
(e.g., where parents and children can “tick off” when a particular treatment has been 
completed) and checking medication supplies (e.g., vials of medication) and devices (e.g., 
nebulisers or blood glucose meters) for indirect evidence of adherence are all potentially 
useful ways of ensuring adequate supervision alongside more general strategies such as the 
use of prompts.  However, he further argues that the monitoring and supervision of treatment 
regimens needs to be done in a way that is sensitive to the needs and developmental 
capacities of the child.  The use of individualised and gentle reminders, alongside a series of 
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other monitoring and encouragement strategies, were said to be helpful for two of the 
adolescent patients in the current study.           
 One can understand why reminders feature so heavily in the daily interactions 
between parent and child when taking into account the literature which suggests that children 
simply forgetting to take their medication is one of the most common barriers to adherence in 
CF and other chronic health conditions (Shemesh et al., 2004; Modi & Quittner, 2006; 
Dziuban et al., 2010; Bregnballe et al., 2011).  Monitoring strategies such as those described 
above and pairing regimen tasks with regularly occurring daily events to aid routinisation 
(e.g., taking aerosol therapy before the evening meal), may help to prompt the type of non-
intentional forgetting that is frequently described within the literature (Park & Kidder, 1996) 
and also featured in the adolescent and parent reports.   
However, there were participants who described more purposeful forgetting which 
was used as a way to prevent them from being reminding of the fact that they had CF.  This 
type of purposeful forgetting can be a significant barrier to adherence in CF (George et al., 
2010).  In a study examining coping and CF, Abbott (2003) suggests that omitting treatments 
can be an attractive option for those who are keen to escape the reality of the condition.  The 
patients’ accounts describing “putting off” taking their aerosol therapy can perhaps be 
understood in a very similar way.  This type of behaviour is not particularly well understood 
and can often be dismissed as the child or adolescent simply “being difficult”.  Whilst 
traditional theories have attempted to understand adherence behaviour in terms of more 
conscious, cognitive processes (e.g., the role of beliefs, perceptions and attitudes), 
psychodynamic approaches posit that less conscious processes may be influencing adherence.   
Alfonso (2011) for example, suggests that traditional psychoanalytic defences such as denial 
(e.g., refusing to acknowledge the painful reality of being diagnosed with a chronic health 
condition), acting out (e.g., acting unacceptably to give expression to the emotional distress 
associated with living with a chronic health condition) and passive aggression (e.g., 
unassertively expressing aggressive feelings towards those involved in their care by overtly 
complying with their treatment advice while covertly resisting this through non-adherence) 
may help to provide a different level of understanding regarding complex adherence 
behaviours.  Systematic research into this intriguing area is limited, although there are some 
good examples of smaller studies which have examined these concepts in the context of non-
adherence to chronic health treatment regimens in older adolescents and adults 
(Ciechanowski, Katon, Russo, & Walker, 2001; Ricart, Cohen, & Alfonso, 2002).  While 
their child forgetting to take their aerosol therapy was a source of frustration for the parents in 
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the current study, Cowlard et al (2010) suggest that it is important for parents and clinicians 
to understand “forgetting behaviour” – particularly purposeful forgetting – in the context of 
children and adolescents attempting to achieve a normal lifestyle and try to allow for 
individuality and flexibility as opposed to seeing it simply as a form of rebellion. 
 Some of the earliest research into the determinants of non-adherence hypothesised 
that inadequate understanding of the illness and treatment would lead to incomplete 
adherence (D’Angelo & Lask, 2001).  Parents in the current study felt that it was vitally 
important that their children understood the purpose of adhering to their aerosol therapy and 
described taking an active role in helping to facilitate this.  Although it is not always the case, 
research has tended to demonstrate that children and adolescents who are less knowledgeable 
about their illness and treatment are less likely to adhere to regimens for diabetes, CF and 
cancer (Tebbi et al., 1986; Gudas, et al., 1991; Holmes, et al., 2006).  Whilst this may be true, 
it is important to acknowledge that increased knowledge about treatments does not always 
translate into improved rates of adherence (McQuaid, et al., 2003).  Although it was clear 
from the interviews that patients and parents were very knowledgeable about the CF 
treatments, analysis revealed that there were numerous additional influences on the process of 
adhering to aerosol therapy.  
 Parents in the current study said that they offered a number of additional supportive 
strategies to attempt to encourage adherence.  Simplifying the process of adhering to aerosol 
therapy was a common strategy identified by the parents as was rewarding and incentivising 
adherence.  The use of rewards and incentives to encourage adherence has been frequently 
examined within the literature.  Token reinforcement programmes (whereby parents provide 
or confiscate points or chips for adherence which can then be used to “purchase” special 
privileges) have demonstrated positive effects on improving adherence to chronic illness 
regimens (Pieper, Rapoff, Purviance, & Lindsley, 1989; da Costa, Rapoff, Lemanek, & 
Goldstein, 1997).  More simplistic strategies such as parents contracting with their children 
about how they will be rewarded for consistent adherence and also what consequences will 
occur as a result of non-adherence can have a similar effect, particularly if communicated 
appropriately and applied on a consistent basis (Rapoff, 2010).  Reports from both parents 
and adolescents in the current study suggested that these types of contracts – which provide 
rewards and incentives for taking aerosol therapy – are commonplace and often helped to 
facilitate adherence. 
In addition, adolescents were also responsible for more self-generated incentives for 
adherence; describing for example, how getting their aerosol therapy done quickly resulted in 
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increased free time and allowed them to engage in more enjoyable activities.  This is 
consistent with the findings reported by George and colleagues (George et al., 2010) who 
suggested that self-generated reward systems can help to facilitate adherence in adolescents 
with CF.  A further example could be found in patient accounts of trying to breathe slowly 
and appropriately in order to ensure accurate administration of the aerosol therapy, which, 
paradoxically helped to speed up treatment times. 
  Parent and adolescent beliefs about the unlikelihood that adherence to aerosol 
therapy would always be one hundred percent were discussed earlier.  There was certainly 
evidence in both the parent and adolescent accounts that some of these beliefs translated into 
actual behaviour.  Having either a planned or more spontaneous break from adhering to 
aerosol therapy was at times described as very likely.  This created mixed emotions in the 
parents whereby feelings of guilt about their child not adhering to the treatment coexisted 
with feelings of relief, particularly about not having to clean the device.  The adolescents 
seemed less concerned and mostly described having a break from adhering to aerosol therapy 
as pleasurable, because it allowed them greater freedom.  Dziuban and colleagues (Dziuban 
et al., 2010) found that adolescents’ believed it was acceptable to miss a treatment every few 
days or when they were busier. 
Although as clinicians, it can be difficult to accept that treatments which keep patients 
well are sometimes not taken, it would seem that there are times when non-adherence to 
treatments such as aerosol therapy is going to be very likely.  Whilst it is imperative that 
treatments are taken in order for their benefits to be realised, Rapoff (2010) suggests that the 
importance of adherence is sometimes inflated.  He argues that it is not only important to 
recognise that adherence problems may be symptomatic of broader psychosocial difficulties 
or family dysfunction that require appropriate psychological support, but that the outcome of 
medical treatment does not depend entirely on adherence.  He goes on to suggest that 
although sub-therapeutic drug assays may reflect a patients’ poor adherence, due attention 
should also be given to issues that are not dependent on patient behaviour, such as inadequate 
dosing, interactions with other drugs and pharmacokinetic variations in drug metabolism (i.e., 
the way peoples bodies metabolise specific treatments differently).  
4.5 Parent and adolescent relationship 
 The day-to-day interactions between parent and adolescent and the way they 
experienced each other’s behaviour – particularly in relation to the process of adhering to 
aerosol therapy – was interesting.  Recall how some of the adolescents’ behaviour in relation 
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to the aerosol therapy (e.g., forgetting to take it, getting distracting, procrastinating and 
inappropriate breathing technique) was a source of frustration for the parents.  Similarly, 
some aspects of the parents’ behaviour (e.g., the use of constant reminders, a lack of 
understanding regarding the treatment burden) had the potential to frustrate the adolescents.  
These irritations, particularly when considered alongside the complex and interacting beliefs 
and emotions experienced by the parents and adolescents, had the potential to lead to conflict.  
Increased conflict and negative parent-child interactions have all been associated with poor 
adherence to treatment in CF (DeLambo et al., 2004; Quittner et al., 2004; Badlan, 2006; 
Smith & Wood, 2007; Modi et al., 2008).  What was clear from the analysis of parent and 
adolescent accounts within the current study was that although there were sources of daily 
frustration related to the process of adhering to aerosol therapy, the strength of the parent-
adolescent relationship had the potential to act as a “buffer” that mediated between frustrating 
behaviour and conflicts.  This is certainly in chorus with previous research which suggests 
that the single most consistent predictor of positive adjustment and good mental health 
throughout adolescence is the quality of the parent-child relationship (Steinberg & Silk, 
2002) 
 Managing the potential for conflict in the difficult adolescence period of development 
can be difficult for healthy children and their parents, but presents unique challenges for 
those living with CF.  Adolescence is an intense period of physical and pubertal development, 
characterised by rapid social and emotional transformation and a thrust toward autonomy 
(Berk, 2006).  The struggle to find a balance between greater autonomy for the adolescent 
and assurance that daily CF treatments are being adhered to was a feature both in these parent 
and adolescent accounts and within the previous research literature.  There was considerable 
variation in the parent and adolescent accounts detailing the amount of responsibility taken 
for the process of adhering to aerosol therapy.  The younger adolescents had less 
responsibility, which is consistent with findings in the literature that suggest parental 
monitoring and supervision is greater during this phase (Fiese & Everhart, 2006).  There was 
certainly an acknowledgement from some of the adolescents that they needed to take on more 
responsibility and although this was beginning to happen, particularly in terms of aerosol 
therapy treatment preparation, this was not always the case.  Parents were still largely 
responsible for ordering the medication, reminding their children to take the aerosol therapy 
and cleaning the device afterwards. 
Barker and Quittner (2010) argue that a reluctance to transfer responsibility may 
result in adolescents failing to learn the necessary skills to independently manage their 
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disease.  They go on to suggest however, that a premature transfer of responsibility and a 
reduction in adequate monitoring and supervision may result in the adolescent becoming 
overwhelmed and non-adherent.  It is clearly a difficult balance.  It has been suggested that 
the benefit of parental supervision may be dependent on the quality of the parent-adolescent 
relationship (Smith & Wood, 2007).  It was clear from one adolescent account (Elizabeth) 
that her ability to take on an impressive degree of responsibility for the management of her 
CF treatments was appropriate for her level of development and encouraged by a series of 
support mechanisms provided by her parents.  Barker and Quittner (2010) suggest that this 
type of supported autonomy is in many ways the optimal strategy: “providing adolescents 
with increasing responsibility for disease management, predicted on their ability to organise 
their time and perform these tasks.”  This model of cooperative parenting is described by 
Maccoby (1984) as coregulation, whereby parents gradually shift responsibilities and 
exercise oversight while at the same time permitting children to be in charge of moment-by-
moment decision making.  In contrast to this model was one parent account (Mary) who 
suggested that she had absolved virtually all responsibility for the process of adhering to 
aerosol therapy to her daughter: “Like the I-neb, that’s up to her to do it … The responsibility 
is on her now you know.”  Recall that, interestingly, her daughter’s adherence rate was the 
lowest of all participants (28%).   
 Further evidence of the strength of the parent-adolescent relationship was found in 
many of the adolescent and parent accounts detailing the way that appropriate empathy and 
support was provided by the parents to their child.  The adolescents described how this 
practical and emotional support helped to facilitate adherence.  In general, support of this 
kind has been found to increase adherence across all illnesses and ages (DiMatteo, 2004).  
Again, the balance appears difficult with some studies suggesting that parents were both 
sources of positive (helpful and appropriate reminders) and negative (drawing attention to the 
illness, nagging etc) behaviours (Graetz, Shute & Sawyer, 2000; Barker, Cohen, & Driscoll, 
2008).  Recall how the adolescents experienced reminders as helpful at times, whilst 
annoying at others, with one patient suggesting that it was the way in which reminders were 
used and communicated that enabled her to experience them as supportive.  Effective 
communication was obviously important to the participants in the current study, with all of 
the adolescents reporting that having clear and consistent instructions from their parents when 
it came to the process of adhering to aerosol therapy was experienced as helpful.  Many of 
them also said that it was frustrating when this was not the case.  Indeed, studies examining 
poor communication between parents and children with chronic health conditions found that 
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it contributed to lower levels of adherence (Gerson et al., 2004; Lewandowski & Drotar, 
2007; Miller & Drotar, 2007). 
Related to the necessity of effective communication were reports by the participants 
detailing how cooperating and negotiating with each other helped to facilitate the process of 
adhering to aerosol therapy.  These skills were also found in some of the parent and 
adolescent reports of having to overcome the specific problems associated with the process of 
adhering to aerosol therapy (e.g., how the aerosol therapy could be taken when the parent and 
child were attending a party).  Better communication and problem solving between parents 
and children have been associated with higher rates of adherence to a number of chronic 
health condition treatment regimens (Bobrow et al., 1985; McQuaid et al., 2005).  Linked to 
this were the parent accounts in the current study that suggested the importance of 
recognising and accommodating specific child preferences – particularly when it came to the 
process of adhering to aerosol therapy (e.g., child not wanting to take their aerosol therapy 
when coming home from school) – as a way of anticipating and managing potential problems 
and conflict.  These supportive elements of the parent-adolescent relationship were 
strengthened by incentives to encourage adherence to aerosol therapy, most of which were 
discussed in detail earlier.  
4.6 The context of adherence 
Studies of “context” in relation to health and illness are becoming increasingly 
widespread (Frohlich, Corin, & Potvin, 2001).  Although fewer studies have examined the 
impact of social and environmental influences on adherence to treatment in chronic health 
conditions, it was clear from the analysis in the current study that the context in which 
adherence to aerosol therapy was taking place was experienced as extremely important for 
the parents and adolescents. 
4.6.1 Everyday life 
 Parent accounts of day-to-day life were characterised by attempts to fit multiple tasks 
(some CF treatment related, some not), for multiple people (child with CF, other children, 
partners, friends and colleagues) into a limited amount of time.  In this way, parents seemed 
to be describing a type of “juggling act” that included the necessity to adhere to aerosol 
therapy as only one of the numerous commitments that needed to be managed. Many of the 
parents held beliefs about the unlikelihood that adherence to aerosol therapy would always be 
one hundred percent, due in no small part to exactly the type of hectic everyday lifestyle 
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described above.  Parents and adolescents described a healthy involvement in numerous 
social and recreational activities, alongside more commonplace commitments such as 
attending school or work.  Perhaps unsurprisingly, increased family social and recreational 
activities outside of the home have been associated with lower rates of adherence to CF 
treatment regimens (Patterson, 1985; Geiss, Hobbs, Hammersley-Maercklein, Kramer, & 
Henley, 1992).  One explanation for this finding is that because families with CF children 
have a finite amount of time, resources and energy to devote to treatment regimens, increased 
recreational activities, however positive, consumes a large portion of that time.  There are 
some who have argued that clinicians need to be mindful not to overburden families by 
prescribing unnecessarily complex regimens which prevent the ability to enjoy recreational 
activities and the maintenance of some semblance of a “normal” family life (Patterson, 1985; 
Rapoff, 2010). 
 Related to the above was the finding in the current study that parties or special 
occasions negatively impacted on adherence to aerosol therapy.  Parents and adolescents 
described adherence taking on less of a priority at these times and provided the opportunity 
for either planned or more spontaneous non-adherence.  However, it would seem that the 
interacting cognitive (e.g., belief in the efficacy and necessity of aerosol therapy) and 
emotional (e.g., feelings of anxiety and guilt) processes of some of the parents led to the 
instigation of specific behavioural responses (e.g., reminding their child about the need to 
take aerosol therapy) which were mediated by the strength of the parent and child relationship 
(e.g., cooperating and problem solving in order to agree upon a solution) and enabled the 
facilitation of adherence to aerosol therapy despite the fact that they were attending a party or 
special occasion.  For others who were faced with the prospect of a party or celebration, it 
appeared that a variation or breakdown of one or more of the interacting processes described 
above led to non-adherence. 
A similar explanation could be used to describe how some adolescents managed to 
adhere to aerosol therapy despite being faced with numerous lifestyle barriers, whereas others 
found adherence more difficult to achieve.  There were some adolescents for example, who 
said that fun activities negatively impacted on the process of adhering to aerosol therapy 
whereas others were able to use the prospect of fun activities to motivate adherence.  Having 
said that, it appeared that as well as observed differences between participants (i.e., in the 
way that these barriers were successfully negotiated), there were also differences within the 
same participants at any given time, suggesting that these interacting processes were not 
static and had the potential to change on a regular basis.  In this way, adherence to aerosol 
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therapy can be understood along similar terms as numerous other health behaviours (e.g., 
attempting to eat a healthy diet, take more exercise etc) which also have a social and 
environmental component as well as a biological and psychological one.   
 The discovery by McNamara and colleagues (McNamara et al., 2009) that evening 
adherence to nebulised antibiotics was significantly better than morning adherence was novel.  
There were a number of interesting findings in the current study which helped to further 
elucidate this claim.  Firstly, the majority of parents felt that it was much easier for their child 
to take their aerosol therapy in the evening because the morning schedule was just too busy.  
There was a caveat to this though, with two parents highlighting that patterns of morning and 
evening adherence were often dependent on the number of nebulised antibiotics prescribed.  
Secondly, while half of the adolescent patients agreed with their parents about evening 
adherence, the other half felt that morning adherence was easier.  Interestingly, their 
perception of morning adherence being easier was not supported by the PLS data downloaded 
from the I-neb™ device which suggested that aerosol therapy was more likely to be taken in 
the evening.  One patient realised this and said that he just “thought” it would be easier to 
take in the morning, whereas the other two patients were more surprised.  There are a number 
of potential explanations for this.  It is possible, for example, that the younger adolescent’s 
preference for adhering to his aerosol therapy in the morning was superseded by his parent’s 
predilection for evening adherence.  While this may also be true for the other two 
adolescents, they were more surprised at the finding which may suggest that although their 
perception was that they thought that morning adherence was easier, the use of objective data 
provided them with a more accurate representation of day-to-day life. 
The finding that participants’ perception of their own adherence behaviour is different 
to more objective measurements is consistent with the existing research literature.  Gordis 
and colleagues (Gordis, Markowitz, & Lilienfeld, 1969) carried out one of the earliest studies 
that directly compared patient and parent reports of adherence with more objective 
measurements (e.g., urine assays) and concluded that self-reports of adherence were “grossly 
inaccurate”.  A number of more recent studies have consistently corroborated this finding, 
reporting that adherence rates are lower as measured by electronic monitors vs. parent and 
patient report (Bender, Wamboldt, O’Conner, Rand, Szefler, & Milgrom, 2000; Butz, 
Donithan, Bollinger, Rand, & Thompson, 2005; Modi et al., 2006).  The findings from the 
current study suggest that although parents and adolescents perceive that it is easier to take 
their aerosol therapy at particular times, this does not necessarily translate into actual 
behaviour.  This again highlights the usefulness of technology such as the PLS data in its 
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ability to be used routinely in order to provide a more accurate and objective view of 
adherence behaviour. 
 Related to the above were the reports from parents and adolescents regarding their 
perceptions of school day vs. weekend adherence to aerosol therapy.  Essentially, preferences 
were evenly matched with approximately half of the parents and adolescents saying that 
school day adherence to aerosol therapy was easier and the other half saying that it was easier 
at the weekend.  Although school days were busier, the planned and regular routines that 
were in place (particularly the after school and evening routines) were said to help facilitate 
adherence.  In contrast, approximately half of participants felt that weekend adherence was 
easier because they were more relaxed and more time was available.  Again, of interest was 
the finding that participants’ perceptions of ease did not necessarily translate into actual 
adherence behaviour.  There were instances for example, of participants’ saying that they felt 
it was easier to adhere to aerosol therapy at the weekend when the PLS data suggested that 
adherence was lower at these times. 
4.6.2 Environmental influences 
 We have considered a number of lifestyle factors identified by the participants as 
influencing the process of adherence.  Although “lifestyle factors” have been increasingly 
studied in relation to their influence on a number of public health priorities (e.g., obesity, 
smoking etc), Frohlich and colleagues (Frohlich et al., 2001) suggest that these studies have a 
tendency  to discuss the term in reference to individual behavioural patterns that affect 
disease status (e.g., Bandura 1984). They go on to argue that this has created a type of 
behavioural determinism whereby so-called health behaviours (e.g., eating healthy food or 
adhering to medication) are studied “independently of the social context, in isolation from 
other individuals, and as practices devoid of social meaning.”  What was clear from the 
findings in the current study was that the participants’ lifestyle was intertwined with the 
social and environmental context within which they operated and that these closely connected 
phenomena had very real influence on the process of adhering to aerosol therapy. 
 The way in which aspects of the home environment acted as a barrier to adherence, 
for example, was of particular interest.  The adolescents described the way that interacting 
with technological devices within the home (e.g., Computer, social networking sites, the TV, 
mobile phones etc) often led to them forgetting to take their aerosol therapy or distracted 
them part way through the administration of the medication.  Although relatively little is 
known about the way characteristics within the home environment contribute to or impede 
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adherence, a recent study found that social demands (such as sitting and watching TV or 
playing on the computer) often acted as a barrier to adherence for adolescents with CF 
(George et al., 2010).  One of the variables within the HBM (Janz & Becker, 1984) describes 
the way that cues to action within a person’s environment can help to enhance or compromise 
health behaviour.  Parents within the current study said that the visibility of the I-neb™ 
device and associated medication and equipment helped to normalise aerosol therapy 
treatment but did not necessarily facilitate adherence.  Although studies are beginning to 
investigate in more detail the impact of the home environment on adherence to treatment 
(e.g., Vaughan, Wagner, Miyashiro, Ryan, & Scott, 2011) much remains unknown about this 
interesting area. 
 Participants said that there were a number of difficulties associated with taking the I-
neb™ device outside of the home environment.  It is perhaps unsurprising therefore, that both 
parents and adolescents highlighted aspects of the external environment that they felt 
negatively impacted on the process of adhering to aerosol therapy.  Going away on holidays 
or school trips was particularly difficult, largely because of the problems identified earlier 
around having to clean the device thoroughly and store all of the associated medication in a 
fridge.  Interestingly, being admitted to hospital caused the same difficulty which is 
surprising considering the recent emphasis on providing appropriate washing facilities as part 
of the NHS infection control strategy (NHS Professionals, 2010).  Staying over in a different 
house was a similar situation, although there were additional complications for those 
adolescents who were reluctant to take their aerosol therapy in front of their friends 
(discussed earlier) and those whose parents were separated.  Having to take the I-neb™ 
device and associated medication and equipment over to another parent’s house when the 
parents were separated was identified as burdensome.  In addition, one parent highlighted that 
she did not allow her son to take his aerosol therapy with him to his father’s house in case he 
forgot to bring it back, resulting in daily non-adherence once a week.  A similar problem was 
fortuitously solved for one of the other participants by having two I-neb™ devices (i.e., she 
was given a new device when her original one malfunctioned and then was then given the 
repaired one back to use as a spare).  It was decided that she would keep one device at her 
father’s house and one at her mother’s because it made the process of adherence much easier.  
Although this is a very specific incident related to divorce, more general research has found 
that parental separation and divorce is associated with lower adherence to treatments in a 
number of chronic health conditions (Brownbridge & Fielding, 1994; Shemesh et al., 2004).  
Clinicians may wish to sensitively explore any specific adherence concerns related to the 
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issue of parental separation (such as those discussed above) so that appropriate support can be 
given or potential solutions to problems can be identified.   
Finally, although greater father involvement (e.g., amount and helpfulness) has been 
related to better adherence to treatment in CF (Wysocki & Gavin, 2006), it has been 
consistently demonstrated that mothers take on the majority of responsibility for their child’s 
adherence to treatment (Rapoff, 2010).  This was both anticipated and realised within the 
current study. 
4.7 Overall summary 
The results of the current study complement and extend previous research on 
adherence in CF.  In particular, it has highlighted the complexity involved, and the 
interactions which have a massive influence on adherence – interactions between the different 
parts of the treatment regimen, interactions between the nebuliser and child and nebuliser and 
parent, interactions between children and their peers, and finally between child and parent. It 
has also placed adherence behaviour in context – the internal context of the beliefs and 
emotions of the child and parent, and the exterior context of the busy and complicated lives 
led by them.  It would appear that these interacting biopsychosocial processes make the 
prospect of consistent, one hundred percent adherence to aerosol therapy very unlikely. 
 
4.8 Methodological considerations 
 The following section will summarise the methodological considerations of the 
current study.  Firstly, the limitations of the study will be highlighted, before moving on to 
consider the study’s strengths. 
4.8.1 Methodological limitations 
4.8.1.1 Researcher bias 
 Some level of interpretation and imposed structure to aid the manageability of large 
quantities of data is considered inevitable in qualitative research (Smith, 2008).  However, 
this creates an added emphasis on the necessity of the researcher to bring into conscious 
awareness their own unique biases and the ways in which these have the potential to 
influence the process of data analysis (Bryant & Charmaz, 2007).  Section 2.9.3 outlined the 
chief investigators previous experiences, clinical and theoretical influences and emotional 
reactions to the current participants in an attempt to highlight sources of potential bias. 
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 Of these, the fact that the chief investigator had prior knowledge of the adherence 
literature was arguably the main source of bias.  This is perhaps reflected in the language 
used within the labelling of some of the core categories within the current study (e.g., 
regimen characteristics) which is representative of many of the previous research findings on 
adherence to treatment.  It is possible that someone with less knowledge of the existing 
literature may have used more novel or interpretive language to describe these observed 
phenomena. 
4.8.1.2 Recruitment bias 
  The detailed process of recruitment was previously outlined in section 2.5.  
Participants were recruited by the specialist CF physiotherapists on a first-come, first-served 
basis (i.e., the patients who had their outpatient clinics scheduled at the earliest date were the 
first to be approached).  Although the NRES committee stipulated that recruitment should be 
carried out in this way by the physiotherapists, it resulted in the chief investigator being 
unable to oversee the recruitment process to ensure that the agreed protocols were being 
appropriately adhered to.  It is therefore possible that recruitment biases may have occurred 
through participants being selected by the physiotherapists in a less random way.  However, 
the chief investigator was in regular contact with the specialist CF physiotherapists 
throughout the process of recruitment and was assured that the agreed protocols were being 
followed.  The fact that the clinicians involved with the study advised that adolescent 
participants with an FEV1 reading <50% over the last 12 months should be excluded may 
have resulted in additional biases in terms of only reasonably healthy CF patients taking part. 
Further reflection on the access to potential participants and the impact this may have 
had on the sample is provided in section 4.8.1.5. 
4.8.1.3 Additional quality checks 
Details of the quality checks employed and the additional strategies considered by the 
chief investigator were provided in section 2.9.2.  Although estimates of inter-rater reliability 
were considered as a method of quality control in the current study, it was discounted on the 
grounds that numerous commentators have suggested that the technique is flawed for use 
within qualitative studies (Bogdan & Biklen, 1992; Marshall & Rossman, 1995).  However, 
respondent validation is considered a useful technique in providing additional quality 
assurance (Smith, 2008) and the fact that the current study was unable to utilise this technique 
due to pragmatic concerns, is a weakness. 
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4.8.1.4 Participants access to internal processes  
One important issue for all qualitative methodologies that rely on narrative accounts is 
that the participants may not actually be aware of the numerous internal and external 
influences on their behaviour (Corbin & Strauss, 2008).  The result is that commonly used 
data collection methods, such as interviews, can only ever access information that the 
participant is consciously aware of.  Even then, these accounts are only ever based on the 
participants’ perceptions (Charmaz, 2006).  A related issue is that participants may be 
consciously aware of a number of influences on their behaviour, but be unwilling to share 
them with the researcher.  This relates to the issues highlighted in section 4.8.1 in that 
additional bias may be created by the effect the researcher’s mere presence has on the people 
that they are studying. 
Although it was clear that the participants in the current study spoke openly and 
provided rich and detailed accounts, the above difficulties cannot be discounted.  These 
issues may have been particularly present in the adolescent accounts in that their 
developmental stage arguably results in a more “surface level” understanding of complex 
phenomena like adherence behaviour.  In addition, the researcher became aware both during 
the interview process and throughout analysis that although adolescent participants appeared 
relaxed and forthcoming, they may have been somewhat reluctant to discuss their parents’ 
behaviour with a stranger.    
4.8.1.5 Sample     
 There are a number of issues to consider in relation to the sample of participants used 
within any form of qualitative research.  Firstly, to ensure that participants are discussing 
their experiences of similar phenomena from a similar perspective, some argue for maximum 
homogeneity within a participant sample (Willig, 2008).  Although many of the participants 
within the current study shared similar characteristics (e.g., all diagnosed with CF or caring 
for someone with CF, all adolescent participants aged between 11 and 16, all live within the 
North of England), there were also observed differences within both the patient and parent 
group.  For example, some of the adolescent participants had co-morbid conditions such as 
CF-related diabetes, arguably making their experience of adhering to treatment different to 
those without a co-morbid condition.  Some of the parent participants worked full-time, some 
part-time and some did not work at all, arguably making their experience of daily time 
pressures different from each other.  In addition, although it was expected that mothers would 
primarily take part in the research (Timko et al., 1992), one father took part.  Again, his 
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experience of a caring for his child is likely to be different to the experiences of the mothers 
taking part in the study. 
One obvious inherent weakness of a homogenous sample, however, is that the smaller 
the sample and the more tightly defined their target characteristics, the less possible it 
becomes to generalise the study results beyond that specific sample (Smith, 2008).  Although 
this may be true, it is also arguably the case for most qualitative research where the small 
sample sizes and emphasis on detailed individual accounts (regardless of homogeneity) make 
generalisabilty difficult.  The current study interviewed six adolescent patients and six 
parents, resulting in a total sample size of 12.  Although this is considered acceptable for 
grounded theory research (whereby the emphasis is on a rich and detailed account of a 
limited number of participants), a smaller sample size results in only tentative 
recommendations (in terms of the applicability of the findings to clinical settings), being able 
to be made.    
 Another consideration is that although the recruitment of participants was largely 
random (see section 2.5), it may well be possible that only “keen” parents and adolescents 
took part in the study, resulting in experiences being discussed from very particular 
perspectives (e.g., those who were proud of their adherence efforts and wanted recognition 
for this or conversely, those who had real difficulties maintaining adherence and so were 
desperate to “try anything” to improve the situation).  Although this is always difficult to 
guard against or even to ascertain, it cannot be discounted as being a potential source of bias 
within the current study. 
4.8.2 Methodological strengths 
4.8.2.1 A detailed focus 
 The design of the current study enabled a detailed, more focussed exploration of one 
part of the CF treatment regimen.  Much of the previous literature has examined adherence to 
the CF treatment regimen more generally (George et al., 2010).  Although there are studies 
that have investigated adherence to specific components (e.g., Williams et al., 2007), 
adherence to aerosol therapy, particularly within the adolescent CF population has not been 
widely researched.  This is problematic given the prominence of aerosolised treatments in 
current CF drug-delivery regimens and the likely increase of their use in the future.  It is 
therefore considered a strength that the current study enabled a detailed exploration of the 
experiences of adhering to aerosol therapy. 
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4.8.2.2 Patient and parent perspectives 
 As well as providing a more detailed focus, the current study enabled experiences of 
adhering to aerosol therapy to be considered from two different perspectives.  The patient 
experience is an obvious imperative, but the important influence of the parent on adherence 
to treatment has also been widely documented (Foster et al., 2001; Modi et al., 2008).  
Although adolescent adherence to the CF treatment regimen is often poor (Zindani et al., 
2006; Riekert, et al., 2007), less is known about the potential influence of parents on the 
process of adhering to aerosol therapy during this key developmental stage.  It is considered a 
strength that the current study enabled both a patient and a parent perspective concerning the 
process of adhering to aerosol therapy to be gained.   
4.8.2.3 The use of the PLS data 
The ability of the I-neb™ device to provide an objective and accurate measure of 
adherence to aerosolised therapy treatments enabled accounts of adherence to be anchored in 
everyday life and understood in the context of day-to-day behaviour.  This was not only 
novel, but enabled adherence behaviour to be explored in situ, as close as possible to its 
actual occurrence, and thus, to an extent, reduce retrospective biases (Reis & Gable, 2000).  
The objectiveness of the data may have also helped to reduce subjective biases and potential 
social desirability effects (i.e., the tendency of participants to answer questions in a manner 
that will be viewed favourably by others).  
A common criticism of qualitative methodologies is that they can only ever access 
information that the participant is consciously aware of.  The fact that the PLS data provided 
a cue to participants about the actual rates of adherence, and prompted discussion of 
particular events helped to bring into conscious awareness the multiple influences on 
adherence. 
4.8.2.4 The Grounded Theory Methodology 
The use of the GTM enabled a systematic approach to the gathering and analysis of 
the generated data.  The use of this methodical approach alongside regular research 
supervision enabled the maintenance of an audit trail which helped to ensure methodological 
and procedural rigour and reduce potential bias.  As such, the resulting theoretical 
formulation was firmly grounded in the data.  The ability of the GTM in developing a 
diagrammatic, theoretical formulation which helped to explain the multiple and interacting 
processes involved in adhering to aerosol therapy is itself considered a strength of the current 
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study.  It is hoped that by providing a verbal narrative of the theoretical formulation, the chief 
investigators understanding is represented in a way that “achieves coherence and integration 
while preserving nuances in the data” (Elliott, Fischer, & Rennie, 1999). 
The GTM encourages the researcher to “own one’s perspective” by recognising and 
disclosing their interests, values and assumptions and the role that these play in influencing 
understanding (Strauss & Corbin, 1990).  By doing this (see section 2.9.3.1), it is hoped that 
the reader of the current study is able to interpret the data and the researchers’ understanding 
of them, and to consider possible alternatives.  The GTM also encourages a description of the 
research participants and their life circumstances.  In providing detailed pen portraits of the 
participants in the current study, it is hoped that the reader will be assisted in judging the 
range of persons and situations to which the findings might be relevant.    
4.9 Clinical implications 
 The results of the current study have been considered in relation to the existing 
research literature.  Although the smaller sample size means that the findings can only be 
used to make tentative recommendations for clinical practice, the following section will 
briefly highlight some of the main clinical implications of the research. 
4.9.1 The aerosol therapy treatment regimen 
 Health care professionals should demonstrate a continued awareness of the burden 
associated with aerosol therapy as only one part of an already complex, demanding and often 
interdependent treatment regimen.  Health professional efforts to ensure that less necessary 
additional treatments are kept to a minimum appear to be valued highly by patients and 
parents.  Where increasing the number of aerosolised therapies is an absolute necessity, 
providing appropriate empathy and exploring and advising how the new regimen may fit into 
their lives may help to motivate patients and parents, particularly where the beliefs in the 
benefits associated with the aerosol therapy are less strong. 
The utility of an M.I. approach (Miller, 1983; Miller & Rollnick, 1981) in facilitating 
these and other patient-health professional and parent-health professional interactions could 
prove worthwhile.  It may be appropriate for training in this well researched approach to be 
encouraged for CF staff teams, as is already the case in some areas (Chiesi Connect, 2011).  
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4.9.2 The aerosol therapy treatment device 
 Advances in AAD technology have resulted in intelligent devices that are more 
effective, easier to use and better able to provide useful feedback that can both encourage 
adherence (e.g., reduced time associated with the TIM mouthpiece) and promote appropriate 
administration technique (e.g., cascading feedback system).  Additional benefits are found in 
the ability of some of these newer devices (e.g., the I-neb™) to provide detailed and more 
objective adherence data than ever before.  The current study extends the findings of those 
previously conducted (Latchford et al., 2009; McNamara et al., 2009) by suggesting that as 
well as providing an objective measurement of adherence, this information can be successful 
used to assist in the empathic and detailed exploration of potential barriers and facilitators of 
adherence to aerosol therapy.  Gaining this in-depth understanding may be important for 
clinicians in helping patients and their parents to identify the numerous interacting biological, 
psychological and social influences on adherence to aerosol therapy, many of which were 
reported within the current study.  In doing so, advice and support may be more appropriately 
targeted. 
 However, the benefits of more advanced devices paradoxically create a number of 
associated difficulties.  Ensuring that the device is appropriately maintained and cleaned 
creates an additional burden which was identified as a potential barrier by participants in the 
current study.  The negative impact that this had on device portability and associated non-
adherence was a particularly relevant concern.  In addition, some of the participants’ 
perceptions of the I-neb™ as fragile and expensive (and the associated fear of losing or 
damaging the device) further prevented the aerosol therapy from being adhered to outside of 
the home environment. 
 It should perhaps be encouraged for appropriate stakeholders (i.e., patients, parents, 
clinicians and device manufacturers) to engage in a cost-benefit analysis, that enables an open 
account of the benefits of continued technological device improvements alongside the 
associated consequences.  In doing so, the rhetoric of continual advancement can be more 
appropriately situated in the context of everyday life.    
4.9.3 Cognitive, affective and behavioural processes 
 The current study found that a wide variety of patient and parent beliefs in the aerosol 
therapy had the potential to influence a series of adaptive and less adaptive affective and 
behavioural responses.  The impact of patient cognitions and beliefs on the process of 
adherence is well documented and was reviewed earlier (e.g., Horne, 2003).  Assisting 
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patients and parents in the identification of these interacting psychological processes (perhaps 
utilising the PLS data where deemed appropriate) may help to target appropriate support, 
particularly for those whose problematic cognitions (e.g., a parent thinking that the aerosol 
therapy is not working) and emotions (e.g., a parent feeling anxiety and guilt) have the 
potential to result in less helpful behaviours (e.g, excessively reminding or “nagging” their 
child to take the aerosol therapy) that may negatively impact on the parent and child 
relationship. 
M.I. is one potential approach to assist clinicians in this task, as are cognitive 
behavioural therapy (CBT) approaches, which are now beginning to demonstrate their 
effectiveness within the wider adherence literature (Duff & Latchford, 2010a).  Again, it may 
be appropriate for training in these approaches to be encouraged. 
4.9.4 The parent and adolescent relationship 
The current study highlighted the importance of a positive parent-adolescent 
relationship both generally and in its ability to act as a “buffer” to counteract some of the 
daily struggles associated with adhering to aerosol therapy. This echoes the findings of 
countless previous research studies, many of which were reviewed earlier.  The current study 
findings suggest that particular concerns may centre around the transfer of adherence 
responsibility, either prematurely (i.e., giving the adolescent too much responsibility for 
managing the process of adhering to aerosol therapy too soon) or inappropriately delayed 
(i.e., failing to provide adolescents with the type of supported autonomy that would be 
appropriate for their developmental stage). 
Clinician’s may feel less able to affect change for those patients and parents where 
less positive aspects of their relationship are negatively impacting on the process of 
adherence.  However, an empathic and understanding approach may allow patients and 
parents to feel able to discuss these difficulties more openly.    
4.9.5 The context of adherence 
 The current study emphasised that adherence to aerosol therapy does not exist in a 
vacuum.  The use of the PLS data within the semi-structured interviews enabled a number of 
lifestyle and environmental influences to be identified.  Again, while clinicians may feel less 
able to intervene to bring about change in any problematic areas, the open discussion of these 
influences (once more, using the PLS data where deemed appropriate) may help to identify 
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specific commitments, times, events or situations which have the potential to negatively 
impact on the process of adhering to aerosol therapy. 
   
One overwhelming finding in the current study was that the interacting 
biopsychosocial processes described above make the prospect of consistent, one hundred 
percent adherence to aerosol therapy very unlikely.  Clinicians may need to openly assess 
their own reactions to this.  Although clinicians are a valuable source of support and may be 
able to help affect positive change, it would appear that non-adherence to a treatment they 
know can help to prolong both the quality and longevity of their patients’ lives is perhaps an 
unfortunate inevitability.   
4.10 Implications for future research 
4.10.1 The strengths and limitations of nebuliser technology 
Advances in AAD technology have resulted in more intelligent devices.  However, 
the current study found that the very real benefits of more advanced devices paradoxically 
create a number of associated difficulties.  The cleaning of the device, for example was 
identified as a particular concern.  Studies that examine both the strengths and limitations of 
nebuliser devices would enhance understanding and may assist in further product 
development.  
4.10.2 The use of M.I. 
 The current study highlighted a number of difficulties (e.g., the multiple 
biopsychosocial interacting influences on adherence to aerosol therapy) that could potentially 
be explored with adolescents and parents during routine CF clinic visits.  The approach taken 
by clinicians is vitally important in determining how successful or otherwise these 
interactions might be (Becker & Maiman 1975; Squier, 1990).  Although M.I. approaches 
have been well documented within the literature (Duff & Latchford, 2010a) further research 
examining M.I. for CF adherence difficulties would help to ascertain their utility within 
routine clinical practice. 
4.10.3 The use of diary studies 
 The current study demonstrated the usefulness of the PLS data downloaded from the 
I-neb™ in helping to qualitatively explore the process of adhering to aerosol therapy.  The 
PLS data was used as a type of diary which helped to cue reflections on actual events around 
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adherence.  The use of diary methodologies (i.e., sequentially collecting data on or from 
individuals within a temporal framework) is becoming commonplace in clinical and health 
psychology research (Ferguson, 2005).  While this method has been previously used to 
examine more general adherence behaviour in CF (e.g., Modi, & Quittner, 2006), studies 
which utilise diary data to examine specific components of the treatment regimen (e.g., 
aerosol therapy) may help to further enhance understanding of the likely multiple, daily 
barriers and facilitators to adherence.   
4.10.4 Psychodynamic and systemic approaches 
 The continued emphasis on research studies in examining largely cognitive, conscious 
processes such as “illness cognitions” and “health beliefs” has contributed to the paucity of 
research from alternative theoretical perspectives.  The current study found that adherence 
behaviours such as “forgetting” for adolescents or “reminding” for parents may have a more 
unconscious foundation than is commonly reported within the literature.  Although there are 
examples of studies examining more psychodynamic approaches to adherence (e.g., Alfonso, 
2011), further research in this area may enhance understanding and help to shift the focus 
away from a largely cognitive approach. 
Similarly, the current study highlighted the numerous social, structural and environmental 
influences on adherence.  Although these findings are not particularly surprising, some have 
argued that research from more systemic approaches would enable a better understanding of 
the way in which social and environmental factors influence adherence (Frohlich et al., 
2001). 
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5.0 CONCLUSION 
In response to the research questions and aim, the following conclusions can be drawn:  
 
1. Although the process of adhering to aerosol therapy is experienced very differently by 
the parents and adolescents, their narrative accounts were actually very 
complementary.  This was reflected in the theoretical formulation which was so 
similar because participants talked about the same material but often from very 
different perspectives. 
2. Although the results identified much that was expected, the theoretical formulation 
adds a richer account and shows how these different biopsychosocial processes 
potentially interact and influence adherence to aerosol therapy. 
3. There were also more novel findings including: 
• the way that certain treatments are interrelated (e.g., aerosol therapy and 
physiotherapy) and the associated burden that this creates which can 
negatively impact on the process of adherence 
• the way that technological advances in the manufacturing of nebuliser devices 
paradoxically create associated difficulties (e.g., the necessity of cleaning the 
device; the device perceived as fragile) 
• the way in which participants are influenced by an internal hierarchy of 
preference for certain CF treatments and the interesting and sometimes 
surprising reasons for this (e.g., preferring certain types of physiotherapy 
because friends can get involved; disliking aerosol therapy because it isolates 
them from their friendship group) 
• the belief, particularly from the parents, that non-adherence to aerosol therapy 
is an unfortunate inevitability because of the influence of the reported 
interacting biopsychosocial processes 
• the seemingly impossible task of achieving an appropriate balance (e.g., 
adolescents adhere more to their aerosol therapy when they are reminded by 
their parents, but also resent this)          
4. The PLS data downloaded from the I-neb™ device provided a cue to participants 
about the actual rates of adherence, and prompted discussion of particular events.  
This helped to bring into conscious awareness the multiple interacting influences on 
adherence to aerosol therapy.
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Appendix 2 – Young person’s information sheet about the research 
 
 
Young person’s information sheet about the research (11 to 13 
Years) 
Version 2 (15.08.11) 
 
Title of Research Study: Experiences of adhering to aerosol therapy in 
adolescents with cystic fibrosis: patient and parent perspectives. 
 
You are invited to take part in a research study conducted by Danny O’Toole 
(Psychologist in Clinical Training) as part of my doctorate degree at the University of 
Leeds.  Before you decide whether or not you would like to take part in this research, 
please read the following information carefully about why the research is being done 
and what it would involve for you.  You can take as much time as you need to 
decide.  You can also talk to other people about it like your family, friends or staff at 
the hospital if you want to.  
 
What is the purpose of the study?  
There have been hardly any studies which have looked at what it is like to take 
aerosol therapy for someone with cystic fibrosis (CF).  Some people take their 
aerosol therapy regularly as prescribed by their doctors while others find it more 
difficult.  I am interested in finding out about your experiences of taking aerosol 
therapy and the experiences of your parent/guardian in supporting you to take your 
aerosol therapy. 
 
Why have we been invited to take part? 
You have been chosen to take part because you have CF, you have been using your 
aerosol therapy device for at least the last 12 months and you are aged between 11 
and 16.  I would also like to talk to one of your parents or the person who looks after 
you about their experiences.  
 
Do we have to take part? 
You do not have to take part in this study; it is up to you to decide.  If you do decide 
to take part you will be asked to sign a form to show that you agree to take part.  
Your parent or guardian will also need to sign this form to show that they agree to 
take part. 
 
You can stop taking part in the study at any time if you change your mind, without 
having to say why.  If you decide not to take part or to stop part way through, this will 
have no effect on the care you get from the team at the hospital.  
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What will happen to us if we take part? 
If you decide you want to take part, I will telephone you to answer any questions you 
may have and to arrange a time to come and meet both you and your mum, dad or 
the person who looks after you at your home.  I will also arrange for 1 weeks worth of 
the information that is regularly downloaded from your aerosol therapy device at your 
next outpatient’s appointment to be sent to me ahead of our meeting so that we can 
use it when we speak to each other to help to jog your memory.  This information will 
be sent to me safely by e-mail and will not have your name or any personal details 
about you contained within it.  Before this is sent to me, both you and your mum, dad 
or the person who looks after you will need to sign a form which says that you agree 
for this information to be sent. 
 
When we meet at your home, I will interview both you and your mum, dad or the 
person who looks after you separate from each other.  I will ask you questions about 
what it is like taking your aerosol therapy and will ask your mum, dad or the person 
who looks after you questions about what it is like trying to support a young person 
who has to take aerosol therapy.  Each interview should last about 60 minutes, 
depending on how much you have to say. 
 
Although we will try to do the interviews separately, you may want someone else to 
sit in with you for support.  This might be another adult member of your family or 
even a friend.  Remember you can also stop the interview and withdraw from the 
study at any time, without giving a reason. 
 
I will tape record both conversations.  This is because afterwards, everything you 
have said on the tape will be written down.  This will allow me to look at what you 
have both said, and try to find the main issues that you talked about. 
 
After I have looked at all the interviews, I will write to everyone who has taken part in 
the research with a summary of what I thought the main issues were. 
 
What are the possible advantages or disadvantages of taking part?  
If you take part I cannot promise that this study will have any direct benefit for you. 
However, some people may find that talking to someone about their experiences 
helpful.  If you do take part, you and your mum, dad or the person who looks after 
you will receive a £15 gift voucher to share. 
 
Although talking about your experiences of taking aerosol therapy is unlikely to 
cause you to become upset, if you do find that you become upset during the 
interview I can let your parent know, if you say that is okay.  If you would like, I can 
also arrange for you to see a member of the CF care team at the hospital so that you 
will be able to talk to them about how you are feeling. 
 
Will our taking part in the study be kept confidential? 
I will ask you and your mum, dad or the person who looks after you to sign a form 
which says you agree to me writing to your G.P. (family doctor).  This is just to let 
them know you are taking part in the study. 
 
After the interview, everything you have said on the tape will be written down.  Any 
information that might show who you are will be kept separately from this written 
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version, and they will both be kept in a safe place, until they are destroyed in 3 years 
time.  The information that is downloaded from your aerosol therapy device will not 
have your name or any personal details about you included within it.  This 
information will also be kept in a secure place, until they are destroyed in 3 years 
time. 
 
I will not tell anyone else what you have said unless I am worried about you or 
someone else getting hurt in some way.  If I am worried about this happening I will 
have to tell someone. 
 
What will happen to the results of this study? 
I will write up the results of this study for my studies.  I will include some of the exact 
things people have said.  It is also possible that I will present the results at a 
conference or write them down in a journal article.  At all times, your privacy will be 
protected.  I will do this by calling you a different name, which you can choose 
yourself if you want. 
 
When I write up this research I will try my best to protect your privacy but because 
you and your parent/guardian know each other so well, you might think that you 
recognise each other from what is being said in the report.  However, it is very 
unlikely that anyone else reading it will be able to tell who you are. 
 
Who has reviewed this study? 
Before any research goes ahead it has to be checked by an independent group of 
people called a Research Ethics Committee (REC).  They make sure the research is 
fair.  This study has been checked by the Humber Bridge REC.  It has also been 
checked by staff at the University of Leeds.   
 
Where can I find out more information?  
If you would like more information, or have any questions about the study you can 
contact me (Danny O’Toole) or Dr Gary Latchford (my research supervisor) on the 
contact details below:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danny O’Toole 
Psychologist in Clinical Training 
Clinical Psychology Training Programme 
Leeds Institute of Health Sciences 
Charles Thackrah Building 
University of Leeds 
101 Clarendon Road 
Leeds 
LS2 9LJ 
 
Tel: 0113 343 0815 
E-mail: undpho@leeds.ac.uk 
 
 
 
 
Dr Gary Latchford 
Consultant Clinical Psychologist 
Clinical Psychology Training Programme 
Leeds Institute of Health Sciences 
Charles Thackrah Building 
University of Leeds 
101 Clarendon Road 
Leeds 
LS2 9LJ 
 
Tel: 0113 343 2736 
E-mail: g.latchford@leeds.ac.uk 
 
 
 
 If you would like to seek independent advice regarding taking part in this study, you can contact the Leeds Teaching Hospitals PALS (Patient Advice and Liaison Service) on 
0113 206 7168) 
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Appendix 3 – Parent information sheet about the research 
 
 
Parent/guardian’s information sheet about the research 
Version 2 (15.08.11) 
 
Title of Research Study: Experiences of adhering to aerosol therapy in 
adolescents with cystic fibrosis: patient and parent perspectives. 
 
You are invited to take part in a research study conducted by Danny O’Toole 
(Psychologist in Clinical Training) as part of my doctorate degree at the University of 
Leeds.  Before you decide whether or not you would like to take part in this research, 
please read the following information carefully about why the research is being done 
and what it would involve for you.  You can take as much time as you need to decide 
and you can talk to others about it if you wish. 
 
What is the purpose of the study?  
There have been hardly any studies which have looked at what it is like to take 
aerosol therapy for someone with cystic fibrosis (CF).  Some people take their 
aerosol therapy regularly as prescribed by their doctors while others find it more 
difficult.  I am interested in finding out about your child’s experiences of taking 
aerosol therapy and your experiences of supporting your child to take aerosol 
therapy. 
 
Why have we been invited to take part? 
Your child has been chosen to take part because they have CF, they have been 
using their aerosol therapy device for at least the last 12 months and they are aged 
between 11 and 16.  I would also like to talk to you about your experiences of 
supporting your child to take aerosol therapy. 
 
Do we have to take part? 
You do not have to take part in this study; it is up to you to decide.  If you do decide 
to take part you will be asked to sign a consent form to show that you agree to take 
part and that you agree for your child to take part. 
 
Both you and your child are free to withdraw from the study at any time, without 
giving a reason.  Not taking part or withdrawing will have no effect on the standard of 
care you or your child receive from the team at the hospital.  
 
What will happen to us if we take part? 
If you decide you want to take part, I will telephone you to answer any questions you 
may have and to arrange a time to come and meet both you and your child to carry 
out an interview at your home.  I will also arrange for 1 weeks worth of the 
information that is routinely downloaded from your child’s aerosol therapy device at 
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your next outpatient’s appointment to be sent to me ahead of our meeting so that we 
can use it in the interview to help to jog yours and your child’s memory.  This 
information will be sent to me via secure e-mail correspondence and will not have 
any personally identifiable details about you or your child contained within it.  Before 
this is sent to me you will need to sign a consent form to show that you agree to this 
being done. 
 
When we meet at your home, I will interview both you and your child separate from 
each other.  I will ask your child questions about what it is like taking their aerosol 
therapy and will ask you questions about what it is like trying to support your child in 
taking their aerosol therapy.  Each interview should last about 60 minutes, 
depending on how much you have to say. 
 
Although we will aim to do the interviews separately, it is fine for someone else to sit 
in with your child for support.  This might be another adult member of your family or 
even a friend, depending on who they prefer.  Remember that you or your child can 
stop the interview and withdraw from the study at any time, without giving a reason. 
 
I will tape record both conversations.  This is because afterwards, everything you 
have said on the tape will be transcribed.  This will allow me to look at what you and 
your child have said, and try to find the main issues that you raised. 
 
After I have analysed all of the interviews, I will write to everyone who has taken part 
in the research with a summary of what I thought the main issues were. 
 
What are the possible advantages or disadvantages of taking part?  
If you decide to take part I cannot promise that this study will have any direct benefit 
for you or your child. However, some people may find that talking to someone about 
their experiences helpful.  If you do take part, you and your child will receive a £15 
gift voucher to share. 
 
Although talking about experiences of aerosol therapy is unlikely to cause you or 
your child distress, if you or your child do find that you become upset during the 
interview I can arrange (with your permission) for either or both of you to see a 
member of the CF care team at the hospital so that you will be able to talk to them 
about how you are feeling.  They may be able to offer you further support and 
advice. 
 
Will our taking part in the study be kept confidential? 
I will ask you to sign a form which says that you agree to me writing to your child’s 
G.P.  This is just to let them know you are taking part in the study. 
 
After the interview, everything you have said on the tape will be transcribed.  Any 
information that identifies who you are will be kept separately from these interview 
transcripts and both sets of information will be kept in a secure location, until they 
are destroyed in 3 years time.  The information that is downloaded from your aerosol 
therapy device will not have any personally identifiable details about you or your 
child contained within it.  This information will also be kept in a secure place, until 
they are destroyed in 3 years time. 
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I will not tell anyone else what you or your child says within the interview unless I am 
concerned about the safety of you, your child or anyone else.  If I am concerned, I 
will have to talk to my supervisors and seek further advice. 
 
What will happen to the results of this study? 
I will write up the results of this study for my doctorate.  I will include some direct 
quotes of what people have said.  It is also possible that I will present the results at a 
conference or publish them in a journal article.  At all times I will protect your 
anonymity and that of your child by using pseudonyms (i.e., I shall refer to you both 
by names other than your own).  You and your child may choose these alternative 
names if you wish. 
 
When I write up this research I will make every effort to protect your anonymity by 
withholding identifying information and using pseudonyms but because you and your 
child know each other so well, you might think that you recognise each other from 
what is being quoted should you read any of my reports.  However, it is very unlikely 
that anyone else reading the work will be able to identify either of you. 
 
Who has reviewed this study? 
All research in the NHS has to be assessed by an independent Research Ethics 
Committee (REC) to ensure your rights, dignity and well-being is protected.  This 
study has been assessed by the Humber Bridge REC.  It has also been reviewed by 
two academic panels at the University of Leeds.   
 
Where can I find out more information?  
If you would like more information, or have any questions about the study you can 
contact me (Danny O’Toole) or Dr Gary Latchford (my research supervisor) on the 
contact details below:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danny O’Toole 
Psychologist in Clinical Training 
Clinical Psychology Training Programme 
Leeds Institute of Health Sciences 
Charles Thackrah Building 
University of Leeds 
101 Clarendon Road 
Leeds 
LS2 9LJ 
 
Tel: 0113 343 0815 
E-mail: undpho@leeds.ac.uk 
 
 
 
 
Dr Gary Latchford 
Consultant Clinical Psychologist 
Clinical Psychology Training Programme 
Leeds Institute of Health Sciences 
Charles Thackrah Building 
University of Leeds 
101 Clarendon Road 
Leeds 
LS2 9LJ 
 
Tel: 0113 343 2736 
E-mail: g.latchford@leeds.ac.uk 
 
 
 
 If you would like to seek independent advice regarding taking part in this study, you can 
contact the Leeds Teaching Hospitals PALS (Patient Advice and Liaison Service) on 
0113 206 7168) 
 175 
Appendix 4 – Consent form 
 
Consent form for Parent/Guardian – Version 2 (15.08.11) 
 
Title of Research Study: Experiences of adhering to aerosol therapy 
 
Name of Researcher: Danny O’Toole 
Please initial the 
boxes if you agree 
 
1. I confirm that I have read and understand the information sheet dated 15.08.11 (version 
2) for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation and that of my child is entirely voluntary.  I understand 
that we are entitled to withdraw from the study at any time without giving any reason and 
without our medical care of legal rights being affected. 
 
3. I agree to the last 7 days of adherence data which has been downloaded as routine at 
this out-patient appointment being sent to the above named researcher via secure e-mail 
correspondence. I understand that this data will not contain any personally identifiable 
information within it. I understand that this data will only be used for the purpose of the 
interview and nothing else. 
 
4. I give permission for the interview to be audio-recorded. 
 
5. I give permission for a letter to be sent to my child’s G.P. advising of our involvement in 
the above study. 
 
6. I understand that any information I offer will be treated anonymously and all material 
arising out of the study will be dealt with on a confidential basis by the researcher 
involved.  The research complies with the Data Protection Act (1998). 
 
7. I understand that data collected during the study may be looked at by individuals from 
regulatory authorities of from the NHS Trust, where it is relevant to my taking part in this 
research.  I give permission for these individuals to have access to this information. 
 
8. I agree to participate in the above named study. 
 
9. I agree to my child taking part in the above named study.   
 
 
___________________ ______________   ___________________  
Name of child    Date     Signature 
participating      
 
___________________ ______________  ___________________  
Name of parent/   Date     Signature 
guardian participating       
 
___________________ ______________    ___________________ 
    Date    Signature 
 
 
 
 
 
 
Name of health 
Professional taking 
consent 
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Appendix 5 – Adolescent patient interview schedule  
 
Semi-structured Interview Guide – Child 
Version 1 – 24.06.11 
 
Aim:   Approximately 8 – 10 key questions per hour session 
 
Q’s Should be: Direct, Forthright, Comfortable, Simple, Clear, Brief, Reasonable, 
Jargon-free, Short (i.e. one-dimensional).  Exact wording may change 
as interviews progress. 
 
Question type: 
• Initial open-ended 
• Intermediate 
• Ending 
(Charmaz, 2006) 
 
 
Interview Question 
 
Prompts  
&  
Topic Guide 
 
Question Type 
Pen portrait and introduction questions? 
 
 
• How old are you? 
• What school do you go 
to? 
Initial 
Open-ended 
Describe a typical day for you? 
 
 
 
• What types of things do 
you do? 
 
Initial 
Open-ended 
Tell me a bit more about what it is like 
living with CF? 
 
 
 
• “Think back” 
• Good/bad 
• Impact 
• Family Relationships 
• Friends 
• Treatments 
 
Intermediate 
Can you tell me a bit more about the 
treatments you take for CF? 
 
 
 
• Which ones? 
• What are they for? 
• What are they like? 
• Which do you prefer? 
 
Intermediate 
What is it like having to take your 
aerosol therapy? 
 
• Like/dislike? 
• Easy/hard? 
Intermediate 
What things make it easier for you to 
take your aerosol therapy? 
 
 
 
 
 
• Think back to a 
particular time… 
• Help/support 
• Being reminded 
• Having time 
• Any days/times when 
it’s easier 
Intermediate 
Looking at this information here, were 
there any days and times that you found 
it easier to take your aerosol therapy? 
 
 
 
 
• Use the I-neb data to 
prompt 
• Tell me a little about day 
X 
• What was it about day 
X/time Y that helped you 
Intermediate 
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What things make it difficult for you to 
take your aerosol therapy? 
 
 
 
• Think back to a 
particular time…  
• Being really busy 
• Forgetfulness 
• Not liking it 
Intermediate 
Looking at this information here, were 
there any days and times that you found 
it more difficult to take your aerosol 
therapy? 
 
 
 
• Use the I-neb data to 
prompt 
• Tell me a little about day 
X 
• What was it about day 
X/time Y that was 
difficult 
Intermediate 
What advice would you give to someone 
who is finding it hard to take their 
aerosol therapy? 
 
 
 Ending 
You’ve told me that (summarise).  Is 
there anything else you think I should 
know to help me understand more about 
what it is like having to take aerosol 
therapy? 
 
 
 Ending 
 
Thank you for your time 
 
 
Remember to record impressions after the interview 
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Appendix 6 – Parent interview schedule 
 
Semi-structured Interview Guide - Parent 
Version 1 – 24.06.11 
 
Aim:   Approximately 8 – 10 Questions per hour session 
 
Q’s Should be: Direct, Forthright, Comfortable, Simple, Clear, Brief, Reasonable, 
Jargon-free, Short (i.e. one-dimensional).  Exact wording may change 
as interviews progress. 
 
Question type: 
• Initial open-ended 
• Intermediate 
• Ending 
(Charmaz, 2006) 
 
 
Interview Question 
 
Prompts  
&  
Topic Guide 
 
Question Type 
Pen portrait and introduction questions? 
 
 
• How old are you? 
• What do you do for a 
job? 
Initial 
Open-ended 
Describe a typical day for you? 
 
 
• What types of things do 
you do? 
 
Initial 
Open-ended 
Tell me a bit more about what it is like 
having a child with CF? 
 
 
 
• “Think back” 
• Good/bad 
• Impact 
• Family Relationships 
• Friends 
• Treatments 
 
Intermediate 
Can you tell me a bit more about the 
treatments your child takes for CF? 
 
 
 
• Which ones? 
• What are they for? 
• What are they like? 
• Which do they prefer? 
• Which do you prefer? 
 
Intermediate 
Tell me some more about your child’s 
aerosol therapy? 
 
• Like/dislike? 
• Easy/hard? 
Intermediate 
What things make it easier for your child 
to take their aerosol therapy? 
 
 
 
 
• Think back to a 
particular time… 
• Help/support 
• Being reminded 
• Having time 
• Any days/times when 
it’s easier 
Intermediate 
Looking at this information here, were 
there any days and times that you think 
your child found it easier to take their 
aerosol therapy? 
 
• Use the I-neb data to 
prompt 
• Tell me a little about day 
X 
• What was it about day 
X/time Y that helped 
your child 
Intermediate 
 179 
• Is that a common 
pattern 
 
What things make it difficult for your 
child to take their aerosol therapy? 
 
 
• Think back to a 
particular time…  
• Being really busy 
• Forgetfulness 
• Not liking it 
Intermediate 
Looking at this information here, were 
there any days and times that you think 
your child found it more difficult to take 
their aerosol therapy? 
 
 
• Use the I-neb data to 
prompt 
• Tell me a little about day 
X 
• What was it about day 
X/time Y that was 
difficult for your child 
• Is that a common 
pattern 
 
Intermediate 
What advice would you give to a parent 
whose child is finding it hard to take 
their aerosol therapy? 
 
 Ending 
You’ve told me that (summarise).  Is 
there anything else you think I should 
know to help me understand more about 
having a child who takes aerosol 
therapy? 
 
 Ending 
 
Thank you for your time 
 
 
Remember to record impressions after the interview 
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Appendix 7 – Example of annonomised PLS diary data sheet  
 
Date 
 
Dose 
Prescribed 
 
Dose Taken Drug Dose Time Taken Duration 
Wednesday 1st February 
 
2 1 Full 08:08 (8.08am) 4 mins 
   
1 
Full 22:14 (10.14pm) 5 mins 
      
Thursday 2nd February 
 
2 1 Full 18:39 (6.39pm) 4 mins 
 
 
 1 Full 21:00 (9.00pm) 4 mins 
      
Friday 3rd February 
 
2 1 Full 08:04 (8.04am) 4 mins 
 
 
 1 Full 21:47 (9.47pm) 4 mins 
      
Saturday 4th February 
 
2 1 Full 10:59 (10.59am) 6 mins 
 
 
 N/A N/A N/A N/A 
      
Sunday 5th February 
 
2 1 Full 13:47 (1.47pm) 4 mins 
 
 
 1 Full 20:18 (8.18pm) 4 mins 
      
Monday 6th February 
 
2 1 Full 07:53 (7.53am) 6 mins 
 
 
 1 Full 21:06 (9.06pm) 4 mins 
      
Tuesday 7th February 
 
2 1 Full 08:49 (8.49am) 3 mins 
 
 
 1 Full 20:45 (8.45pm) 3 mins 
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Appendix 8 – Example of the open coding process 
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Appendix 9 – Example of the axial code subcategory process  
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Appendix 10 – Example of a diagram used during the parent data analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
